{
  "OPTISAGE": {
    "TITLE": "full title phase iii study comparing gvhd prophylaxis with atg thymoglobulin to atlggrafalon in elderly patients with acute myeloid leukemia or myelodysplatic syndrome and receiving an allogeneic hematopoietic stem cell transplantation with a 10 10 hla matched unrelated donor following a reduced intensity conditioning regimen by fludarabinetreosulfan",
    "JUSTIFICATION": "scientific justification allogeneic hematopoietic stem cell transplantation allo hsct remains the only curative therapy in acute myeloid leukemia aml and myelodysplastic syndrome mds most of the patients requiring an allohsct are above 50 years of age and are transplanted with a reduced intensity conditioning ric regimen the optimal ric and gvhd prophylaxis regimen allowing a good control of the disease while preventing gvhd remains to be determined for elderly patients a phase iii trial comparing the conventional ric fludarabinebusulfan 2 days to fludarabinetreosulfan demonstrated an advantage for the flutreosulfan arm in terms of event free survival efs that should therefore be considered as the new standard of ric regimen for aml and mds gvhd prevention has a crucial role in posttransplant outcomes by potentially interfering with the graftversusleukemia gvl effect and immune reconstitution antithymocyte globulins atg are recommended to reduce the risk of acute and chronic gvhd in transplants performed with matched unrelated donors however the optimal type of atg between the 2 approved brands atg thymoglobulin and atlggrafalon displaying distinct characteristics and the optimal dose of atg are still unknown in a retrospective study of patients transplanted mainly with ric with matched related and unrelated donors for haematological malignancies we observed that atlg was associated with a reduction of grade iiiv acute gvhd in comparison to atg without increasing the incidence of relapse",
    "OBJECTIVE": "main objective and primary endpoint main objective to compare the incidence of grade iiiv acute gvhd at day 100 posttransplantation in mds or aml patients transplanted with a 10 10 matched unrelated donor mud following a reduced intensity conditioning with fludarabinetreosulfan between patients receiving a gvhd prophylaxis with atgthymoglobulin versus atlggrafalon primary endpoint incidence of grade iiiv acute gvhd according to the magic classification appendix 19 9 section 1 at day 100 posttransplantation secondary objectives and endpoints secondary objectives 1 to evaluate the effect of the 2 gvhd prophylaxis on the engraftment and graft failure 2 to evaluate the effect of the 2 gvhd prophylaxis on the incidence of grade i acute gvhd and of chronic gvhd 3 to evaluate the effect of the 2 gvhd prophylaxis on incidence of infections 4 to evaluate the effect of the 2 gvhd prophylaxis on progression free survival 5 to evaluate the effect of the 2 gvhd prophylaxis on relapse incidence 6 to evaluate the effect of the 2 gvhd prophylaxis on nonrelapse mortality 7 to evaluate the effect of the 2 gvhd prophylaxis on overall survival 8 to evaluate the effect of the 2 gvhd prophylaxis on gvhd and relapse free survival grfs 9 to evaluate the effect of the 2 gvhd prophylaxis on healthrelated quality of life fact bmt 10 to evaluate the effect of the 2 gvhd prophylaxis on chimerism 11 to evaluate the effect of the 2 gvhd prophylaxis on immune reconstitution t b nk regulatory t cell levels in the peripheral blood 12 to evaluate the effect of the 2 gvhd prophylaxis on days of hospitalisation during the first 12 months posttransplantation",
    "DESIGN": "design of the study phase iii multicenter randomized controlled openlabel trial comparing gvdh prophylaxis with atg versus atlg in patients with aml or mds transplanted with a mud following fludarabinetreosulfan ric ancillary study bio collection of pbmc plasma and dry pellets from total blood cells will be performed on d9 base line d14 21 28 56 100 m6 and m12 in 60 patients per arm for future biological studies that would be performed after finding complementary funding the collections will be organized via cryostem in order to better understand the modulation of the immune response between the two atg brands plasma collection for atg pk analysis in the atlg arm samples collected before and after each administration of atlg on days3 to 1 and at day 0 14 m1 m2 and d 100 frozen in each center data will be analyzed according to preconditioning lymphocyte counts and correlated to posttransplant outcomes gvhd relapse nrm to be able to determine of a formula to optimize atlg dose to lymphocyte counts for future studies this plasma collection will start including patients after finding complementary funding",
    "INCLUSION CRITERIA": "population of study participants patients above 50 years of age presenting aml or mds with an indication for allogeneic stem cell transplantation inclusion criteria 1 age 50 and 70 years 2 patient between 50 and 55 years should be unfit for a myeloblative conditioning 3 aml requiring allogeneic stem cell transplantation intermediate or highrisk aml in complete cytologic response cr1 or above or mds requiring allogeneic stem cell transplantation ipss 1 5 or ipssr 4 5 or ipssr 34 5 with risk features rapide blast increase lifethreatening neutropenia 0 3 g l or thrombopenia 30g l or high transfusion needs 2 month for 6 months 4 without an hla matched related donor 5 having an identified matched hla 10 10 unrelated donor 6 with usual criteria for hsct a ecog performans status 2 b no severe and uncontrolled infection c cardiac left ventricular ejection fraction 50 d lung dlco 40 e adequate organ function asat and alat 3n total bilirubin 2n creatinine clearance 50 ml min except if those abnormalities are linked to the hematological disease 7 with health insurance coverage 8 having signed a written informed consent 9 contraception methods must be prescribed during all the duration of the research nb the authorized contraceptive methods are",
    "EXCLUSION CRITERIA": "exclusion criteria 1 carcinomas in the last 5 years except basal cell carcinoma of the skin or in situ carcinoma of the cervix 2 uncontrolled infection 3 seropositivity for hiv or htlv1 or active hepatitis b or c 4 yellow fever vaccine and all others live virus vaccines within 2 months before transplantation 5 heart failure according to nyha ii or more or left ventricular ejection fraction 50 6 lung dlco 40 7 preexisting acute hemorrhagic cystitis 8 renal failure with creatinine clearance 50ml min 9 pregnancy βhcg positive or breastfeeding 10 patients with any debilitating medical or psychiatric illness which would preclude the realization of the sct or the understanding of the protocol 11 patient under state medical aid 12 patient under legal protection protection of the court or in curatorship or guardianship 13 for grafalon any contraindication mentioned in the smpc of grafalon 14 for thymoglobulin hypersensitivity to rabbit proteins or to any of the excipients 15 participation in other clinical trials on medicinal products for human use or being in the exclusion period at the end of a previous study 16 any contraindication mentioned in the smpc of all auxiliary medicinal products planned to be used in the trial cyclosporine mycophenolate mofetil fludarabine treosulfan",
    "INTERVENTION": "investigational medicinal product s phase iii grafalon 10 mg kg day iv for 3 consecutive days day 3 to 1 before transplantation transplantation modalities 1 conditionning regimen all patients will receive the same conditioning regimen  fludarabine 30 mg m2 day iv for 5 days day6 to day 2  treosulfan 10 g m2 day iv for 3 days day 4 to day 2 2 donor and stem cell source hla 10 10 matched unrelated donor only gcsfmobilized peripheral blood stem cells will be accepted cd34 target dose 4 10 6 kg of body weight 3 gvhd prophylaxis prophylaxis of gvhd will depend on the randomization arm atlggrafalon 10 mg kg day iv for 3 consecutive days day 3 to 1 atlggrafalon or atgthymoglobuline atgthymo two schedules of administration of antithymocyte globulin atg are accepted 2 5 mg kg day iv for 2 consecutive days day3 and 2 or 0 5 mg kg iv on day 4 followed by 2 mg kg iv on day 3 and 2 5 mg kg on day 2 in addition patients will receive cyclosporine csa 3 mg kg day and mycophenolate mofetil mmf 30 mg kg day as follows csa from day1 to month 4 or 6 after a progressive withdrawal starting by 3 months post sct if no agvhd and according to the practice of the center and mmf from day 1 to day 45 in both arms",
    "STATISTICS": "statistical analysis our hypotheses are based on a reduction on the incidence on day 100 posthsct of grade iiiv acute gvhd from 40 atg arm to 23 atlg arm and assuming a 10 risk of randomised patients who would not reach transplant and an incidence of 5 for the competing risk death without gvhd in each arm when accounting for competing risks a twosided logrank test with an overall sample size of 324 subjects 162 in the control group and 162 in the treatment group achieves 91 power at a 0 05 significance level to detect a hazard ratio of 0 50 with a followup time of 100 days in total 162 162 324 patients will be included no interim analysis is scheduled to be performed",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference optisage aphp230276 eu ct n 202350455527 00",
    "INVESTIGATOR": "coordinating investigator pr régis peffault de latour bmt department hôpital saint louis avenue vellefaux 75010 paris email regis peffaultdelatour aphp fr scientific director pr marie thérèse rubio hematology department chru nancy hôpital brabois allée du morvan 54500 vandoeuvre les nancy france email m rubio chrunancy fr",
    "NUMBER OF INCLUSIONS": "number of participants included 324",
    "SITES": "number of centres 26 in france",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources the study is funded by industrial support from neovii and medac"
  },
  "MSC-SLE": {
    "TITLE": "full title treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord",
    "JUSTIFICATION": "scientific justification systemic lupus erythematosus sle is a rare prevalence 40 50 100 000 persons heterogeneous autoimmune and autoinflammatory disease ad affecting both sexes and all races with a peak incidence prevalence among black people and a predilection for women in the 3rd4th decade of life sle is characterized by successive periods of flares and remission which may all vary in duration and quality prognosis of severe forms of sle which affect lung heart or brain in addition to renal involvement has improved but still evolution remains pejorative in a subset of patients whose 10 years mortality remains 10 15 even in tertiary referral centers for 20 years no new prospective clinical trial in the course of sle has demonstrated its effectiveness new biological therapies have not yet made the long awaited breakthrough in the treatment of severe sle and only antiblys monocolonal antibody has gained indication in moderately active sle in addition serious adverse side effects progressive multifocal leukoencephalopathy observed with several biologics in ad patients has dampened their expected benefits for sle subjects resistant to 1er or 2nd line conventional treatment there is a need to develop more effective therapies with fewer long term side effects based on new immunomodulatory and immunosuppressive strategies according to their in vitro immunomodulatory properties and ability to induce tissue repair mechanisms mesenchymal stem cells msc have been proposed as a new therapy for several ad including sle the use of allogeneic umbilical cordderived msc is based on experimental and human clinical data particularly produced by nanjing team pr sun in china it is also logical to select sle patients with the same severity criteria as those used worldwide to validate the efficacy of antiblys therapies similarly the analysis of the expected results should take into account criteria similar or comparable to those used for the pivotal clinical trials this trial is a unique opportunity to set up collaboration between saintlouis aphp clinical expert center for cell therapy in ad and university college london for cell manufacturing",
    "OBJECTIVE": "main objective and primary endpoint main objective to assess the tolerance of allogeneic umbilical cord derived msc administration for severe sle refractory to standard therapies cyclophosphamide mycophenolate mofetil and corticosteroids with or without anti cd20 primary endpoint immediate tolerance as assessed during the first injection and 10 days after the allogeneic msc injection according to standards ctcae side effects secondary objectives and endpoints secondary objectives 1 feasibility of allogeneic ucmsc administration in the treatment of severe sle subjects refractory to conventional therapies 2 tolerance three months after injection considering the observed morbidity and the overall survival in sle treated subjects until 1 year after the procedure 3 analysis of biological and clinical response on routine clinical and biological examination and criteria for monitoring lupus using selena sledai bilag sf36 eq5d sri sliccsle scores 4 analysis of the efficacy at 3months after injection of allogeneic uc mscs according to the proportion of subjects with major clinical response rcm 5 percentage of subjects with partial clinical response cpr during the 12 months of followup study 6 evaluation of the immunomodulatory effect of msc by a routine laboratory criteria including immunophenotyping every 3 months during the followup period b analysis of specific cytokine production at m0 m1 and m3 7 analysis of msc immunogenicity at m0 m1 and m3 secondary endpoints 1 safety tolerance will be assessed during the injection and within the first 10 days following the msc injection at m1 m3 m6 and m12 according to side effects defined by ctcae standards miller results of cancer treatment cancer 1981 47 1 207  214 treatmentrelated toxicity will be analyzed according to the international world health organization who maximum degree of toxic attacks by the body an injection will be considered as not tolerated for any toxicity criteria above grade 3 2 proportion of subjects with major clinical response mcr and the proportion of subjects with partial response clinic pcr during the 12 months of study followup at 3 6 9 and 12 months m3 m6 m9 and m12 3 disease activity measured by the bilag scores 0 and 72 and selenasledai 0 to 105 every 3 months as compared to inclusion until the end of the followup period m3 m6 m9 and m12 4 sri response rate measured every three months m3 m6 m9 and m12 during followup a sri response is defined as a 4 points reduction of selena sledaiscore no new bilag a score for an organ and no more than one new bilag b score and no worsening increase of 0 3 in the overall evaluation of the physician as compared to inclusion values 5 presence of comorbidities according scliccsle index at m0 and every three months during study followup m3 m6 m9 and m12 and charlson comorbidity index at eligibility",
    "DESIGN": "design of the trial single center phase iii open study with national recruitment within the fai2r network scope of the trial the immunosuppressive and or immunomodulatory action of allogeneic mscs from umbilical cords of a healthy donor will allow beneficial action on patients with severe sle resistant to conventional treatments",
    "INCLUSION CRITERIA": "population of trial subjects sle active subjects refractory to prior standard therapies inclusion criteria patient 1 age 18 years and 70 years 2 diagnosis of systemic lupus erythematosus sle according to the acr criteria with positive antinuclear antibodies 3 subjects with sustained disease activity defined by a selena sledai sle activity index 6 at baseline 4 inefficacy or adverse effects necessitating discontinuation of first and second line therapies of sle including a prednisone orally 6 mg day or equivalent for at least 28 days b at least one or more of the following immunosuppressive therapies for 3 months in total",
    "EXCLUSION CRITERIA": "exclusion criteria subjects 1 pregnancy breastfeeding or lack of appropriate contraception during study duration 2 presence of a renal failure calculated creatinine clearance of 30 ml min b cardiac failure clinical signs of congestive heart failure left ventricular ejection fraction 40 on echocardiography uncontrolled ventricular arrhythmia c hepatitis defined by abnormal levels of transaminases ast alt 2 x normal not related to disease activity d respiratory disease mean pap 50 mmhg echocardiography respiratory failure defined by a resting blood pressure of oxygen at pao 2 70 mmhg and or paco2 50 mmhg without oxygen 3 severe psychiatric disorders including severe psychosis related to sle which would prevent to give informed consent or to undergo the procedure 4 active neoplasia or concomitant myelodysplasia except for basal cell carcinoma or squamous cell carcinoma or in situ cervix carcinoma 5 bone marrow failure defined by neutropenia 0 5 109 l thrombocytopenia 30 109 l anemia 8 g dl lymphopenia cd4 200 x 106 l caused by another disease than sle 6 acute or chronic uncontrolled infection hiv 1 2 htlv1 2 hepatitis b hbs ag surface antigen hepatitis c with positive pcr optional pcr 7 patient having received belimumab intravenously or subcutaneous within 2 months of baseline or having received rituximab or other b cell depleting biologic therapy within 6 months of baseline 8 current substance abuse or recent within 60 days history of substance abuse 9 patient in periods of exclusion from the national roster of researchers 10 patient with linguistic or psychological incapacity to sign informed consent 11 patient already included in another study at the same time 12 poor patient compliance patient under legal protection",
    "INTERVENTION": "investigational medicinal product s phase iii allogeneic umbilical cord derivedmscs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study at doses of  1 106 csm kg  2 106 csm kg  4 106 csm kg 1 injection during 30min to 1h by intravenous infusion comparator treatment na",
    "STATISTICS": "statistical analysis initially 5 subjects at the initial dose of 2 106 csm kg recipient weight will be included the following 5 subjects will be enrolled in a dose  1 106 ms kg there is a high probability of excessive toxicity* at 2 106 msc kg  4 106 csm kg if there is a low probability of excessive toxicity* 2 106 csm kg *the toxicity criteria are described in ctcae classification each patient cohort will be scanned in a sequential bayesian approach to estimate the probability of toxicity to the administered dose allowing an adaptation of the function of the toxicity observed in the dose previous subjects",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym mscsle",
    "INVESTIGATOR": "coordinating investigator professor dominique fargebancel internal medicine autoimmune diseases and vascular pathology uf 04 hôpital stlouis 1 avenue claude vellefaux paris 75010 paris",
    "NUMBER OF INCLUSIONS": "number of subjects included 10 patients",
    "SITES": "number of sites monocentric st louis hospital",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial subvention de recherche thérapie génique et cellulaire en néphrologie subv thérapie génique fdrafm airg 2014 funding by fondation du rein and l association française contre les myopathies afm téléthon in collaboration with l airg france and drci sponsor aphp"
  },
  "CAALLF01": {
    "TITLE": "name of the study caallf01 a french protocol for the treatment of acute lymphoblastic leukemia all in children and adolescents",
    "JUSTIFICATION": "main backgrounds 1 all is now a curable disease in 8090 of children and 7080 of the adolescents nevertheless numerous problems remain these good results are obtained with intensive and prolonged treatments which include risk of toxic death sequelae and secondary malignancies results are still insufficient for highrisk forms particularly those exhibiting an early resistance to chemotherapy early bone marrow relapses less than 30 months after diagnosis still have a dismal prognosis which renders their prevention mandatory all is an extremely heterogeneous disease in terms of biology and response to treatment to envisage targeted treatments in the future renders key to decipher this heterogeneity the two cooperative groups fralle and the french centers of the eortcclcg have decided to elaborate a common protocol for the treatment of childhood and adolescent all childhood and adolescent allfrance 01 caallf01 the two previous studies from these groups have comparable results eventfree survival overall survival 5 years 8 years 5 years 8 years fralle 2000 2146 pts 84 0 82 91 89 eortc 58951 1947pts 82 6 81 3 89 7 88 1 2 a still major question in the field of all is the optimal use of lasparaginase asnase it is known that administering asnase results in the depletion of asparagine circulating in the blood which starves the leukemic cells and results in their death but indeed the use of asnase varies between protocols considering the different brands the dose and the administration modalities rythm routeim or iv three major forms of asnase are currently available e coli asparaginase kidrolase in france erwinia asparaginase erwinase for patients with allergy and a pegylated form of e coli asparaginase oncaspar in usa and in europe 2 1 oncaspar in the usa oncaspar pegylated e coli asparaginase or pegaspargase manufactured initially by enzon and now shire servier was developed with the goal of reducing the immunogenicity of the native asnase in addition oncaspar because of its prolonged serum terminal halflife t1 2 can be dosed less frequently than native asnase with achievement of similar pd in the usa ccg1962 was the pivotal clinical trial supporting firstline use of oncaspar children with standard risk all n 118 were randomized to receive native or pegylated e coli asparaginase api from merck as part of induction and 2 delayed intensifications di phases oncaspar was administered intramuscularly",
    "OBJECTIVE": "questions asked in the caallf01 protocol this french protocol will be the first in europe to use the oncaspar lonza used in the usa since 2012 first approval in 1994 was for another oncaspar manufactured with a merck api randomized question what is the best way to administer pegaspargase a cohort of children and adolescents with standard or medium risk all will be randomized to receive during induction either one infusion of oncaspar lonza 2500 iu m2 at d12 or two infusions of oncaspar lonza at 1250 iu m2 each at d12 and d26 patients will then receive 2500 iu m2 or 1250 iu m2 per dose during consolidation and delayed intensification according to the initial arm of randomization non randomized question in the high very high risk groups a non randomized intensification of the scheme of asparaginase administration is proposed during induction therapy 2 infusions of 2500 iu m2 day d12 and d26 will be administered all patients will receive 2500 iu m2 per dose during consolidation and delayed intensifications primary objectives 1 for children and adolescents with standard or medium risk all the study has two primary objectives 1 to assess the superiority in terms of pk at d33 of the fractionated scheme 2 to assess the equivalence in the tolerance of the 2 schemes from d12 of induction to d49 2 in the high very high risk group two primary objectives have been defined 1 to assess the pk at d33 2 to assess the toxicity of the intensified scheme from d12 of induction to d49 main endpoints o adequate asparaginase activity 100 iu l at d33 of induction o toxicity incidence of severe toxicities grade 3 directly asparaginase related cns thrombosis pancreatitis anaphylaxia and hyperbilirubinemia between d12 and d49 of treatment and anyway before d8 of consolidation secondary endpoints 1 linked to the study drug pharmacokinetics pharmacodynamics immunogenicity a comparison of the 2 arms will be made for the patients with standardrisk or mediumrisk all a non comparative assessment will be made for patients belonging to the highrisk very high riskgroups the criteria will include cid 16 asparaginase activity and asparagine levels at defined timepoints cid 16 incidence of asparaginase antibodies cid 16 incidence of silent inactivation in both arms during induction consolidation and intensification phase s cid 16 allergic reaction rate in both arms during induction consolidation and intensification phase s cid 16 percentage of patients without switch to erwinia asparaginase cid 16 percentage of patients receiving more than 95 of the intended dose of asparaginase efficacy a comparison of the 2 arms will be made for the patients with standardrisk or mediumrisk all a non comparative assessment will be made for patients belonging to the highrisk very high riskgroups the criteria for efficacy will include cid 16 morphological cr rates assessed on the whole population or on subgroups blineage all tcell all cid 16 minimal residual disease mrd at the end of induction tp1 and at the later timepoint tp2 tp3 for a subgroup of patients assessed by ig tcrbased rqpcr this evaluation will be made in the whole population and within subgroups cid 16 cumulative incidence of relapses overall",
    "DESIGN": "study design this is a french prospective multicentric cohort study of children and adolescents with all stratified on i the type of all b vs t and ii the anticipated risk stratified in 3 groups for bcpall and 2 groups for tcell all a randomized clinical trial will be performed in the population of patients composed of the bsr bmr tsr after checking the eligibility criteria using a two paralell arm randomization design patients will be allocated either to receive one infusion of oncaspar 2500 iu m2 vs or 2 infusions of 1250 iu m2 during induction therapy the dose per infusion after induction therapy is the dose per infusion attributed by the initial randomization no randomized question will be asked in the high very high risk groups of the b and t lineage these patients receiving 2 infusions of oncaspar 2500 iu m2 during induction and 2500 iu m2 infusion afterwards nevertheless these patients will be submitted to the same evalauation in terms of pk pd toxicity and efficacy all patients will be included in the caallf01 study before day 8 of induction treatment randomization will take place between d8 and d11 i e 14 days before the first infusion of pegaspargase d12 for patients belonging to the bsr bmr tsr groups",
    "INCLUSION CRITERIA": "inclusion criteria cid 120 children and adolescents age 12 months but 18 yearsblineage or t lineage all cid 120 written informed consent obtained before day 8 of treatment nb patients with down syndrome can be included but not randomized see details in the protocol section 532",
    "EXCLUSION CRITERIA": "non inclusion criteria cid 120 l3 burkitt s leukemia lmb type protocols cid 120 mixed phenotype acute leukemia who criteria cid 120 infant all age 365 days interfant 06 protocol cid 120 secondary leukemia exclusion criterion cid 120 ph bcrabl all esphall protocol cid 120 cns thrombosis before d12",
    "INTERVENTION": "investigational drug oncaspar pegaspargase is supplied as a sterile solution at the beginning of the trial and replaced by a powder for solution for injection both are packaged in type i singleuse vials containing 3 750 international units of native asparaginase per 5 ml solution oncaspar is to be stored under refrigeration at 2 c to 8 c product must not be shaken or frozen and must be protected from light",
    "STATISTICS": "first interim analysis will be performed based on all patients randomized before january 1 2018 as requested by the dsmb of the study on november 2017",
    "DSMB": "",
    "ACRONYM": "",
    "INVESTIGATOR": "",
    "NUMBER OF INCLUSIONS": "number of subjects chosen 2000 patients could be enrolled to obtain bsr bmr tsr 1578 evaluable patients bhr thr 250300 evaluable patients",
    "SITES": "centres 28 amiens nantes angers nice besançon paris bordeaux armand trousseau brest robert debré caen saintlouis clermontferrand poitiers dijon reims grenoble rennes lille rouen limoges saintetienne lyon strasbourg marseille toulouse montpellier tours nancy",
    "FUNDING": "study sponsor assistance publiquehôpitaux de paris"
  },
  "HAPLO-EMPTY": {
    "TITLE": "full title haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide in patients with acquired refractory aplastic anemia a nationwide phase ii study",
    "JUSTIFICATION": "scientific justification outcomes for patients with severe aplastic anemia saa who are refractory to firstline immunosuppressive therapy ist and who lack a matched unrelated donor mud remain poor recently the use of eltrombopag elt has shown blood count improvements in 40 of these patients 1 however most refractory patients do not respond to elt or other secondline treatment and are therefore exposed to lifethreatening infections and bleeding during the past 2 decades there has been a significant decrease in infection related mortality in patients with saa unresponsive to initial ist but clonal evolution including paroxysmal nocturnal hemoglobinuria pnh myelodysplastic syndrome mds and acute myeloid leukemia aml still occur in the longterm with a grim prognosis overall the overall survival of such patients with acquired refractory saa to elt is about 6070 at 2 years 2 hematopoietic stem cell transplantation hsct using alternative donor sources i e mismatched unrelated donors cord blood cbt and haploidentical family donors may be curative in patients with refractory saa despite carrying much higher rates of complications than in transplantations from matched related or unrelated donors recently our group showed that cbt is a valuable curative option for young adults with refractory saa 3 however not all patients have available cb and cbt treatment related mortality is high in adult patients haploidentical haplo related donor stem cell transplantation haplosct have improved dramatically outcomes using tcell replete grafts with administration of posttransplantation cyclophosphamide ptcy preliminary results in a little number of patients with refractory saa at kings college london uk and john hopkins baltimore usa seem promising 4 5 we retrospectively analyzed data from 36 patients median age 42 years transplanted between 2010 and 2017 in europe on behalf of the saa working party of the european blood and marrow transplantation group the 1year overall survival was about 80 suggesting that this approach might be a valid option in this particular poor clinical situation 6",
    "OBJECTIVE": "main objective and primary endpoint main objective to demonstrate a benefit in term of the 2year overall survival rate from 60 historical rates in patients with acquired refractory idiopathic aplastic anemia up to 80 using haplosct with ptcy primary endpoint 2year overall survival rate of 80 secondary objectives and endpoints secondary objectives clinical and biological outcomes  graft failure graft versus host disease gvhd progression free survival relapse nonrelapse mortality overall survival  quality of life",
    "DESIGN": "design of the study a phase ii multicenter national prospective cohort study",
    "INCLUSION CRITERIA": "population of study participants patients aged from 3 to 35 years with acquired refractory idiopathic aplastic anemia and with an indication of an haploidentical allogeneic hematopoietic stem cell transplantation inclusion criteria patients  aged from 3 to 35 years old  suffering from refractory acquired idiopathic aplastic anemia at least one course of immunosuppression with antithymocyte globulin  absence of genoidentical donor or 10 10 matched donor  with identification of a haploidentical donor brother sister parents adult children or cousin  absence of donor specific antibody detected in the patient with a mfi 1500 antibodies directed towards the distinct haplotype between donor and recipient  with usual criteria for hsct ecog 2 no severe and uncontrolled infection cardiac function compatible with high dose of cyclophosphamide  adequate organ function asat and alat 2 5n total bilirubin 2n creatinine 150 µmol l",
    "EXCLUSION CRITERIA": "exclusion criteria patients  with no morphologic evidence of clonal evolution patients with isolated bone marrow cytogenetic abnormalities are also eligible  with uncontrolled infection  with seropositivity for hiv or htlv1 or active hepatitis b or c defined by a positive pcr hbv or hcv and associated hepatic cytolysis  cancer in the last 5 years except basal cell carcinoma of the skin or in situ carcinoma of the cervix  pregnant βhcg positive or breastfeeding  who received attenuated vaccine within 2 months before transplantation  uncontrolled coronary insufficiency recent myocardial infarction 6 month current manifestations of heart failure uncontrolled cardiac rhythm disorders ventricular ejection fraction 50  with heart failure according to nyha ii or more  preexisting acute hemorrhagic cystitis  renal failure with creatinine clearance 30ml min  with urinary tract obstruction  with contraindications to treatments used during the research  who have any debilitating medical or psychiatric illness which preclude understanding the inform consent as well as optimal treatment and followup  under tutorship or curatorship",
    "INTERVENTION": "transplant modalities 1 conditioning regimen fludarabine 30mg m2 day i v day 6 to day 2 pretransplant cyclophosphamide 14 5 mg kg day i v day 6 and day 5 and total body irradiation 2 gray on day1 2 stem cell source bone marrow 3 gvhd prophylaxis rabbit atg dosed at 0 5 mg kg on day 9 and 2 mg kg on days 8 and 7 cyclophosphamide 50 mg kg day at d 3 and d 4 tacrolimus residual 812 microg l and mycophenolate mmf",
    "STATISTICS": "statistical analysis justification of sample size we hypothesize the 2year overall survival os will be of 80 versus 60 in historical controls a twosided onesample logrank test calculated from a sample of 31 subjects achieves 80 7 power at a 0 050 significance level to detect a proportion os of 80 in the new group when the proportion os in the historic control group is 60 at 2 years terminal analysis will be realized after the observation of the required number of events",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference haploempty",
    "INVESTIGATOR": "coordinating investigator pr régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of participants included for an objective of 31 patients to be allografted we anticipate 35 patients to include",
    "SITES": "number of centres 36 centres in france",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources ministry of health  phrcn 2019"
  },
  "KAPVEC": {
    "TITLE": "full title phase ii multicenter study of talimogene laherparepvec in classic or endemic kaposi sarcoma",
    "JUSTIFICATION": "scientific justification kaposi sarcoma ks is a lymphangioproliferation associated with human herpes virus 8 hhv8 promoted by immunosuppression hivrelated ks and iatrogenic posttransplantation ks are treated by immune restoration in association with local or systemic therapies as chemotherapies if required conversely in classic and endemic ks the underlying relative immunosuppression cannot be directly targeted treatment is poorly codified mostly based on surgery or radiotherapy for localized ks most aggressive forms with visceral involvement are treated with chemotherapies or interferon which give at best 3060 of transient responses and may not be well tolerated in elderly patients talimogene laherparepvec is the first oncolytic immunotherapy approved by the fda in metastatic or unresectable melanoma with injectable nodal or cutaneous lesions it is designed to induce tumor regression of injected lesions through direct lytic effects and of uninjected lesions through induction of systemic antitumor immunity in merkel cell carcinoma mcc another virusinduced tumor treatment with pd1 pdl1 axis inhibitors have proven efficacy thus providing a proof of principle that immunotherapy could be effective in virusinduced tumors two cases of metastatic mcc succesfully treated with talimogene laherparepvec were recently reported suggesting that talimogene laherparepvec may also be an effective therapeutic option considering the high immunogenicity of viral epitopes in ks tumors the role of the immune evasion in the development of ks and the cutaneous manifestations 90 of patients that can be easily injected classic and endemic ks is a good tumor model to be targeted with talimogene laherparepvec",
    "OBJECTIVE": "main objective and primary endpoint the main objective is to assess whether talimogene laherparepvec is clinically inactive partial complete response probability π0 10 or truly active partial complete response probability π1 40 in classic and endemic kaposi sarcoma the primary endpoint is the best overall response rate borr defined by the occurrence of complete response or partial response of the injected lesions following pga criteria pga 0 to 4 recorded from the start of treatment secondary objectives and endpoints secondary objectives  safety profile of talimogene laherparepvec in classic and endemic kaposi sarcoma  other parameters of efficacy best response response rate duration of response  efficacy on injected and uninjected lesions  quality of life exploratory objectives  to characterize the efficacy of talimogene laherparepvec related to immunologic and viral assessment on tumor biopsies and blood samples secondary endpoints  adverse events following the ctcae v5 0  borr according to the actg criteria response rate at month 3 and 6 response rate on lymphedema time to response duration of response  response on injected and uninjected target lesions  deaths from any cause  ksadapted dlqi score exploratory endpoints  characterize the immune tumor infiltrate immune cells quantification viral infiltrate and tumor necrosis before and after treatment  hhv8 viral load in blood and tumor cells hhv8 sequencing",
    "DESIGN": "design of the trial phase ii multicentre single arm open label trial scope of the trial kaposi sarcoma",
    "INCLUSION CRITERIA": "population of trial subjects adult patients inclusion criteria  classic or endemic histologically confirmed kaposi sarcoma ks that is progressive but does not require a systemic therapy  injectable and measurable disease defined as at least 2 cutaneous lesion 10mm in its largest diameter in a not previously irradiated field at least 2 other cutaneous lesion 10mm in their largest diameter available for repeated cutaneous biopsies in a not previously irradiated field nb each cutaneous lesion can be replaced by a cluster of small lesions with edge to edge distance 2 mm if the biggest diameter of each cluster meet the previous criteria  be willing to provide tissue from cutaneous biopsy  at least 4 weeks washout for all ks specific therapies including topical treatment chemotherapy radiotherapy and immunotherapy including interferon  provide written informed consent prior to the performance of any study specific procedures",
    "EXCLUSION CRITERIA": "exclusion criteria  known history of organ transplantation including allogeneic stemcell transplantation or hiv hiv 1 2 antibodies detected at selection  symptomatic visceral involvement of ks including brain metastases  active autoimmune disease that requires systemic treatment or has required systemic treatment in the past 2 years i e with use of disease modifying agents corticosteroids or immunosuppressive drugs replacement therapy eg thyroxine insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc is not considered a form of systemic treatment patients with vitiligo type i diabetes mellitus hypothyroidism psoriasis non requiring systemic treatment are permitted to enrol  evidence of clinically significant immunosuppression such as the following primary immunodeficiency state such as severe combined immunodeficiency disease concurrent opportunistic infection  receiving systemic immunosuppressive therapy including oral steroid doses 10 mg day of prednisone or equivalent within 7 days prior to enrolment  clinically significant cardiac dysfunction symptomatic heart failure clinically significant arrhythmia or conduction disorders  active herpetic skin lesions or prior complications of hsv 1 infection eg herpetic keratitis or encephalitis",
    "INTERVENTION": "investigational medicinal product s talimogene laherparepvec dose 10 6 pfu ml at week 1 then 10 8 ml at week 4 and every 2 weeks up to 4ml for each injection route intralesional injection duration of treatment 6 months 12 cycles comparator treatment ",
    "STATISTICS": "statistical analysis simon s 2 stage optimal design interim analysis planned after 9 patients",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym kapvec",
    "INVESTIGATOR": "coordinating investigator pr céleste lebbe oncodermatologie  hopital saint louis",
    "NUMBER OF INCLUSIONS": "number of subjects included 9 patients will be enrolled in the first part of the study with another 11 patients in the second part total 20 patients it implies to screen a maximum of 40 patients",
    "SITES": "number of sites national multicenter study 2 sites",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial amgen"
  },
  "FIBRAPLO": {
    "TITLE": "full title haploidentical transplantation in patients with myelofibrosis a phase 2 prospective multicentric study",
    "JUSTIFICATION": "scientific justification the only curative treatment in patients with primary or secondary myelofibrosis is allogeneic hematopoietic stem cells hsct it has been reported that intermediate and higher risk patients according to international prognostic scores benefit from hsct in terms of survival kröger et al 2015 in 2013 we conducted in france a prospective trial testing the use of ruxolitinib before transplantation jakallo study nct01795677 outcome of patients was better in patients transplanted with a matched sibling donor than an unrelated donor confirming other studies kröger et al 2009 rondelli et al 2014 in the jakallo trial acute gvhd incidence was high often hyperacute and severe recently the ebmt group has reported a registry study on familial haploidentical transplantation haplo in patients with myelofibrosis raj et al 2018 posttransplant cyclophosphamide was used in 59 of cases oneyear overall survival os and diseasefree survival dfs were 61 and 58 which favorably compared to outcome after unrelated transplantation genova team has also reported impressive results after haploidentical transplantation in their center bregante et al 2015 bregante et al have reported outcome of 2 cohorts transplanted from 2000 to 2010 and from 2011 to 2014 the main difference between the 2 periods is the more frequent use of haplo in the second period 54 versus 5 outcome was much better in the second period with os at 70 versus 49 and authors suggest that this improvement is related to the best outcome among haplo transplantation the improvement of outcome after haplo has been attributed to a better gvhd prophylaxis especially with the use of posttransplant cyclophosphamide given the poor outcome after unrelated transplantation and especially in hla mismatched unrelated setting and encouraging results in family haplo identical transplantation this current study proposes to test haploidentical transplantation in myelofibrosis patients without a matched related donor",
    "OBJECTIVE": "main objective and primary endpoint the main objective is diseasefree survival and without rejection one year after haploidentical transplantation in patients with primary or secondary myelofibrosis the main criteria of judgement is disease and rejection free survival 12 months after hsct secondary objectives and endpoints to assess incidence of acute gvhd grade 2 4 at 100 days incidence of acute gvhd grade 3 or 4 at 100 days engraftment at 100 days incidence of chronic gvhd at 12 months nonrelapse mortality at 12 months overall survival at 12 months relapse progression incidence at 12 months rejection incidence at 12 months time to neutrophil engraftment at 100 days time to platelet engraftment at 100 days infection incidence at 100 days and at 12 months cytokine profile during transplantation day7  1 day day 0 and day 7  1 day impact of genetic alterations on overall survival at 12 months and nonrelapse morality at 12 months",
    "DESIGN": "design of the trial this a phase 2 multicentric study scope of the trial our goal is to show that haploidentical hsct using thiotepa fludarabine in combination with treosulfan gives acceptable results which can even be better than a transplantation from an hla mismatched 9 10 donor and close to a matched unrelated donor in patients with myelofibrosis",
    "INCLUSION CRITERIA": "population of trial subjects patients with a myelofibrosis who have no contraindication to transplant and who have an advanced disease by international scores could be proposed to the trial if they do not have an hlamatched donor inclusion criteria patients aged between 18 and 70 years primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia or polycythemia vera proven by marrow biopsy the myelofibrosis should combine at least 2 of the following criteria o constitutional symptoms weight loss 10 in one year fever without infection recurrent muscle bone or join pains extreme fatigue o anemia with hemoglobin 10 gr dl or red blood cell transfusion requirement o thrombocytopenia 100 g l o peripheral blast count 1 at least found 2 times o white blood cell count 25 g l before a cytoreductive treatment o karyotype 8 7 7q i 17q 5 5q 12p inv 3 11q23 performance status according to ecog at 0 1 or 2 with health insurance coverage having signed a written informed consent",
    "EXCLUSION CRITERIA": "exclusion criteria myelofibrosis transformed into acute leukemia poor performance status with ecog 3 or more cardiac failure with ef or 50 currently or in the past even if corrected after treatment renal failure with creatininemia 130 µmol l or clearance 50ml min respiratory function altered with vital capacity 70 or forced expired volume 70 biological significant liver abnormalities asat or alat 2 x normal range bilirubin 1 5 x normal range hla matched donor available tutorship or curatorship unwilling or unable to comply with the protocol pregnant woman or breastfeeding contraindications to treosulfan o hypersensitivity to the active substance o active noncontrolled infectious disease o fanconi anaemia and other dna breakage repair disorders o administration of live vaccine contraindications or any circumstance that precludes the use of the drugs involved in the protocol especially thiotepa and fludarabine",
    "INTERVENTION": "investigational medicinal product treosulfan the investigational medicinal product will be used in conditioning regimen for haploidentical transplantation treosulfan which received euwide approval for toxicity reduced conditioning therapy prior to allogeneic haematopoietic stem cell transplantation on june 25 2019 will be provided by medac treosuflan in the conditioning regimen will be administered as followed 10 gr m2 per day at 4 3 and 2 iv route it will be used in combination with the standard association thiotepa 5 mg kg on day 6 fludarabine 30 mg m2 per day from day 5 to day 1 therefore thiotepa and fludarabine indissociable of treosulfan will be also considered as medicinal product comparator treatment na",
    "STATISTICS": "statistical analysis the analysis will be based on the intenttotreat basis that is including all patients whatever they were administered the treatment under study or not a sensitivity analysis will be performed in patients who will actually receive the graft only patient consent withdrawals with positive report of not using their data if any will be excluded baseline summary statistics namely percentages or median interquartile range iqr will be performed the right censored endpoint will be estimated using nonparametric methods kaplan meier curves and cumulative incidence curves will be considered in case of noninformative or informative censoring based on the logrank test or the gray test respectively adjustment on potential confounders will used the cox proportional hazards models model assumptions will be checked using a test for proportional hazards and spline smoothing of residuals for the loglinearity assumption statistical analyses will be performed on sas sas inc cary nc and r https www rproject org software packages",
    "DSMB": "trial will have a data safety monitoring board yes",
    "ACRONYM": "acronym fibraplo",
    "INVESTIGATOR": "coordinating investigator dr marie robin hôpital saintlouis aphp paris",
    "NUMBER OF INCLUSIONS": "number of subjects included 28",
    "SITES": "number of sites 22",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial industrial grant"
  },
  "SONIMEL": {
    "TITLE": "full title safety and efficacy of blood brain barrier bbb opening with implantable device sonocloud combined with nivolumab used alone or an association with ipilimumab in brain metastases from patients with malignant melanoma",
    "JUSTIFICATION": "scientific justification anti pd1 monoclonal antibodies nivolumab and pembrolizumab alone or in association with antictla4 ipilimumab are established as indisputable treatment of metastatic melanoma with unprecedented overall survival and are indicated for firstline treatment including patients with braf mutation given their high molecular weight their penetration in the brain sanctuary is uncertain and relies on disruption of the bbb which occurs occasionally sonocloud is an implantable device delivering low intensity pulsed ultrasound us along with systemic injection of an us resonator sonocloud demonstrated safe and efficient at repetitively opening the bbb we anticipate that bbb opening could help at increasing brain penetration of monoclonal antibodies and potentially boosting immunity in the brain this could translate in controlling brain disease with the same magnitude as for extracranial disease this would also open avenues for optimizing the treatment of brain metastases in combination with checkpoint inhibitors in many other cancers",
    "OBJECTIVE": "main objective and primary endpoint one single objective one single endpoint the main objective will be the determination of the most successful dose msd defined as the dose with the highest probability of bbb opening efficacy without toxicity directly related to the ultrasound emission primary endpoint success defined as grade 2 or 3 bbb opening disruption with pulsed us using the sonocloud system without toxicity related to the device assessed clinically and using brain mri dlt evaluated during the first 4 weeks of treatment for nivolumab alone and 6 week of treatment for nivolumab ipilimumab thus the primary endpoint will be the success defined as efficacy without toxicity during the first 4 weeks of treatment for nivolumab alone and 6 week of treatment for nivolumab ipilimumab secondary objectives and endpoints secondary objectives  clinical efficacy of nivolumab  ipilimumab in the context of bbb opening in the study population safety of nivolumab alone or combined to ipilimumab in the context of bbb opening",
    "DESIGN": "design of the study 21 patients treated at maximum considering that a maximum of 10 would withdraw from participating in the research a budget for 21 2 23 patients will be considered",
    "INCLUSION CRITERIA": "population of study participants advanced brain metastases melanoma patients age 18 years inclusion criteria  patients with histologically confirmed metastatic melanoma  patients must have recovered from all side effects of their most recent systemic or local treatment for metastatic melanoma grade 1  at least one measurable brain metastasis between 5mm and 35mm in diameter not previously treated with surgery and or radiosurgery and located less than 5 cm from the skull  patients may have received or not prior radiosurgery and or surgery for brain metastases if they have received prior local treatment they must have at least 1new rano and recist assessable brain metastases  braf status wild type or mutated and in that case previous treatment with braf inhibitor and mek inhibitor allowed  eastern cooperative oncology group ecog performance status ps 1  age 18 years  hemoglobin 10g dl  platelets 100000mm3",
    "EXCLUSION CRITERIA": "noninclusion criteria  ocular melanoma  symptomatic leptomeningeal involvement  symptomatic hemorrhagic brain metastases  symptoms of incoercible intracranial pressure patients receiving corticosteroids and patients presenting intermittent seizures can be enrolled if they have a stable dose of corticosteroids 30mg day corticotherapy and antiepileptic treatment since at least 2 weeks before enrolment  indication for urgent neurosurgery or radiotherapy  prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured or stage i untreated chronic lymphoid leukemia  known hiv infection and any ongoing infectious disease or significant background  concurrent administration of any anticancer therapies other than those administered in this study  treatment with any cytotoxic and or investigational drug antictla4 or targeted therapy 4 weeks or 5 halflives for targeted therapies or chemotherapy prior to day 1 of study  prior whole brain radiotherapy  pregnant or lactating women  patient with auto immune disease  contraindications to nivolumab alone or an association with ipilimumab as defined in spc https www vidal fr substances 24410 nivolumab  serious or uncontrolled medical disorders that in the opinion of the investigator may increase the risk associated with study participation or study drug administration impair the ability of the patient to receive protocol therapy or interfere with the interpretation of study results  allergy to iodine gadolinium lidocaine  contraindications to sonovue hypersensibility to sulfur hexafluoride recent acute coronary syndrome or unstable ischemic heart disease exclusion criteria  implantation of the sonocloud not possible according to neurosurgeon any patient morphological characteristics e g skin characteristics bone thickness other which from neurosurgeons opinion prevent implantation of the device or may impair the ability of the patient to receive treatment with sonocloud would be excluded",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis an adaptive bayesian doseescalation model continual reassessment method crm will be used the selected version of the crm is a modelbased design where the dose dlt relationship is modelled through a cumulative function corresponding to a oneparameter power model the parameter of which is sequentially estimated from the data via a bayesian estimation in this setting the mtd is a populationparameter and refers to the π 10th percentile of the dosetoxicity relationship a total of 3 us dose levels will be evaluated 0 78 0 9 and 1 03 mpa a minimum of three patients will be included at each dose level as of october 3 2022 3 patients were treated at level 1 0 78mpa and 1 patient was at level 2 0 9mpa no side effects or toxicity were observed very good tolerance since the crm design recommends that a new patient could be treated at the higher level 1 03mpa the patient n 5 will receive the 1 03mpa dose",
    "DSMB": "trial will have a data safety monitoring board yes",
    "ACRONYM": "acronym sonimel 01",
    "INVESTIGATOR": "coordinating investigator pr céleste lebbe service de dermatologie 2 hôpital saint louis 1 avenue claude vellefaux 75 010 paris tel 0142499590 fax 0142499078 email celeste lebbe aphp fr",
    "NUMBER OF INCLUSIONS": "",
    "SITES": "",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of monetary support phrc 2016"
  },
  "PARADISE": {
    "TITLE": "full title prospective randomized controlled trial of crohn s disease exclusion diet vs corticosteroids in adults and pediatric patients with active crohn s disease",
    "JUSTIFICATION": "",
    "OBJECTIVE": "main objective and primary endpoint main objective to assess whether cded is superior to corticosteroids in terms of endoscopic response in patients with mildly to moderately active luminal inflammatory cd primary endpoint endoscopic response at week 16 without corticosteroids or further therapeutic intervention assessed by a centralized pseudonymized and blinded double lecture panel of panenteric pillcam crohn s capsule pcc endoscopic response is defined by a decrease of at least 50 in the lewis score for patients with small bowel cd decrease of sescd of at least 50 in patients with colonic cd and both of these in patients with small bowel and colonic cd compared to baseline values secondary objectives and endpoints compare between the 2 arms of the trial  steroidfree clinical remission hbi 5 and response a decrease of at least 3 points in hbi  steroidfree clinical remission cdai 150 and response a decrease of at least 70 points in cdai  need for further therapeutic intervention i e steroids immunosuppressants new biologic or surgery  decrease of fecal calprotectin of at least 50 off steroids  fecal calprotectin of less than 250 µg g less than 100 µg g and less than 50 µg g  crp serum level  median hbi cdai calprotectin and crp  endoscopic remission as defined as lewis score 135 in the small bowel and or sescd 02 in the colon without further therapeutic intervention surgery biologics or dietary intervention  endoscopic response and remission graded by eliakim scores  segmental endoscopic response and remission  gut microbiota composition pcr 16s pcr 18s for fungi and protists metabolomics and shotgun metagenomics  compliance to corticosteroid treatment medication adherence report scale  compliance to cded o dietary habits questionnaires o 72h food diaries  body weight arterial pressure and fasting serum glucose  safety will be assessed by the adverse events either severe or not and the susar",
    "DESIGN": "design of the study this is a multicentre openlabel comparative randomized 2 1 controlled single blind superiority",
    "INCLUSION CRITERIA": "population of study participants patients with active crohn disease inclusion criteria  patients aged 16 to 70 years  with mild to moderate luminal active cd defined by a hbi of 5 to 16 involving the small bowel and or the colon  not treated with corticosteroids at baseline  patients either naïve or previously exposed to a maximum of two classes of biologics or currently receiving a biologic therapy and exposed to a maximum of two classes of biologic therapy including the current one  patent small bowel as assessed by the patency capsule  active endoscopic lesions as defined by lewis score 225 in the small bowel and or sescd 4 in the colon the eligibility of the patient will be determined by at least one central reader  informed consent to participate in this study  in patients from france and israel who are aged less than 18 parents informed consent to participate in this study parents agreement is not required in patients aged 16 to 18 in the netherlands  affiliation to social security or any health insurance",
    "EXCLUSION CRITERIA": "exclusion criteria  inability to follow the cded during 16 weeks  prior intolerance to corticosteroids  ongoing infections evolving virus diseases  live vaccines  psychotic state not controlled by treatment  arthritis or uveitis as main presenting symptoms  patients with severe and or predominant rectal or perianal disease  heavy smokers more than 10 cigarettes per day  infliximab adalimumab vedolizumab ustekinumab rizankizumab upadacitinib methotrexate or azathioprine initiated less than 3 months before inclusion in this trial  change in methotrexate azathioprine infliximab adalimumab vedolizumab upadactinib risankizumab or ustekinumab dosage less than 2 months before inclusion  severe pubertal delay tanner 1 or tanner 2 and or height velocity zscore 2 5 and or bone mineral density zscore hip or lumbar spine 2 5 if known  pregnant or lactating women  patients already included in a biomedical research other than an observational study e g registry cohort biobank persons deprived of their liberty by a judicial or administrative decision persons subject to psychiatric care under sections l 32121 and l 32131 and persons admitted to a health or social institution for purposes other than research l 11216 in france  present or past history of eating disorder including anorexia nervosa",
    "INTERVENTION": "comparator arm oral corticosteroids prednisolone or budesonide",
    "STATISTICS": "statistical analysis it will be based on the intenttotreat principle itt based on the available literature we hypothesize that 50 of patients will reach the primary endpoint in the cded arm versus 20 in the corticosteroid arm we plan to screen 140 patients to include 80 patients 54 will be randomized to cded and 26 to corticosteroids",
    "DSMB": "data safety monitoring board no because there is no expected safety issue raised by cded epidemiological and experimental studies have suggested that diet plays an important role in cd pathophysiology",
    "ACRONYM": "acronym reference paradise",
    "INVESTIGATOR": "coordinating investigator prof franck carbonnel aphp chu kremlinbicêtre service de gastroentérologie université paris saclay 78 rue du général leclerc 94275 le kremlinbicêtre cedex france franck carbonnel aphp fr",
    "NUMBER OF INCLUSIONS": "number of participants included 80 randomized about 140 screened",
    "SITES": "number of centres 17 in france israel and the netherlands",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources phrc nestlé gift of a patient"
  },
  "MARVEL": {
    "TITLE": "full title exploring venlafaxine pharmacokinetic variability by a phenotyping approach",
    "JUSTIFICATION": "scientific justification regarding the direct costs and the social value of depression the decision of an antidepressant treatment prescription must be optimized as much as possible the development of a personalized medicine in psychiatry may reduce treatment failure intolerance or resistance and hence burden and costs of affective disorders there is hope that biomarkers will be found to guide treatment selection it might be of decisive interest to be able to assess an individual s metabolism activity we propose here to explore the relationship between the activity of drugmetabolizing enzymes dme and transporters assessed by a phenotypic approach and the efficacy of antidepressants we will focus on venlafaxine v that provides a reasonable secondstep choice for patients with depression and is used extensively in psychiatric practice and the metabolism of which involves several cytochromes cyp p450 enzymes and the transporter pgp",
    "OBJECTIVE": "primary objective to study the correlation between the concentration of v and its metabolite odesmethylv v odv and drug metabolism variability assessed by a phenotypic approach secondary objectives to compare between responders and non responders as well as between patients with or without side effects  the cyp2c19 activity and the prevalence of each profile of metabolism  the cyp2d6 activity and the prevalence of each profile of metabolism  the cyp3a4 activity and the prevalence of of each profile of metabolism  the pgp activity and the prevalance of each profile of transport to study the correlation between v odv concentration dose and v odv concentration and antidepressant efficacy and tolerance criteria of assessment v odv concentration the cyp2c19 activity 5hydroxyomeprazole omeprazole at 2 hours and auc of the metabolic ratio 2 3 and 6 hours after 2 3 6 omeprazole oral administration the cyp2d6 activity dextrorphan dextromethorphan ratio two hours after dextromethorphan oral administration the cyp3a4 activity 1hydroxymidazolam midazolam ratio two hours after midazolam oral administration the pgp activity fexofenadine auc based on fexofenadine 2 3 6 concentrations at 2 3 and 6 hours after fexofenadine oral administration antidepressant efficacy madrs hamd qids antidepressant tolerance prisem fisber antidepressant observance mars circulating mrna and mirna transcripts allelic variations cyp2c19 2* and cyp2d6 4* and 5*",
    "DESIGN": "experimental design interventional study recherche biomédicale",
    "INCLUSION CRITERIA": "population involved patient with major depressive disorder and madrs 20 despite 4 weeks of v regardless of the dose inclusion criteria patient hospitalized or outpatient with major depressive disorder and madrs 20 at visit of selection patients non responders to v after 4 weeks of v regardless of the dose decision of the psychiatrist to increase the dose of v at visit of selection male and female age 18 years understanding of french language and able to give a written inform consent informed consent signed to participate to the study individuals covered by social security regimen",
    "EXCLUSION CRITERIA": "noninclusion criteria patients treated by more than one antidepressant other than mirtazapine or mianserine patients currently treated with one of the drug substrate of the cocktail and or by esomeprazole sensitivity or contraindication to any of the substrate drugs used current pregnancy desire to get pregnant or breastfeeding bipolar disorder and schizophrenia",
    "INTERVENTION": "challenge agents for the assessment of drugmetabolizing enzyme activity the patients will be given the cocktail probe drugs by oral route one time during the study a capsule of omeprazole 10mg 6 8 ml of an oral liquid formulation of dextrométhorphane bromhydrate tussidane 1 5mg ml syrup 1 mg of an injectable solution of midazolam for oral administration midazolam 1mg ml injectable solution a tablet of fexofenadine 120mg",
    "STATISTICS": "statistical analysis the statistical analysis will be performed once the sample size has been reached and all the end point measures available our hypothesis is that the prevalence of patients with a cyp2c19 um profile is twice as high in nonresponders in comparison with responders who have a cyp2c19 metabolic profile comparable to that of caucasians 20 to demonstrate that the prevalence is two fold that observed in nonresponders with a type i error at 0 05 and a statistical power of 80 the sample size is tabulated below according",
    "DSMB": "data safety monitoring board anticipated non",
    "ACRONYM": "acronym marvel",
    "INVESTIGATOR": "coordinating investigator frank bellivier department of psychiatry fernand widal hospital 200 rue du faubourg saint denis 75475 paris cedex 10 inserm umrs 1144 variabilité de réponse aux psychotropes universités paris descartes paris diderot tel 01 40 05 42 01",
    "NUMBER OF INCLUSIONS": "number of subjects chosen 205",
    "SITES": "number of centers 12 clinical centers in france 7 centers of clinical investigations in france 4 centers involved in biological analysis 3 in france and 1 in switzerland",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding source phrc aom 14562 and for dosages for the determination of phenotypes department of pharmacologytoxicology geneva"
  },
  "DREPA-RIC": {
    "TITLE": "full title a prospective multicenter trial comparing allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen with standard of care in adolescents and adults with severe sickle cell disease",
    "JUSTIFICATION": "scientific justification although the survival of children with sickle cell disease scd has dramatically improved over the last decades in the us and europe mortality remains high in adults moreover many children and most adults develop a chronic debilitating condition due to organ damage allogeneic hematopoietic stem cell transplantation hsct is currently the unique curative approach it allows the cure of more than 95 of children transplanted from a matched related donor mrd after a myeloablative conditioning regimen 1 2 to date few studies have addressed the role of hsct in scd adults due to the risk of graft versus host disease gvhd and to the toxicity expected in older patients with a higher risk of organ damage the development of safe nonmyeloablative conditioning regimens that allow stable mixed chimerism and avoid gvhd appears as an attractive option for hsct to cure adults with severe scd four groups have previously reported encouraging results in a total of 81 patients transplanted from matched related mobilized peripheral blood cells after a non myeloablative conditioning regimen alemtuzumab and low dose of total body irradiation tbi followed by posttransplant sirolimus these studies demonstrate a high scd free survival rate no death related to transplant 6 graft failures and no gvhd ninety two percent of these patients were cured with normalized hemoglobin levels resolution of hemolysis and stable hemoglobin a levels identical to the proportion observed in the donor 3 6 however outcome comparison of patients transplanted with patients not transplanted are lacking we design a prospective multicenter trial targeting patients over 15 years with severe scd and compare nonmyeloablative transplant when a matched related donor mrd is identified versus no hsct for patients lacking mrd",
    "OBJECTIVE": "main objective and primary endpoint the main objective is to assess the benefit of hsct on the 2 year event free survival calculated from inclusion compared to standard care the primary endpoint is the 2year event free survival an event is defined as a death from any cause b or an acute grade iiiv gvhd according to the magic consortium 2016 appendix 20 3 or a moderate or severe chronic gvhd according to the nih classification c or 3 hospitalizations for voc defined according to usual criteria d or one acs defined by usual clinical criteria and a pulmonary infiltrate on chest film and or thoracic computedtomography ct scan e or a stroke defined as a clinical event confirmed by an mri or a cerebral or cervical stenosis 25 in a new territory evaluated by mri and mra or apparition of a silent infarct f or increased of at least 10 of tricuspid regurgitation velocity confirmed by 2 echocardiographies performed with a delay of at least 3 months compared with pre inclusion value for patients with trv 2 7 at inclusion we hypothesize that the 2year event free survival will be of 80 after hsct versus 40 in the notransplant group secondary objectives and endpoints the secondary objectives compare in the both groups at 2 years overall survival total days requiring hospitalization after the first 5 months postinclusion acute complications of scd voc acs priapism stroke silent infarct cerebral or cervical stenosis on mra mri hemolytic index hematologic and biochemical parameters organ function kidney eyes heart lung liver bone grade iiiiv infectious complications need for transfusion from 6 months postinclusion alloimmunization rate iron overload chronic used of oral opioids nutritional involvement gonadic function and fertility quality of life anxiety and depression cost to evaluate in the transplant group chimerism engraftment gvhd patients free of sirolimus at 1 and 2 year posttransplant the secondary end points death number of days requiring hospitalization with exclusion of the 5 first months postinclusion clinical adverse events number of voc and acs requiring hospitalization number of hospitalization in intensive care unit number of priapism number of stroke",
    "DESIGN": "design of the study quasi experimental design phase 3 prospective controlled multicenter cohort study with 2 groups of patients defined by genetic randomization once the eligibility criteria and the informed consent have been obtained hla typing will be performed to identify potential hla mrd and define 2 groups group 1 exposed patients if an hla identical sibling is identified patients will receive hsct group 2 unexposed patients patients lacking an hla identical sibling will received the best standard care transplant arm  redcell exchange will be performed to reduce hemoglobin s levels to 30 or less during the 3 months preceding transplant",
    "INCLUSION CRITERIA": "population of study participants adolescents and young adults 1545 years inclusion criteria of patients scd patients ss sβ0 aged 15 to 45 years with at least one nonscd sibling 16 years from the same parental couple who presented at least one of the following criteria  2 voc requiring hospitalization over the last 2 years  at least 1 severe acs within the past 2 years defined as followed acs requiring red cell transfusion or hospitalization in intensive care unit or acs with pao2 60mmhg or arterial blood ph 7 35 or pac02 50mmhg or need more than 4 liters of 02 mn for reaching sat02 98  1 voc requiring hospitalization over the last 2 years and history of recurrent acs three or more  history of ischemic stroke or cerebral cervical arterial stenosis 25 or apparition of silent infarct in the last 2 years  pulmonary hypertension defined by mean pulmonary artery pressure 25 mmhg at rest determined by right heart catherization  osteonecrosis of at least 2 joints including one diagnosed in the past 2 years  sickle nephropathy estimated glomerular filtration rate by ckd epi formula 100 ml min 1 73m2 and persistant microalbuminuria microalbuminuria creatininuria ratio 10 mg mmol without other cause of nephropathy requiring treatment with hydroxyurea or chronic transfusion or already treated by hydroxyurea or transfusion program tp at inclusion for patients already receiving chronic transfusions for voc or acs not responding to hydroxyurea they will be eligible if they provided before the beginning of chronic transfusions at least  2 voc requiring hospitalization over the last 2 years  at least 1 severe acs within the past 2 years defined as followed acs requiring red cell transfusion or hospitalization in intensive care unit or acs with pac02 60mmhg or arterial blood ph 7 35 or pac02 inclusion criteria of donors age 16 to 60 years hb electrophoresis aa as or ac donor with usual clinical and biological eligibility criteria for gcsf mobilization and peripheral blood stem cell bone collection including legal viral serologies assessment authorizing the transplant being hla identical with the patient negative covid19 test at time of hsct mobilization in patient with several potential donors several matched sibling donor abo matched donor will be chosen in priority",
    "EXCLUSION CRITERIA": "exclusion criteria of patients performance status ecog scale 1 pulmonary function fev1 et fvc 50 of the theorical value post capillary and severe precapillary pulmonary hypertension with measured mean pulmonary artery pressure at rest 35 mmhg cardiac ejection fraction 45 estimated glomerular fraction rate gfr 50ml mn 1 73m2 conjugate bilirubin 50 µmole l cirrhosis alat 4n severe uncontrolled infection known hypersensitivity of alemtuzumab known hypersensitivity to murin proteins and to the following excipients disodium edetate polysorbate 80 potassium chloride potassium phosphate monobasic sodium chloride dibasic sodium phosphate water for injections positivity for hiv pregnancy or breastfeeding women alloimmunization or delayed hemolytic transfusion reaction precluding red cell transfusions previous solid organ transplant or hematopoietic stem cell transplant uncontrolled hypertension history of arterial dissection of the cervicocephalic arteries history of angina pectoris or myocardial infarction",
    "INTERVENTION": "comparator arm patients will receive the best standard care according to their situation and their previous treatment initiation of hydroxyurea continuation or optimization of the dose of hydroxyurea initiation or continuation of tp initiation of a new drug proved to improve scd and having authorization to use in france",
    "STATISTICS": "statistical analysis a single efficacy analysis is planned efs will be compared between two groups using logrank test and the effect of hsct assessed by hazard ratio using a cox model the primary endpoint is event free survival at 2 years calculated from inclusion event will be defined as followed a death from any cause b or an acute grade iiiv gvhd according to the magic consortium 2016 appendix 20 3 or a moderate or severe chronic gvhd according to the nih classification c or 3 hospitalizations for voc defined according to usual criteria d or one acs defined by usual clinical criteria and a pulmonary infiltrate on chest film and or thoracic computedtomography ct scan e or a stroke defined as a clinical event confirmed by an mri f or a cerebral or cervical stenosis 25 in a new territory evaluated by mri and mra g or increased of at least 10 of tricuspid regurgitation velocity confirmed by 2 echocardiographies performed with a delay of at least 3 months compared with pre inclusion value for patients with trv 2 7 at inclusion h or apparition of a silent infarct or a cerebral cervical stenosis 25 in a new territory or increase 25 of previous stenosis evaluated mri and mra event free survival at 2 years calculated from inclusion will also be described in the hsct group overall survival will be defined as the time between date of inclusion and death due to any cause or to date of last followup a propensity score matching analysis will be also performed as a sensitivity analysis to handle potential residual imbalances between arms in confounders a sequential analysis of tolerance data will be performed using bayesian methods we hypothesize that the 2year event free survival will be of 80 after hsct versus 40 in the notransplant group",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym dreparic",
    "INVESTIGATOR": "coordinating investigator dr nathalie dhedin hematology saint louis hospital aphp paris scientific director adult scientific director dr jean benoit arlet internal medicine georges pompidou hospital aphp paris pediatric scientific director dr corinne pondarre pediatric hematology chi créteil",
    "NUMBER OF INCLUSIONS": "number of participants included 78 patients",
    "SITES": "number of valued sites 37 centres 22 recruiting centres and 15 transplant centres some recruiting site also transplant patients",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of monetary support french ministry of health phrc n2017"
  },
  "PIPAC": {
    "TITLE": "full title pressurized intraperitoneal aerosol chemotherapy pipac in gastric carcinomatosis phase ii randomized study",
    "JUSTIFICATION": "scientific justification peritoneal metastasis is a common pattern in advanced gastric cancer leading to a terminal condition in a very short time whatever recent progress regarding systemic chemotherapy using multi drugs association median survival is limited to 6 months with altered quality of life qol after 4 months for all patients we postulated that a new innovative health technology for delivering intraperitoneal pressurized aerosol of chemotherapy doxorubicin and cisplatin during laparoscopy can transform that situation offering to double the survival with qol preservation interestingly pipac procedure is made to be applied repeatedly every 6 weeks  2 weeks this therapeutic strategy allows to improved ip drugs impregnation and maintained iv chemotherapy meanwhile our pipac estok 01 project is supported by the six main carcinomatosis national centers and should gather medical and surgical teams that daily support peritoneal carcinomatosis to demonstrate the efficacy of pipac procedure in gastric carcinomatosis and make a radical shift in management of these patients that will break with past strategies",
    "OBJECTIVE": "main objective and primary endpoint main objective of the clinical study the primary objective is to evaluate and compare 24 month progression freesurvival in patients with peritoneal carcinomatosis of gastric cancer treated either with iv chemotherapy and pressurized intraperitoneal aerosol chemotherapy pipac or with iv chemotherapy alone with preservation of quality of life primary endpoint the primary endpoint corresponds to the 24month progression freesurvival defined as the number of patients with no clinical or morphological sign of progression or death 24 months after the treatment secondary objectives and endpoints secondary objectives and assessment criteria patients related  the morbidity will be evaluated on postoperative day 30 by the clavien dindo classification i to v 17 and the comprehensive complication index ranging from 0 to 100 and calculated on a website https www assessurgery com about cci calculator 19  evaluation of treatmentrelated toxicity based on ct cae classification v5 0  postoperative pain measured using a numeric",
    "DESIGN": "design of the trial prospective multicenter randomized openlabel controlled parallelgroup phase ii clinical trial designed to evaluate the effects of pipac with doxorubicin and cisplatin on patients with gastric peritoneal metastasis and pci 8 scope of the trial peritoneal carcinomatosis of gastric cancer",
    "INCLUSION CRITERIA": "population of trial subjects major subjects with peritoneal carcinomatosis of gastric cancer inclusion criteria patients related 1 age 18 years 2 performance status who 2 3 white blood cells 3 500 mm3 neutrophils 1 500 mm3 platelets 100 000 mm3 4 creatinemia 1 5 mg dl and creatinine clearance 60 ml min and serum total bilirubin 2 mg dl 5 an acceptable nutritional condition with bmi 18 5 kg m2 and or albumin 30 g l and or pre albumin 110 mg l 6 effective contraception for patients of childbearing age 7 written consent obtained prior any act of the research 8 patient with social insurance disease related 9 patient having synchronous or metachronous peritoneal or ovarian metastasis pathologically proven of a gastric and or siewert iii adenocarcinoma cancer including adci adenocarcinoma with independent cells and or linitis 10 patients with or without primary gastric tumor can be included 11 pci peritoneal cancer index 8",
    "EXCLUSION CRITERIA": "exclusion criteria patients related 1 weight loss 20 of total body weight in the last",
    "INTERVENTION": "investigational medicinal product s intraperitoneal pressurized aerosol of chemotherapy of cisplatin 10 5 mg m2 and doxorubicin 2 1 mg m2 during laparoscopy were given for 30 min at 37 c and 12 mmhg at 6weeks  2 weeks intervals at least 3 successive pipac are scheduled by the protocol the patient will receive pipac procedure until progression toxicity or nonfeasibility of the procedure the research is opened by the sponsor only in centers that already practice the pipac procedure as part of the treatment the investigators who will be declared as part of this research will have to undergo training in the use of this new pipac procedure comparator treatment patient will receive standard poly chemotherapy proposed by the oncologist as eox epirubicin oxaliplatin and capecitabine ecx epirubicin cisplatin and capecitabine folfox folfiri ecf epirubicin cisplatin and fluorouracil or flot or any new standard validated during the study until progression or toxicity",
    "STATISTICS": "statistical analysis the 24month progression freesurvival will be estimated using kaplan meier estimator on the total sample and per arm estimation with 95 confidence intervals ci will be given test between survival curves will be performed using logrank test hazard ratio will be estimated using cox model sensitivity analyses will be performed considering per protocol population",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym pipac estok 01",
    "INVESTIGATOR": "coordinating investigator clarisse eveno puph digestive surgery department claude huriez hospital chu of lille",
    "NUMBER OF INCLUSIONS": "number of subjects included 94 patients 47 in each arm",
    "SITES": "number of sites 20 participating national centres",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial inca phrc k 2016"
  },
  "JAKAHDI": {
    "TITLE": "full title jak inhibitor in acquired hemophagocytic syndrome in the intensive care unit",
    "JUSTIFICATION": "scientific justification hemophagocytic syndrome hs is a rare condition that can be responsible for severe organ failure therapeutic guidelines are mainly based on observational studies and expert opinions no therapeutic advance has been developed for years explaining why mortality in hs remains high icu mortality ranging from 40 to 70 if etoposide remains the gold standard in critically ill hs patients nearly 20 of patients are refractory to this therapy treatment escalation is common most often requiring the administration of intensive treatments generating high toxicity ruxolitinib is the first approved jak inhibitor it has been associated with improvement of hs manifestations and survival in a preclinical murine model data in humans are scarce but promising",
    "OBJECTIVE": "main objective and primary endpoint we aim to demonstrate that ruxolitinib in association with standard of care may reverse organ failure as represented by sofa score better than standard of care alone in critically ill patients with acquired hs the primary end point will be survival with a decrease in sofa score 3 points at day 7 secondary objectives and endpoints  to demonstrate that ruxolitinib may improve overall survival in hs critically ill patients  to demonstrate that ruxolitinib may reverse clinical temperature sofa score and biological ferritin level cd25 soluble receptor dosage fibrinogen level triglycerides level hemoglobin level white blood cells count platelets count manifestations related to hs  to analyse the impact of ruxolitinib on biological inflammatory markers il2 il6 il10 il12 gmcsf ifn gamma tnf alpha  to demonstrate the safety of ruxolitinib in critically ill hs patients",
    "DESIGN": "design of the study this will be a multicenter national uncontrolled phase ii trial based on a fleming 2stage design",
    "INCLUSION CRITERIA": "population of study participants adult patients older than 18 years inclusion criteria  adult patients older than 18 years  acquired hemophagocytic syndrome regardless of etiology defined by the presence of 5 or 6 hlh2004 criteria or hscore 200  admission in the icu  need for symptomatic treatment of hs in relation with organ failure as defined by sofa score 4  informed consent signed by the patient or informed consent signed by a family members trustworthy person if his condition does not allow him to express his consent in written as per l11116",
    "EXCLUSION CRITERIA": "exclusion criteria  moribund defined by a life expectancy 48 hours  pregnant or lactating patients women of childbearing potential must have a negative urine or blood human chorionic gonadotropin pregnancy test prior to trial entry  no affiliation to health insurance  known hypersensitivity to ruxolitinib  lactose intolerance  hypersensitivity to cellulose microcrystalline magnesium stearate silica colloidal anhydrous sodium starch glycolate type a povidone k30 hydroxypropylcellulose 300 to 600 cps  preexisting decisions of withholding withdrawing care  history of progressive multifocal leukoencephalopathy  uncontrolled cutaneous cancer  persons under psychiatric care that would impede understanding of informed consent and optimal treatment and followup  adults subject to a legal protection measure guardianship curatorship and safeguard of justice  patients deprived of their liberty by a judicial or administrative decision  participation in another interventional research",
    "INTERVENTION": "investigational medicinal product s patients will receive oral ruxolitinib twice a day 10 mg x 2 during 28 days in association with standard of care in hs comparator treatment none",
    "STATISTICS": "statistical analysis based on the 2stage fleming design an interim analysis will be performed once day 7 status of the 21th consecutively enrolled patient has been observed terminal analysis based on the intentiontotreat population will be performed once all patients have been recruited unless early stopping",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference jakahdi",
    "INVESTIGATOR": "coordinating investigator dr sandrine valade scientific director dr eric mariotte",
    "NUMBER OF INCLUSIONS": "number of participants included 42 maximal sample size",
    "SITES": "number of centres 9",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources ministry of health"
  },
  "METIMGAST": {
    "TITLE": "full title phase ii trial to evaluate the combination of capmatinib spartalizumab in advanced oesogastric adenocarcinoma",
    "JUSTIFICATION": "scientific justification oesoastric advanced adenocarcinoma have a poor prognosis without improvement in the last decades recently immunotherapy with antipd1 antibodies provides encouraging results on a subset of patients capmatinib a met inhibitor shown imunomodulatory effect and a synergy with spartalizumab a pd1 inhibitor this combination is currently evaluated in the treatment of hepatocellular carcinoma whatever met expression",
    "OBJECTIVE": "main objective and primary endpoint to evaluate the tumor response to the regimen at 6 months after inclusion the overall response rate orr will be assessed by imaging every 9 weeks and will be defined as the proportion of patients with at least one objective tumour response complete or partial according to recist v1 1 criteria within 6 months secondary objectives and endpoints  to evaluate the safety of the regimen during the first and second cycles of administration up to day 42 d42 cf chap 4 1 2  to evaluate the safety and tolerability of the regimen during the whole course of treatment for all kind of toxicities and up to 2 years for immunotherapyrelated toxicity cf chap 10 3 2  to characterize the tumor response to the regimen duration time to response  to estimate the progression free survival up to 2 years after inclusion  to estimate the overall survival up to 2 years after inclusion  according to the results of interim analysis to evaluate tolerance and efficacy of spartalizumab monotherapy in patient with nonamplified met tumor ancillary studies",
    "DESIGN": "design of the study multicenter singlearm phase ii trial with 2 cohorts according met amplification level cohort 1 tumor without met amplification 6 copies cohort 2 tumor with met amplification 6 copies treatment capmatinib 400 mg mgbid spartalizumab300 mg q3w for a maximum of 12 months or until progression patient s refusal or unacceptable toxicity for the cohort 1 interim analysis for the primary endpoint on the first 30 evaluable enrolled patients the rules for stopping or continuing the trial are specified in table 1 of paragraph 12 1",
    "INCLUSION CRITERIA": "population of study participants patients with advanced oesogastric adenocarcinoma that have received at least one previous chemotherapy line with platinium salt and fluoropyrimidin and with a documented progression during or after chemotherapy inclusion criteria  histologically or cytologically documented locally advanced or metastatic oesogastric adenocarcinoma  unresectable tumor  patients must have received at least one prior systemic chemotherapy based on platinium salt and fluoropyrimidine with documented progression during or after chemotherapy  patients must have received trastuzumab in case of her2 positive tumor her2 or her2 and fish or sish  determination of tumor met amplification by fish available  ecog performance status 1  measurable tumoral disease according to recist 1 1 criteria  patients must be willing and able to swallow and retain oral medication  age 18 years  women of childbearing potential and males who are sexually active must agree to follow instructions for method s of contraception for the duration of study treatments with capmatinib and spartalizumab until 7 days after the last dose of capmatinib and 150 days after the last dose of spartalizumab  consent to participate in the trial after information  affiliated to a social security system",
    "EXCLUSION CRITERIA": "exclusion criteria  previous treatment with immunotherapy or met inhibitor  impossibility to take oral medication  persistent toxicities related to prior treatment of grade greater than 1 except for alopecia any grade and grade 2 neuropathy related to previous treatment with platinium salt  presence or history of another malignant disease that has been diagnosed and or required therapy within the past 3 years exceptions to this exclusion include completely resected basal cell and squamous cell skin cancers and completely resected carcinoma in situ of any type  use of any live vaccines within 4 weeks of initiation of study treatment  history of severe hypersensitivity reactions to other monoclonal antibodies mabs  history or current interstitial lung disease or non infectious pneumonitis  active autoimmune disease or a documented history of autoimmune disease patients with vitiligo controlled type i diabetes mellitus on stable insulin dose residual autoimmunerelated hypothyroidism only requiring hormone replacement or psoriasis not requiring systemic treatment are permitted  allogenic bone marrow or solid organ transplant  uncontrolled active infection  human immunodeficiency virus hiv infection  untreated active hepatitis b infection hbsag positive patients with active hepatitis b hbsag positive may be enrolled provided viral load hbv dna at screening is 100 ui ml patients may receive antiviral treatment with lamivudine tenofovir entecavir or other antiviral agents before the initiation of study treatment to suppress viral replication  untreated active hepatitis c hcv rna positive patients that achieved a sustained virological response after antiviral treatment and show absence of detectable hcv rna 6 months after cessation of antiviral treatment are eligible  untreated or symptomatic central nervous system cns lesion however patients are eligible if a all known cns lesions have been treated with radiotherapy or surgery and b patient remained without evidence of cns disease progression 4 weeks after treatment and c patients must be off corticosteroid therapy for 2 weeks  clinically significant uncontrolled heart diseases  recent acute coronary syndrome or unstable ischemic heart disease  congestive heart failure class iii or iv as defined by new york heart association  long qt syndrome 480 ms in women and 470 ms in men family history of idiopathic sudden death or congenital long qt syndrome",
    "INTERVENTION": "investigational medicinal product s capmatinib 400 mg bid spartalizumab 300 mg q3w for a maximum of 12 months or until progression patient s refusal or unacceptable toxicity comparator treatment not applicable",
    "STATISTICS": "statistical analysis two cohorts will be constituted  cohort 1 to enrol patients with no met amplification 6 copies specifically a total of 81 patients will ensure 90 power with a 5 type i error rate to detect a 30 response rate compared to reference 15 including an interim analysis after 30 patients have been included with a futility stopping rule using a bayesian optimal timeto event phase ii design lin r et al jnci 2020 in case the trial is terminated early for futility inclusions will continue but spartalizumab monotherapy for 51 additional patients in cohort 1 total 81 in that case this sample of 50 patients with spartalizumab monotherapy will allow to detect 20 response rate in patients under monotherapy against 8 as unacceptable with 80 power and a 5 type i error rate using a binomial exact comparison  cohort 2 to enrol patient with met amplification 6 copie for exploratory purpose only the enrolment in cohort 2 will be ongoing until cohort 1 is completed and for a maximum of 9 patients a sequential continuous toxicity montoring will be conducted across both cohorts ivanova et al clin invest 2015 endpoints will be described with count and percentage for categorical endpoints toxicity aes and with mean median 95 confidence interval or 95 credibility",
    "DSMB": "study will have a data safety monitoring board a data safety monitoring board will meet every 6 months for the duration of the study and may be consulted at any time by the vigilance sector or the scientific committee through drci s promotion sector",
    "ACRONYM": "acronym reference metimgast",
    "INVESTIGATOR": "coordinating investigator pr thomas aparicio hôpital saint louis paris scientific director if applicable na",
    "NUMBER OF INCLUSIONS": "number of participants included 90",
    "SITES": "number of centres 10 clinical centers of 7 public hospitals or institute located in france  hôpital saint louis paris gastroenterology and digestive oncology department clipp and cic  centre léon bérard lyon medical oncology clipp  centre georges françois leclerc dijon medical oncology clipp and unité de phase précoce  institut gustave roussy villejuif digestive oncology clipp  institut universitaire du cancer toulouse medical oncology clipp  hôpital haut levêque bordeaux hepato gastroenterology and unité de recherche clinique  centre hospitalier régional universitaire jean minjoz de besançon medical oncology",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources inca and novartis"
  },
  "RUBI": {
    "TITLE": "full title a multicenter randomized multiarm trial comparing the efficacy and safety of adalimumab anakinra and tocilizumab in subjects with noninfectious refractory uveitis",
    "JUSTIFICATION": "scientific justification rubi is the first prospective randomized head to head study comparing adalimumab to either anakinra or tocilizumab in refractory niu there is no firm evidence or randomized controlled trials directly addressing the best biologic agent in severe and refractory niu niu can cause devastating visual loss and up to 20 of legal blindness corticosteroids and immunosuppressants failed to demonstrate sustainable remission over 70 of refractory relapsing severe uveitis the incidence of blindness in niu has been dramatically reduced in the recent years with the use of biologics raising the question of whether these compounds should be used earlier in the treatment of severe non infectious uveitis contrasting with immunosuppressors biotherapies act rapidly and are highly effective in steroid s sparing thus preventing occurrence of cataract and or glaucoma despite a strong rationale these compounds are not yet approved in uveitis which guarantees the innovative nature of this study that aims selecting or dropping any arm when evidence of efficacy already exists",
    "OBJECTIVE": "primary objective and assessment criterion primary objective to evaluate the efficacy of adalimumab 80mg then 40mg 14 days compared to anakinra 100mg day and tocilizumab 162mg 7 days in subjects with refractory noninfectious intermediate posterior or pan uveitis niu and with a prednisone dose 0 1 mg kg day of prednisone or equivalent oral corticosteroid at week 16 primary endpoint efficacy measured by the percentage of patients with at least 2step reduction in vitreous haze according to miami 9step scale and with a dose 0 1 mg kg day of prednisone or equivalent oral corticosteroid at w16 secondary objectives and assessment criteria secondary objectives to evaluate the change in best corrected visual acuity bcva to evaluate the safety of adalimumab anakinra and tocilizumab in patients with niu to evaluate the change in macular edema",
    "DESIGN": "experimental design this is a prospective phase ii clinical trial multicenter multiarm randomized 1 1 1 clinical trial comparing the efficacy and safety of adalimumab anakinra and tocilizumab in subjects with active and refractory noninfectious intermediate posterior or panuveitis oral corticosteroids should be at a stable dose 30 days prior to the first study drug administration on day 0 all systemic immunosuppressants must have been discontinued 30 days prior to the first study drug administration on day 0 patients will have access to oral corticosteroids if needed before day 0",
    "INCLUSION CRITERIA": "population involved adult patients with active and refractory noninfectious uveitis niu 1 active disease either the presence of vh 4 on the miami 9step scale and or macular edema crt 300 microns and or other signs of intraocular inflammation eg perivascular sheathing of retinal vessels or leakage of retinal vessel on fa 2 recently active disease evidence of activity within the 3 months prior to inclusion visit as per vh 4 on the miami 9step scale or vh 1 according to sun classification and or macular edema crt 300 microns and or other signs of intraocular inflammation e g perivascular sheathing of retinal vessels or leakage of retinal vessels on fa the activity status active disease or recently active disease has to be confirmed for all patients before the randomization by the reading center evaluation of vh oct and fa assessments inclusion criteria the eligibility criteria will be checked at the selection visit which takes place four weeks maximum prior to inclusion visit and at the inclusion randomization visit adult patients meeting the following criteria may be included in the study 1 provide written informed consent prior to the performance of any studyspecific procedures 2 diagnosis of noninfectious intermediate posterior or panuveitis in at least one eye fulfilling the international study group classification criteria standardization of uveitis nomenclature sun criteria of posterior or pan uveitis confirmed by documented medical history 3 currently uncontrolled uveitic disease uncontrolled uveitic disease is defined as fulfilling 1 of the two following criteria within 4 weeks prior to inclusion a active inflammatory chorioretinal and or inflammatory retinal vascular lesions and or macular edema crt 300 microns or b vitreous haze grade 4 on the miami 9step scale or vh 1 according to sun nei classification 4 a patient who are receiving prednisone 10 mg day and 80mg day or equivalent dose of another corticosteroid at stable dose 30 days prior to the first study drug administration on day 0 and who received at least 1 other systemic immunosuppressant all systemic immunosuppressants must have been discontinued 30 days prior to the first study drug administration on day 0 or b patient who received ifn all systemic immunosuppressants must have been discontinued 30 days prior to the first study drug administration on day 0 or c to be intolerant to immunosuppressant 5 best corrected visual acuity bcva by etdrs to 20 400 in either eye 6 stable dose for two weeks prior to inclusion of topical corticosteroids and or nsaids 7 male or female age 18 years at inclusion 8 weight 40 120 kg 88 2 264 lbs at inclusion 9 chest xray or thoracic ct scan results posteroanterior and lateral within 12 weeks prior to inclusion with no evidence of active tuberculosis active infection or malignancy 10 for female subjects of childbearing age a negative serum or urine pregnancy test 11 for subjects with reproductive potential a willingness to use contraceptive measures adequate to prevent the subject or the subject s partner from becoming pregnant during the study and 3 and 5 months after stopping therapy for roactemra and adalimumab",
    "EXCLUSION CRITERIA": "noninclusion criteria subjects will not be included in the study if they meet any of the following criteria 1 infectious uveitis masquerade syndromes idiopathic uveitis is permitted 2 isolated anterior uveitis 3 presence of cataract or posterior capsular opacification so severe that an assessment of the posterior segment of either eye is inadequate or impossible 4 contraindication to mydriasis in either eye or presence of posterior synechiae in the study eye such that mydriasis is inadequate for posterior segment examination 5 intraocular pressure 25mmhg by goldmann tonometry or advanced glaucoma in either eye 6 monocular patient 7 active tuberculosis 8 known positive syphilis serology hiv antibody hepatitis b surface antigen and or antinucleocapsid antibody of hepatitis b virus and or hepatitis c virus within 1 month prior to inclusion 9 history of malignancy within 5 years prior to inclusion other than",
    "INTERVENTION": "treatment being tested eligible patients with active and refractory niu will randomized at 1 1 1 ratio between arm 1 adalimumab 80mg then 40mg 14 days subcutaneously n 40 for 16 weeks arm 2 anakinra 100 mg day subcutaneously n 40 for 16 weeks arm 3 tocilizumab 162 mg 7 days subcutaneously n 40 for 16 weeks the three treatment groups will receive the same corticosteroid regimen all patients with niu will receive oral prednisone 0 5 mg kg day with a maximum of 40 mg day of prednisone or equivalence the following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive  0 5 mg kg day of prednisone until week 4",
    "STATISTICS": "statistical analysis we will use a bayesian multiarm multistage mams design that aim at comparing several new treatments multiarm in order to select or drop any treatment arm to move forward when such evidence already exists based on interim analyses the randomization will be stratified by retinal vasculitis macular oedema and underlying disease at randomization the patient will be under treatment with prednisone as single therapy",
    "DSMB": "data safety monitoring board anticipated yes",
    "ACRONYM": "acronym rubi refractory uveitis biotherapies",
    "INVESTIGATOR": "coordinating investigator pr david saadoun centre national de référence des maladies autoimmunes et systémiques rares department of internal medicine and clinical immunology hospital pitie salpetriere tel 0142178088 email david saadoun psl aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects chosen 120",
    "SITES": "number of centres 37 departments of 17 french public hospitals",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding source phrc 2015"
  },
  "EFRAIM-II": {
    "TITLE": "full title empirical steroids and or antifungals in immunocompromised patients with acute respiratory failure from undetermined etiology a multicenter doubleblind randomized controlled trial",
    "JUSTIFICATION": "scientific justification acute respiratory failure arf is the leading reason of icu admission in immunocompromised patients failure to identify the arf etiology is associated with increased mechanical ventilation and mortality rates this was confirmed in the large efraim 1 study published in 2017 where undetermined arf etiology affected 609 1611 38 patients at day 3 402 25 patients at day 7 and 199 12 3 patients overall and was associated with a case fatality of 55 vs 40 in other patients in lung biopsy autopsy findings from these patients invasive fungal infection steroid sensitive affections organized pneumonia non infectious interstitial involvement drugrelated pulmonary toxicity and lung infiltration by the underlying disease lymphoma carcinomatous lymphangitis systemic vasculitis connective tissue diseases etc were the leading etiologies no study has evaluated survival benefits from empirical steroids and or antifungals in immunocompromised patients with arf from undetermined etiology",
    "OBJECTIVE": "main objective and primary endpoint main objective to reduce the 90day mortality in immunocompromised patients with arf from undetermined etiology at day3 the intervention would evaluate the impact of steroids isavuconazole for 14 days or until icu discharge primary endpoint mortality at day 90 secondary objectives and endpoints the secondary study objectives are to evaluate  how early empirical therapy can affect icu hospital and day28 mortality  whether steroids increase the proportion of patients with icu acquired microbiologically documented bacterial infections within 3 months following randomization  the proportion of patients with invasive fungal",
    "DESIGN": "design of the study multicenter doubleblind randomized controlled trial based on a 2x2 factorial design",
    "INCLUSION CRITERIA": "population of study participants in immunecompromised patients with acute respiratory failure arf from undetermined etiology either intervention steroids and or antifungals will be associated with improved day90 survival acute respiratory failure arf is the leading reason of icu admission in immunocompromised patients admission inclusion criteria 1 age 18 years and 90 years 2 a immunosuppressive drug b solid organ transplant c solid tumor d hematological malignancies e primary immune deficiency 3 icu admission for acute respiratory failure as defined by a respiratory distress with tachypnea respiratory rate 30 min b cyanosis c laboured breathing d need for more than 6l of",
    "EXCLUSION CRITERIA": "exclusion criteria 1 patient who improved enough to be discharged from the icu before inclusion 2 documented invasive fungal infection requiring antifungal therapy 3 patient needing or receiving prophylactic or empirical antifungal treatment for clinical care 4 patient receiving corticoid therapy 5 palliative care with comfort measures only do not intubate dni and do not resuscitate dnr patients can be included 6 pregnant or breastfeeding 7 no social security coverage 8 known hypersensitivity to isavuconazole or to any of excipients of cresemba specialty 9 treatment with ketoconazole ritonavir or any cyp3a4 5 inductor 10 short qt syndrome and or patient with a family history of short qt syndrome 11 liver insufficiency any stage 12 moribund patients 13 participation in another interventional research on acute respiratory failure 14 person deprived of liberty 15 person subject of psychiatric care 16 patient under enforced hospitalization 17 adults under legal protection or unable to give their consent 18 isolated hi",
    "INTERVENTION": "investigational medicinal products methylprednisolone will be given once a day at a dose of 2 mg kg day for three days as recommended in fibrosing pneumonitis in deeply hypoxemic patients as of day 4 the daily dose will be tapered to 1 mg kg day until day 7 followed by 0 5 mg kg day from day 8 to day 14 isavuconazole will be given at a dose of 200 mg every 8 hours for 2 days 6 administrations and then once daily until day 14 or icu discharge which event occurs first patients of one of the arms will receive isavuconazole and methylprednisolone whith an established interaction the investigator must check the smpc comparator treatment placebo methylprednisolone and placebo isavuconazole",
    "STATISTICS": "statistical analysis an interim analysis will be performed after the recruitment of 120 patients or after 50 day90 deaths whichever will occur first",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference efraimii",
    "INVESTIGATOR": "coordinating investigator prof elie azoulay service de réanimation médicale hôpital saint louis paris france office phone 33 0 1 42 49 34 21 fax 33 0 1 42 49 94 26 email elie azoulay aphp fr",
    "NUMBER OF INCLUSIONS": "number of participants included 420",
    "SITES": "number of centers 19 centers in france",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources phrcn 2018"
  },
  "UVB": {
    "TITLE": "full title multicenter randomized prospective trial comparing the efficacy and safety of adalimumab to that of tocilizumab in severe uveitis of behçet s disease",
    "JUSTIFICATION": "scientific justification uvb is the first randomized prospective head to head study comparing adalimumab to tocilizumab in sight threatening uveitis of bd antitnf has been used for bd uveitis for 15 years the incidence of blindness in bd has been dramatically reduced in the recent years with the use of biologics there is no firm evidence or randomized controlled trials directly addressing the best induction therapy in severe bd uveitis bd uveitis is considered as the most devastating inflammatory ocular disease risk of visual loss reaches 25 at 5 years and 80 of patients have a bilateral involvement contrasting with immunosuppressors or interferonalpha biotherapies act rapidly and are highly effective in steroid s sparing thus preventing occurrence of cataract and or glaucoma however antitnfα failed to demonstrate sustainable complete remission over 50 of severe sight threatening uveitis there is little published information on use of biologics other than antitnf for severe bd uveitis tocilizumab has been used with success in severe and or resistant cases and is one of the most promising biologics in bd il6 expression correlates with bd activity and other immunological data provide a strong rationale for targeting bd with tocilizumab despite a strong rationale these compounds are not yet approved in bd which guarantees the innovative nature of this study that aims selecting or dropping any arm when evidence of efficacy already exists",
    "OBJECTIVE": "main objective and primary endpoint to assess the benefit of tocilizumab comparatively to that of adalimumab in sightthreatening behçet s disease uveitis at week 16 primary endpoint efficacy will be defined by a complete remission of ocular involvement complete resolution of retinal vasculitis and or macular edema with prednisone or prednisolone only if prednisone is out of stock in the market lower or equal to 5 mg day at week 16 after randomization secondary objectives and endpoints 1 to estimate and compare the change in best corrected visual acuity bcva 2 time to complete remission at week 4 8 12 24 36 and 48",
    "DESIGN": "design of the study bayesian design for phase ii randomized clinical trial that aims at comparing a new treatment to a reference based on a binary end point which offers greater flexibility and simplicity of inference for the monitoring of patient safety and evidence of efficacy in small randomized trials",
    "INCLUSION CRITERIA": "population of study participants adult patients with sightthreatening behçet s disease associated uveitis inclusion criteria 1 age 18 at inclusion 2 provide written informed consent prior to the performance of any studyspecific procedures 3 diagnosis of behçet s disease according to the international criteria for behçet s disease icbd see appendix 18 2 or history of aphtosis 4 diagnosis of noninfectious intermediate posterior or panuveitis in at least one eye fulfilling the international study group classification criteria standardization of uveitis nomenclature sun criteria of posterior or pan uveitis 5 sight threatening uveitis defined according to the validated international definition as 2 lines of drop in visual acuity on a 10 10 scale and or retinal inflammation macular oedema and or retinal vasculitis 6 chest xray posteroanterior and lateral or ctscanner results within 12 weeks prior to inclusion with no evidence of active tuberculosis active infection or malignancy 7 for female subjects of childbearing potential premenopausal female capable of becoming pregnant a negative serum pregnancy test plasmatic or urinary 8 for subjects with reproductive potential a willingness to use contraceptive measures adequate to prevent the subject or the subject s partner from becoming pregnant during the study and 3 and 5 months after stopping therapy for tocilizumab and adalimumab respectively birth control methods which may be considered as highly effective methods that can achieve a failure rate of less than 1 per year when used consistently and correctly are considered as highly effective birth control methods according to ctfg recommendations such methods include for female subjects",
    "EXCLUSION CRITERIA": "non inclusion criteria 1 infectious uveitis masquerade syndromes or uveitis due to causes other than bd uveitis 2 active tuberculosis or history of untreated tuberculosis and or severe infection 3 positive hiv antibody and or positive hepatitis b surface antigen and or positive hepatitis c rna results obtained within 1 month prior to inclusion 4 history of malignancy within 5 years prior to inclusion other than carcinoma in situ of the cervix nonmetastatic squamous or basal cell carcinoma of the skin 5 history of severe allergic or anaphylactic reactions to monoclonal antibodies 6 history of multiple sclerosis and or demyelinating disorder 7 hypersensitivity to the active substance or an excipient of the imp or the auxiliary medicine 8 active or suspected ocular infection 9 active or suspected systemic infection 10 history of intestinal ulceration or diverticulitis 11 known porphyria",
    "INTERVENTION": "investigational medicinal product s after the collection of their free and informed consent eligible patients with sight threatening behçet s disease uveitis will be randomized into one of 2 groups at the randomization visit d0 arm a adalimumab 80 mg at d0 then 40 mg subcutaneous at week 1 3 5 7 9 11 13 and 15 arm b tocilizumab 162 mg subcutaneous each week for 15 weeks comparator treatment not applicable",
    "STATISTICS": "statistical analysis the experimental design is an open multicenter randomized clinical trial stratified on the characteristics of the initial uveitis in behçet s disease retinal inflammation retinal vascularitis and or macular edema and according to the diagnosis newly diagnosed or relapsing disease with evaluation of the primary assessment criteria at 16 weeks the primary assessment criteria will be reviewed by a scientific committee blinded of the randomization the rct will use a bayesian design for phase ii randomized national multicenter clinical trial that aims at comparing a new treatment to a reference based on a binary endpoint i e complete remission at week 16 which offers greater flexibility and simplicity of inference to the monitoring for patient safety and evidence of efficacy of small randomized trials it will use a betabinomial model with a noninformative prior berry 2006 the posterior probability that the remission rate is at least 0 65 will be estimated in both arms and the probability that the rate of remission in arm b is above that in arm a will be computed with b indicating the tocilizumab group and a the adalimumab group we will use a bayesian inference framework where 𝜋 𝑃 𝑌 1 𝐴 𝐴 denotes the probability of remission in the arm a after inclusion of n a patient in arm a and y complete remission observed using a beta a be 𝑎 𝑏 prior for 𝜋 the posterior probability of 𝜋 is still a beta 𝐴 𝐴 𝐴 𝐴 distribution given by be 𝑎 𝑦 𝑏 𝑛 𝑦 due to the natural conjugate 𝐴 𝐴 𝐴 𝐴 𝐴 property of the beta family for binomial sampling in our setting the efficacy of the drug in arm a will be first assessed by comparison to some historical minimal value of interest sometimes called the minimum required treatment remission rate it has been set at 0 65 in this trial thus we will compute 𝑃 𝜋 0 65 𝑦 𝑛 𝐴 𝐴 𝐴 similar analyses will be performed in arm b",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym uvb treatment of uveitis in behçet s diseases with biologics",
    "INVESTIGATOR": "coordinating investigator pr bahram bodaghi department of ophthalmology centre national de référence des uvéites centre national de référence des maladies autoinflammatoires et de l amylose inflammatoire hospital pitie salpetriere tel 01 42 16 37 28 email bahram bodaghi aphp fr scientific director pr david saadoun department of internal medicine and clinical immunology centre national de référence des maladies autoimmunes systémiques rares centre national de référence des maladies autoinflammatoires et de l amylose inflammatoire pitie salpetrière hospital 43 boulevard de l hôpital 75013 paris tel 01 42 17 80 88 email david saadoun aphp fr",
    "NUMBER OF INCLUSIONS": "number of participants included 60 patients 30 patients in each arm",
    "SITES": "number of sites multicenter national study including 26 centers",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial phrc national 2019  ministère des solidarités et de la santé"
  },
  "MSC-AT-SSC": {
    "TITLE": "full title phase i ii randomized clinical trial of allogeneic adipose tissuederived mesenchymal stromal cells systemic infusion in severe systemic sclerosis",
    "JUSTIFICATION": "scientific justification systemic sclerosis ssc is a rare severe and chronic systemic autoimmune disease ad characterized by vasculopathy immune dysregulation and fibrosis leading to multiorgan dysfunction primarily skin lungs heart gastrointestinal tract and kidneys with high morbidity and mortality altered healthrelated quality of life all at high cost for patients and society treatment are mostly symptomatic and only autologous hematopoietic stem cell transplantation ahsct has shown long term improvement in overall and eventfree survival with diseasemodifying properties however ahsct is contraindicated in case of advanced visceral involvement and in eligible patients it is still associated with risk of toxicity there is an urgent need to identify safe and effective treatments for severe ssc mesenchymal stromal cells msc are multipotent cells which carry immunomodulatory proangiogenic and anti fibrotic properties that can target ssc pathogenesis and its clinical manifestations the increasing use of msc harvested from bone marrow msc m adipose tissue msc at or umbilical cord msc uc in a variety of indications provides consistent evidence supporting their safety in humans the efficacy of msc m intravenous iv injection for treating acute graft versus host disease led to their marketing approval in 2012 and msc at alofisel were approved for severe crohn s fistula in 2018 msc represent a promising therapeutic approach for ssc we have previously a shown diseasespecific abnormalities in msc m from ssc patients providing strong rationale to use allogeneic msc to treat ssc patients b published the first phase i ii dose escalation trial using allogenic msc m infusion in 20 severe ssc patients clinicaltrials gov nct02213705 phrc aom 11250 with no safety issues significant improvement in skin fibrosis at 3 to 6 months after infusion which appeared lower thereafter thereby supporting the need for repeated infusions",
    "OBJECTIVE": "main objective and primary endpoint main objective to evaluate the safety one month after allogeneic 2x106 msc at kg intravenous administration once or twice at 3 months interval m0 m3 in severe ssc patients primary endpoint the rate of treatmentrelated severe adverse events sae defined as adverse events ae of grade equal or above 3 using the nci common terminology criteria for adverse events ctcae v5 0 classification at one month after each infusion m1 m4 all adverse events will be adjudicated by a data and safety monitoring committee secondary objectives and endpoints secondary objectives  safety during the infusion within the first 24 hours of infusion and during all study followup  efficacy signals to inform future studies using outcome measures on skin sclerosis lung function and quality of life previously validated in ssc or used in other cell therapy trials  analysis of the response to treatment progressionfree survival pfs global rank composite score grcs at m3 m6and m12 and acr provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis criss for early ssc patients at m3 m6 and m12  analysis of the overall survival and assess causes of death  impact of allogeneic msc at iv once or twice at 3 months interval on the immune response including immunophenotyping and alloimmunization up to m6 after starting therapy  cost effectiveness of the allogeneic msc at infusion once or twice versus no treatment in severe ssc patients secondary endpoints  rate of treatmentrelated sae defined as ae of grade equal or above 3 ctcae v5 0 at time and",
    "DESIGN": "design of the study multicentre threearm randomized placebocontrolled doubleblind phase iii trial",
    "INCLUSION CRITERIA": "population of study participants adult patients with refractory severe systemic scleroderma inclusion criteria 1 provide signed and dated informed consent 2 willing to comply with all study procedures and be available for the duration of the study 3 male or female aged 18 and 70 years of age",
    "EXCLUSION CRITERIA": "exclusion criteria 1 age 18 years or 70 years 2 pregnancy or unwillingness to use adequate contraception 3 lifethreatening endorgan damage defined as dlco corrected for hemoglobin 30 predicted left ventricular ejection fraction 40 by cardiac echocardiography pulmonary hypertension with baseline resting systolic pulmonary arterial pressures 50 mmhg by cardiac echocardiography or mean pulmonary artery pressure 40 mmhg on right heart catheterization glomerular filtration rate 30ml min 4 active or chronic hepatitis asat alat 3 upper limit normal 5 neoplasms of less than 5 years except for basal cell or in situ cervix carcinoma or concurrent myelodysplasia 6 uncontrolled hypertension 7 uncontrolled acute or chronic infection 8 hiv1 or hiv2 infection 9 bmi 16 5 kg m2 10 severe psychiatric disorder 11 bone marrow insufficiency defined as neutropenia 1 x 109 l thrombopenia 50 x 109 l anemia 8 g dl lymphopenia 0 5 x 109 l 12 inability to provide informed consent 13 patient included in another interventional clinical trial 14 patient under tutelle",
    "INTERVENTION": "investigational medicinal product s allogeneic adipose tissue derivedmscs msc at or placebo will be injected by slow intravenous infusion according to the recipient body weight and to the study experimental arms  arm 0 placebo at m0 and m3 comparator treatment placebo",
    "STATISTICS": "statistical analysis we propose to conduct a multicenter threearm randomized doubleblind placebocontrolled trial we will enroll a total of 18 ssc patients each patient will be 1 1 1 randomized to one of two treatment arms 1 infusion of msc m0 or 2 infusions of msc m0 m3 or a placebo arm total of 6 patients per arm using randomization block of size 6 inclusions will be staggered to allow the detection of sae prior to inclusion of subsequent patients according to the following waiting rules  at least one week between two consecutive randomizations  interval of at least one month every three randomizations continuous monitoring of the primary endpoint by the sponsor will be implemented to allow continuous bayesian toxicity monitoring with a stopping rule implemented on the primary endpoint on cell infusions see section 13 for details",
    "DSMB": "study will have a data safety monitoring board yesthe data and safety monitoring board dsmb will be composed of 3 external reviewers with expertise in ssc msc and early phase trials in case of any safety data reported to the safety department the dsmb will be informed hold meeting and determine whether the trial should be held or proceed yesthe data and safety monitoring board dsmb will be composed of 3 external reviewers with expertise in ssc msc and early phase trials in case of any safety data reported to the safety department the dsmb will be informed hold meeting and determine whether the trial should be held or proceed",
    "ACRONYM": "acronym reference mscatssc",
    "INVESTIGATOR": "coordinating investigator and scientific director prof dominique farge mathec centre de référence des maladies auto immunes systémiques rares d iledefrance filière fai2r irsl ea3518 université de paris hôpital saint louis 1 avenue claude vellefaux 75010 paris",
    "NUMBER OF INCLUSIONS": "number of participants included 18 patients",
    "SITES": "number of centres 1 centre for patients treatment  unité de médecine interne uf 04 mathec centre de référence des maladies",
    "FUNDING": "sponsor assistance publique hôpitaux de paris"
  },
  "COMBINATION-LOCK01": {
    "TITLE": "full title combinationlock01  impact of aminoglycosidesbased antibiotics combination and protective isolation on outcomes in criticallyill neutropenic patients with sepsis a randomized 2 by 2 factorial design randomized pragmatic trial",
    "JUSTIFICATION": "scientific justification sepsis remains the leading cause of icu admission in neutropenic patients this condition remains associated with a high morbidity and mortality with hospital mortality of 60 when vasopressors are required full protective isolation including geographic isolation technical isolation highefficiency air filtration and digestive decontamination proved to be efficient in patients with profound and prolonged neutropenia with regard to infection rate however these studies are biased and were performed up to 40 years ago more recent studies performed in patients with less profound neutropenia or performed without digestive decontamination or with partial protective isolation led however to negative results more importantly isolation has been demonstrated to limit access to patients room and to be associated with suboptimal monitoring with increased rate of severe and avoidable adverse events this may explain the uneven use of protective isolation in hematology ward and expert s suggestion to appraise protective isolation benefits using large well conducted rct in neutropenic patients with suspected sepsis urgent broad antibiotic therapy is mandatory and failure to initiate adequate antibiotic therapy within 1 hour has been associated with a 10 fold increase in adjusted mortality current idsa guidelines recommend using preferentially large antipseudomonas betalactam therapy routine antibiotic combination using aminoglycosides is controversial and not recommended on one hand meta analyses suggested notonly a lack of benefit from this association but also increased rate of renal failure and a trend towards a higher mortality rate with aminoglycosides use on the other hand subgroup analysis and lowlevel evidences studies suggest however a benefit from aminoglycosides in criticallyill patients patients with severe sepsis or those with documented gram negative infection along this line both the recent cochran systematic review and the recent french guidelines focusing on neutropenia management in criticallyill",
    "OBJECTIVE": "main objective and primary endpoint to evaluate the impact on day90 mortality of two strategies separately using a 2x2 factorial design rct intervention 1  routine association of aminoglycoside to initial antibiotic therapy when compared to standard of care intervention 2  lack of routine use of protective isolation when compared to standard of care primary endpoint day90 mortality secondary objectives and endpoints to evaluate the impact of the studied interventions on  day28 and hospital outcome  incidence severity and duration of aki  incidence of clinically apparent loss of hearing  rate of adherence of hand hygiene  rate of selected adverse events  rate of nosocomial bacterial viral and fungal infection episodes  organ support during icu stay and organ support duration  failure of initial antibiotic therapy  antibiotic duration  rate of aminoglycosides overdosage and overuse secondary endpoints  day28 and hospital mortality  incidence and severity of aki according to kdigo definition  major adverse kidney events at day28 and day 90 composite of death new renal replacement therapy or persistent renal dysfunction  incidence of clinically apparent loss of hearing at end of icu stay and day 90  rate of adherence to adequate hand hygiene as assessed by external observer  incidence density of selected serious adverse events including unexpected cardiac arrest  incidence density of new bacterial viral or fungal episode  number of days free from organ support therapy mechanical ventilation vasopressors or rrt at day 28  rate of clinical cure  frequency of initial antibiotic therapy inadequate as regard to microbiological documentation",
    "DESIGN": "design of the trial prospective randomized open label controlled multicenter 2x2 factorial pragmatic clinical trial scope of the trial after checking the eligibility criteria the patients will be randomized according to a balanced scheme and will be allocated in one arm of each intervention",
    "INCLUSION CRITERIA": "population of trial subjects adult patients admitted to intensive care inclusion criteria  age 18 years  admitted in one of the participating icu  sepsis or septic shock as defined by sepsis3 definition  underlying tumor allogeneic stem cell transplantation or hematological malignancy  neutropenia defined by either absolute neutrophil count 500 mm3 or leucocytes 1000 mm3 related to an underlying malignancy or its treatment  informed or deferred consent",
    "EXCLUSION CRITERIA": "exclusion criteria  pregnancy and breastfeeding  moribund patients death expected within 48 hours by attending physician  previous participation to this study  no affiliation to social security  patients under legal protection according to french law  patient having received more than 1 injection of aminoglycosides in the 3 days preceding icu admission  contraindication to aminoglycosides as mentioned in spc section 4 3 o hypersensitivity to amikacin to other antibiotics from the aminoglycoside family or to any excipient from the amikacin used o patients with documented allergy to aminoglycosides o myasthenia gravis o concomitant administration of intravenous polymyxin  delay between onset of sepsis and inclusion 24 hours",
    "INTERVENTION": "investigational strategy and medicinal product s intervention 1  association of aminoglycoside to initial antibiotic therapy intervention 2  lack of routine use of protective isolation weak protective isolation comparator strategy and treatment intervention 1  antibiotic therapy without systematic adjunction of aminoglycosides intervention 2  standard of care protective isolation",
    "STATISTICS": "statistical analysis according to previous studies by our study group day90 mortality in the studied population is expected to be of 60 assuming a 15 target effect for each of the interventions compared with their respective control a type i error rate of 0 05 and a power of 80 each group should include 170 patients on the basis of a twosided logrank test no correlation is expected between interventions only main effects will be estimated and interaction between interventions tested aucune analyse intermédiaire n est prévue",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym combinationlock01",
    "INVESTIGATOR": "coordinating investigator michael darmon service de médecine intensive et réanimation chu saintlouis aphp tel 01 42 49 94 22 michael darmon aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects included 340",
    "SITES": "number of sites 14 icus in france",
    "FUNDING": "sponsor assistance publique hôpitaux de paris sources of funding for the trial phrck18102"
  },
  "INTORETAK": {
    "TITLE": "full title multicentre randomized prospective trial evaluating the efficacy and safety of infliximab to tocilizumab in refractory or relapsing takayasu arteritis",
    "JUSTIFICATION": "scientific justification takayasu arteritis ta is a vasculitis of unknown origin resulting in progressive thickening and stenosis of large and medium arteries the aorta and its major branches and the pulmonary arteries first line therapy of ta consists of high dose corticosteroids cs mukhtyar et al 2009 between 20 and 50 of cases respond to cs alone with subsequent resolution of symptoms and stabilization of vascular abnormalities shelhamer et al 1985 maksimowicz mckinnon et al 2007 although secondline agents methotrexate azathioprine mercaptopurine mycophenolate mofetil may result in initial remission relapses remain common when prednisone is tapered maksimowiczmckinnon et al 2007 thus 50 of cs resistant or relapsing ta patients may achieve sustained remission with the addition of methotrexate hoffman et al 1994 during the last decade biologics such as antitumor necrosis factor alpha anti tnfα and antiinterleukin6 antiil6 have been used as thirdline treatment in refractory or relapsing ta almost 90 of cs methotrexate resistant ta cases responded to infliximab an anti tnfα and sustained remission was obtained in 37 to 76 of the cases schmidt et al 2012 comarmond et al 2012 mekinian et al 2012 tocilizumab an antiil6 has given similar results with 68 of sustained remission in refractory ta abisror et al 2013 irrespective of classical cardiovascular risk factors the systemic inflammation and cs use play a pivotal role in the occurrence of cardiovascular thrombotic events cves roubille et al 2015 as cves overlap with ta complications it is primordial to drastically taper cs in that vasculitis we therefore hypothesize that infliximab or tocilizumab can achieve a remission in more than 70 of refractory relapsing ta cases to cs associated to a secondline agent intoretak first randomized prospective study in ta has an original design testing infliximab and tocilizumab propensity to achieve over 70 of sustained remission in refractory relapsing ta and evaluating jointly the 2 arms",
    "OBJECTIVE": "primary objective and assessment criterion to obtain by arm 70 of patients at 6 months posttreatment with prednisone or the prednisolone * 0 1mg kg per day and inactive disease nih score 1 during the last 3 months proportion at 6 months posttreatment of patients with prednisone or the prednisolone 0 1mg kg per day and sustained inactive disease nih score 1 from m3 to m6 and same biological therapy from since the treatment among randomized patients in each arm secondary objectives and assessment criteria to estimate the incidence of relapse between 3 and 6 months post treatment in each arm to estimate the incidence of traitement failure at 3 months post treatment in each arm",
    "DESIGN": "experimental design this open randomized clinical trial is based on a simon s twostage design simon 1989 that will be used separately in both arms the randomization and thus allocation concealment between both arms will insure the absence of selection bias in allocating the experimental treatments to the patients with no betweenarm comparison test only estimates of difference in the end points between treatment arms will be provided",
    "INCLUSION CRITERIA": "population involved adult patients with refractory or relapsing takayasu arteritis inclusion criteria diagnosis of takayasu arteritis if at least 3 of the 6 criteria of the american college of rheumatology acr are met appendix 1 age at disease onset or 1st symptoms 40 years old limb claudication anisotension 10mm hg between brachial systolic arterial pressures decreased brachial artery pulse one or both arteries bruit over subclavian arteries or aorta",
    "EXCLUSION CRITERIA": "noninclusion criteria active tuberculosis or untreated latent tuberculosis infection currently treated less than 3 weeks evidence of active infection includes chronic infection infection requiring treatment with antibiotics within 2 weeks prior to the inclusion randomization visit infection with positive human immunodeficiency virus hiv serology positive hepatitis c rna or a positive hepatitis b surface antigen pregnancy or lactation inability to comply with study guidelines inability to provide informed consent alcohol or drug abuse that in the investigator s opinion could prevent a subject from fulfilling the study requirements or that would increase the risk of study procedures",
    "INTERVENTION": "treatment being tested arm a patients will receive infliximab 5mg kg intravenously at week 0 2 6 14 22 following prescription recommendations during 6 months arm b patients will receive tocilizumab 8mg kg intravenously at week 0 4 8 12 16 20 24 following prescription recommendations during 6 months",
    "STATISTICS": "statistical analysis we will randomize 25 patients in each arm for each arm the null hypothesis response rate 0 40 will be tested against a onesided alternative response rate 0 70 with 0 0248 type i error rate and power 0 8061 the first stage includes 10 patients in each arm if 5 or fewer responses are observed in these patients the arm is stopped otherwise 15 additional patients are accrued the null hypothesis will be rejected if 14 or more responses are observed in the 25 patients",
    "DSMB": "data safety monitoring board anticipated yes",
    "ACRONYM": "acronym intoretak infliximab and tocilizumab in refractory relapsing takayasu arteritis",
    "INVESTIGATOR": "coordinating investigator dr tristan mirault national reference centre for rare vascular diseases georgespompidou european hospital university hospital paris ouest paris descartes university sorbone paris cite aphp paris france tristan mirault aphp fr 33 1 56 09 30 51",
    "NUMBER OF INCLUSIONS": "number of subjects chosen 50 patients",
    "SITES": "number of centres multicentre national study including 18 centres",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding source phrcn 2016 french ministry of health"
  },
  "TRIBECA": {
    "TITLE": "full title multicenter randomized doubleblind study comparing the efficacy and safety of belimumab in the treatment of noninfectious active cryoglobulinemia vasculitis compared to placebo",
    "JUSTIFICATION": "scientific justification cryoglobulinemia vasculitis is associated with significant morbidity and mortality and requires therapeutic intervention the management of noninfectious mixed cryoglobulinemia vasculitis is currently based on corticosteroids and rituximab during the last decade several groups have reported on the efficacy of anti cd20 monoclonal antibody rituximab in patients with cryoglobulinemia vasculitis rituximab infusions proved effective on main vasculitis signs with a complete clinical response in 6570 of patients however cryoglobulinemic vasculitis relapse is noted in up to 40 patients within few days to nineteen months after the last rituximab infusion we and other have previously shown that serum blys concentration was correlated with serum cryoglobulin level and with cryoglobulinemia vasculitis and cryoglobulinemia associated b non hodgkin s lymphoma in agreement with data in systemic lupus erythematosus and sjögren s syndrome we also observed decrease in blys binding and in br3 staining which was correlated with disease severity following rituximab serum blys concentration significantly increased and may favour the survival of autoreactive b cell clones and relapses of cryoglobulinemia vasculitis a recent study has shown that rituximab does not reset defective early b cell tolerance checkpoints an obvious solution to prevent the rise in baff levels from precipitating a flare of disease following rituximab therapy and thus to achieve sustained remission of disease would be to combine rituximab with baff blockade in mice a combination of b cell depletion and baff inhibition removes b cells in the marginal zone and follicular compartments more effectively than either treatment alone a combination of b cell depletion and baff blockade was superior to b cell depletion alone with respect to reducing the numbers of plasmablasts and plasma cells as well as reducing disease severity in three different mouse models of lupus in addition promising results have been observed in patients with cryoglobulinemia vasculitis treated by rituximab plus",
    "OBJECTIVE": "main objective and primary endpoint to evaluate efficacy of belimumab compared to placebo in patients with noninfectious active cryoglobulinemia vasculitis complete clinical response rate of vasculitis symptoms at week w 25 with corticosteroid withdrawal prednisone at 0 mg day at week w 12 secondary objectives and endpoints secondary objectives safety and tolerability of treatments as assessed by frequency and severity of adverse clinical events complete partial improvement in some but not all organs involved at baseline and non clinical no clinical improvement response rate rate of complete renal response rate of cryoglobulinemia clearance rate of negativation of rheumatoid factor activity rate of normalization of c4 complement level early failure rate at w5 non clinical response at w5 clinical relapse rate and the time to relapse between the two treatments groups cumulative dose of corticosteroids received between the two treatments groups evolution of gammaglobulin and of cd19 b cells levels quality of life scores sf36 appendix 1 between the two treatment groups rate of infections severe or not and other complications lymphoma bvas activity score appendix 2 secondary endpoints safety and tolerability of treatments as assessed by frequency and severity of adverse clinical events at w25 and at w48 complete partial and non clinical response rate at w13 w25 and at w48 complete renal response rate at w13 w25 and w48 rate of cryoglobulinemia clearance of negativation of rheumatoid factor activity and of normalization of c4 complement level at w13 w25 and at w48 rate of early failures non clinical response at w5 clinical relapse rate defined by de novo appearance or reappearance of a manifestation attributable to cryoglobulinemia vasculitis during 48 weeks of follow up rate and time to relapse from baseline to w48 cumulative dose of prednisone at w25 and at w48 quality of life score sf36 at baseline w25 and w48 rate of infections severe or not and other complications during the 48 weeks of followup evolution of gammaglobulin and of cd19 b levels from baseline to w48 bvas activity score at baseline w13 w25 and w48",
    "DESIGN": "design of the trial this is a bayesian phase ii randomized clinical trial that aims at evaluating the best treatment strategy of cryoglobulinemia vasculitis based on difference in the response rate as measured at week 25 after randomization scope of the trial phase ii prospective randomized multicentre double blind study group i belimumab administered subcutaneously 200mg weekly from w1 to week 24 group ii placebo of belimumab administered subcutaneously weekly from w1 to week 24 randomization will be centralized stratified on previous treatment history naive patients versus relapsing patients and the severity of vasculitis i e extensive skins necrosis glomerulonephritis multiple mononeuropathy myocarditis digestive or central nervous system specific involvement in a 1 1 ratio between groups both groups will have the same corticosteroid tapering scheme with an initial dose of 30 mg day the following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive 30 mg day week w 0w2 20 mg day w2w4 15 mg day w4w6 10 mg day w6w8 5 mg day w8w10 between w10w12 the strategy for stopping glucocorticoids is left to the investigator s discretion stopping glucocorticoid therapy at w12 at each step the prednisone dose will be reduced only in the absence of signs of vasculitis activity",
    "INCLUSION CRITERIA": "population of trial subjects adult patients with noninfectious active cryoglobulinemia vasculitis inclusion criteria 1 age 18 years 2 written inform consent 3 active cryoglobulinemia vasculitis at initiation of rituximab define by a clinically active vasculitis with skin joint renal peripheral nerve central neurological digestive pulmonary and or cardiac involvement and history of positive cryoglobulinemia 4 affiliated to national french social security system 5 having received rituximab as induction therapy within 6 weeks 1 to 4 infusions dose at the discretion of the investigator 6 female subjects of childbearing potential must have a negative serum or urinary pregnancy test at inclusion visit and confirmed monthly while in study out to at least 92 days 5 half lives post last dose 7 for subjects with reproductive potential male or female a willingness to use contraceptive measures adequate to prevent the subject or the subject s partner from becoming pregnant during the study from 2 weeks prior to administration of the 1st dose of study agent until 92 days after the last dose of study agent therefore the subjects agree to 1 of the following a complete abstinence from intercourse from 2 weeks prior to administration of the 1st dose of study agent until 92 days after the last dose of study agent sexual inactivity by abstinence must be consistent with the preferred and usual lifestyle of the subject periodic abstinence e g calendar ovulation symptothermal post ovulation methods and withdrawal are not acceptable methods of contraception or b consistent and correct use of 1 of the following acceptable methods of birth control for 1 month prior to the start of the study agent during the study and 92 days after the last dose of study agent o oral contraceptive either combined or progestogen alone o injectable progestogen o implants of levonorgestrel or etonogestrel o estrogenic vaginal ring",
    "EXCLUSION CRITERIA": "exclusion criteria 1 patient with a vasculitis unrelated to cryoglobulinemia 2 patient with non active cryoglobulinemia vasculitis at initiation of rituximab patients with inactive vasculitis following rituximab administration may be included 3 excluded concomitant medications a 365 days prior to investigational medicinal product belimumab or placebo o any biologic investigational agent e g abetimus sodium anti cd40l antibody bg9588 idec 131 investigational agent applies to any drug not approved for sale in the country in which it is being used b 180 days prior to investigational medicinal product belimumab or placebo c intravenous cyclophosphamide 30 days prior to investigational medicinal product belimumab or placebo or 5 half lives whichever is greater o any nonbiologic investigational agent investigational agent applies to any drug",
    "INTERVENTION": "investigational medicinal product s belimumab benlysta administered subcutaneously 200 mg weekly from w1 to week 24 comparator treatment placebo of belimumab administered subcutaneously weekly from w1 to week 24",
    "STATISTICS": "statistical analysis this is a bayesian phase ii randomized clinical trial that aims at evaluating the treatment strategy of cryoglobulinemia vasculitis based on difference in the response rate as measured at week 25 after randomization randomized phase ii trials are still poorly used with still large use of singlearm phase ii trial results that are interpreted relative to historical control subjects introducing selection bias and confounding that may limit the validity of the conclusions thus planning a phase ii randomized trial appears a worthy investment considering finite patient and financial resources this design is adapted to binary outcomes observed at the end of a fixed followup period and analyzed using an absolute difference in proportions that has been shown to greatly reduce sample size requirements we thus used the approach for phase ii randomized trials proposed by simon r wittes re and ellenberg ss that aims at controlling the probability of detecting a given difference in response rates we hypothesize that up to 70 of the patients receiving placebo of belimumab and 85 of those treated by belimumab will achieve a complete remission of cryoglobulinemia vasculitis at week 25 w25 and with steroid therapy stopped 0 mg day at w12",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym tribeca treatment after rituximab with belimumab in cryoglobulinemia associated vasculitis",
    "INVESTIGATOR": "coordinating investigator pr david saadoun department of internal medicine and clinical immunology centre national de référence des maladies autoimmunes et systémiques rares hospital pitié salpétrière tel 0142178009 email david saadoun aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects included 48 patients 24 patients in each arm",
    "SITES": "number of sites multicentre national study including 20 centres",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial gsk who will also provide belimumab benlysta and placebo of belimumab"
  },
  "PCL-2": {
    "TITLE": "full title primary plasma cell leukemia a prospective phase ii study incorporating daratumumab to chemotherapy and stem cell transplantation",
    "JUSTIFICATION": "scientific justification primary plasma cell leukemia ppcl is a rare form of plasma cell malignancy 24 of multiple myeloma with poor prognosis overall survival os 12 months with conventional chemotherapy bortezomibbased regimens have shown promising results in small retrospective studies and transplantation auto and or allograft may improve os for selected young patients the ifm group recently published a prospective study in 40 ppcl patients with alternate bortezomibdexamethasone doxorubicin cyclophosphamide pad vcd as induction before high dose melphalan plus autologous stem cell transplantation hdm asct followed by reduced intensity conditioningallograft ricallo or second hdm asct plus consolidation maintenance with bortezomiblenalidomidedexamethasone lenalidomide overall 27 patients 69 were responder to induction and 35 achieved vgpr or better one patient underwent a syngeneic allograft and 25 hdm asct 16 of them subsequently received a ricallograft 7 a second transplant followed by consolidation maintenance the median pfs and os were 15 and 36 months respectively os seems to be superior in the double transplant maintenance group compared to the allotransplant group on landmark analysis the italian group also recently reported a prospective trial in ppcl involving 23 patients treated with lenalidomidedexamethasone overall the median pfs and os were 14 and 28 months respectively nine of 15 patients eligible for transplant could receive hdm asct after induction and pfs and os were 27 months and not reached respectively daratumumab a monoclonal antibody against cd38 that is highly expressed by plasma cells is highly effective in relapsed refractory patients with multiple myeloma mm alone and in combination with lenalidomide the combination daratumumab and bortezomiblenalidomidedexamethasone daravrd has been recently tested for newly diagnosed multiple myeloma patients with",
    "OBJECTIVE": "main objective and primary endpoint the primary objective is to determine the best overall response rate at completion of induction phase very good partial response or better the primary endpoint is the vgpr or better rate at the completion of induction phase according to the imwg response criteria secondary objectives and endpoints the main secondary objective is to evaluate progressionfree survival the other secondary objectives are  to assess overall hematological response rates  to evaluate overall survival  to assess safety and toxicity according to nci ctcae  to assess cytogenetic abnormalities of tumoral plasma cell  to analyze the prognostic value of minimalresidual disease mrd by sequencing ngs after completion of induction before second consolidation before len consolidation and at the end of treatment  to evaluate quality of life eortc qlqc30 domain scores the secondary endpoints are  progressionfree survival overall survival time to progression and duration of response  overall hematological response rates  assess safety by type frequency severity relationship of adverse events to study treatment and changes in vital signs physical exams incidence of treatment emergent adverse event teae serious adverse event sae and laboratory abnormalities using national cancer institute nci common toxicity criteria cctae v4  evaluate response according to chromosomal structural abnormalities such as del 17p t 4 14 t 11 14 t 14 16 t 14 20 amp 1q and del 1p  minimal residual disease mrd assessed by ngs  quality of life eortc qlqc30 domain scores",
    "DESIGN": "design of the study induction phase",
    "INCLUSION CRITERIA": "population of study participants screening and eligibility the investigator is responsible for keeping a record of all subjects who sign an informed consent form for entry into the study all subjects will be screened for eligibility that must take place within 21 days prior to initiation of therapy the patients must meet the eligibility criteria below to enter the study inclusion criteria 1 male or female patients 18 to 69 years old 2 patient with primary plasma cell leukemia disease as defined by the recent international myeloma working group imwg 2021 5 circulating plasma cells in peripheral blood smears 3 voluntary written consent must be given before performance of any study related procedure not part of standard medical care with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care 4 eastern cooperative oncology group ecog performance status and or other performance status 0 1 or 2 5 eligible for high dose melphalan therapy with asct 6 total bilirubin 2 the upper limit of the normal range uln 7 alanine aminotransferase alt and aspartate aminotransferase ast 3 uln 8 calculated creatinine clearance 20 ml min mdrd formula should be used for calculating creatinine clearance values 9 female patients who  have been postmenopausal for at least 2 years before the screening visit or  are surgically sterile or if they are of childbearing potential agree to practice 2 effective methods of contraception at the same time from the time of signing the informed consent form through 90 days after the last dose of study drug or  agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject periodic abstinence e g calendar ovulation symptothermal and postovulation methods and withdrawal are not acceptable methods of contraception",
    "EXCLUSION CRITERIA": "exclusion criteria 1 male or female patients 18 or 69 years old 2 history of malignancy within 3 years before the date of inclusion exceptions are squamous and basal cell carcinomas of the skin carcinoma of the skin carcinoma in situ of the cervix or breast or other noninvasive lesion that in the opinion of the investigator with concurrence with the coordinating investigatior is considered cured with minimal risk of recurrence within 3 years 3 prior history of symptomatic myeloma with previous chemotherapy for myeloma except corticotherapy dexamethasone 40 mg d for 4 days max 4 any other uncontrolled medical condition or comorbidity that might interfere with subject s participation 5 pregnant or breast feeding females 6 known positive for hiv 7 known seropositive for hepatitis c except in the setting of a sustained virologic response svr defined as a viremia at least 12 weeks after completion of antiviral therapy 8 seropositive for hepatitis b defined by a positive test for hepatitis b surface antigen hbsag subjects with resolved infection ie subjects who are hbsag negative but positive for antibodies to hepatitis b core antigen antihbc and or antibodies to hepatitis b surface antigen antihbs must be screened using realtime polymerase chain reaction pcr measurement of hepatitis b virus hbv dna levels those who are pcr positive will be excluded exception subjects with serologic findings suggestive of hbv vaccination anti hbs",
    "INTERVENTION": "investigational medicinal product s bortezomib daratumumab lenalidomide and dexamethasone",
    "STATISTICS": "statistical analysis the primary endpoint of the trial is the vgpr or better rate at completion of induction phase according to the imwg response criteria in our previous published phase ii trial 36 of patients achieved vgpr or better after induction using a phase 2 one stage a hern design with a lowest acceptable response rate of 35 p0 and an expected response rate of 60 p1 with type 1 and type 2 error levels of 5 and 20 26 patients are needed to account for 10 of nonevaluable patients 29 patients will be recruited",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference pcl2",
    "INVESTIGATOR": "coordinating investigator bruno royer immunohematology unit st louis hospital paris",
    "NUMBER OF INCLUSIONS": "number of participants included 29",
    "SITES": "number of centres 16 french sites ifm sites are planned",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources  phrck 2018  pharmaceutical companies will provide the study drugs subcutaneous daratumumab and lenalidomide"
  },
  "ITAC": {
    "TITLE": "full title multicenter randomized prospective trial comparing the efficacy and safety of infliximab to that of cyclophosphamide in severe behçet s disease",
    "JUSTIFICATION": "scientific justification itac is the first randomized prospective head to head study comparing infliximab to that of cyclophophamide in severe manifestations of bd behçet s disease bd is a systemic vasculitis of arterial and venous vessels of any size involving young patients from 12 to 45 years bd significantly increases morbidity and mortality therape utic management of bd depends on the clinical presentation and organ involved although colchicine nonsteroidal antiinflammatory agents and topical treatments are often sufficient for mucocutaneous and joint involvement more aggressive approach with immunosuppressive agents is warranted for severe manifestations such as retinal vasculitis cardiovascular or neurological involvement early recognition and vigorous use of immunosuppressives with high dose steroids have changed the prognosis of patients with severe bd bd is a severe systemic vasculitis leading to a 5year mortality rate of 15 in patients with major vessel or neurological involvement cyclophosphamide has been used for lifethreatening bd for 40 years however the outcome of severe complications of bd is still poor the european league against rheumatism eular recommendation updated in 2016 for the management of bd advocated cyclophosphamide or antitnf plus glucocorticoids for lifethreatening manifestations i e neurological and or major vessel involvement but recommendations on vascular disease and neurological involvement are based largely on expert opinion and uncontrolled evidence from open trials and observational studies the need for further properly designed controlled clinical trials is apparent tnfa antagonists have been used with success in severe and or resistant cases in addition the incidence of blindness in bd has been dramatically reduced in the recent years with the use of antitnf however there is no firm evidence or",
    "OBJECTIVE": "main objective and primary endpoint to assess the benefit of infliximab comparatively to that of cyclophosphamide in severe lifethreatening behçet s disease primary assessment criterion will be the complete clinical response at week 22 after randomization secondary objectives and endpoints to estimate and compare the rate and time to occurrence of relapses or worsening to estimate and compare the cumulative dose of steroids to estimate and compare the adverse events to estimate and compare the mean change in sf36 qualityoflife see appendix 3 to estimate and compare the rate of remission according to organs involved to compare the changes in acutephase reactants to estimate and compare the changes in cns involvement to estimate and compare the changes in cardiovascular involvement survival and event free survival to estimate and compare the changes in other bd manifestations to estimate and compare the changes in behcet s disease current activity form see appendix 2 to assess serum concentration measurement of tnfa inhibitor secondary endpoints  complete clinical response at week 12 and 48  remission of cns and or cardiovascular involvement at week 12 22 and 48  measures of corticosteroid sparing o percent meeting targets 0 1 mg day kg of prednisone at week 22 and 48 o mean dose at week 12 22 and 48 o cumulative dose at week 12 22 and 48  time to response onset  measures of acutephase reactant o creactive protein crp every 4 weeks  relapse o time to relapse relapse will be defined as the reappearance of clinical and or paraclinical features of active disease or by the occurrence of new lesions at week 48 o rate of relapse  worsening",
    "DESIGN": "design of the trial bayesian design for phase ii randomized clinical trial that aims at comparing a new treatment to a reference based on a binary end point which offers greater flexibility and simplicity of inference to the monitoring for patient safety and evidence of efficacy of small randomized trials scope of the trial after the collection of their free and informed consent eligible patients with active behçet s disease will be randomized into one of 2 groups at the randomization visit d0 arm a infliximab 5mg kg intravenously at week 0 2 6 12 and 18 arm b cyclophosphamide 0 7g m2 up to 1 2 g m2 intravenously at week 0 4 8 12 16 and 20",
    "INCLUSION CRITERIA": "population of trial subjects adult and pediatric patients with severe lifethreatening behçet s disease inclusion criteria 1 age 12 years old 2 written inform consent informed consent should be obtained from the legal guardian in accordance with regional laws or regulations for patients 12 to 17 years of age 3 diagnosis of bd according to international criteria for bd icbd see appendix 1 4 life threatening active bd defined as 1 of the following disease categories and according to the validated international definition  major vessel disease arterial aneurysms or arterial stenosis myocarditis and or major deep vein thrombosis i e inferior vena cava superior vena cava cardiac cavity thrombosis pulmonary embolism supra hepatic vessels renal and mesenteric vessels diagnosis",
    "EXCLUSION CRITERIA": "non inclusion criteria subjects will be not included from the study if they meet any of the following criteria 1 evidence of active tuberculosis 2 hiv or active hbv infection hbs ag 3 pregnancy or lactation 4 have been taking an oral daily dose of a glucocorticoid of more than 20 mg prednisone equivalent for more than 6 weeks continuously prior to the inclusion visit or taking more than 3000 mg methylprednisolone 4 weeks prior to the inclusion visit 5 alcohol or drug dependance",
    "INTERVENTION": "investigational medicinal product s infliximab 5mg kg intravenously at week 0 2 6 12 and 18 comparator treatment cyclophosphamide 0 7g m2 up to 1 2 g m2 intravenously at week 0 4 8 12 16 and 20",
    "STATISTICS": "statistical analysis the experimental design is a multicentric open multicenter randomized clinical trial stratified on the characteristics of the initial behçet s disease with evaluation of the primary assessment criteria at 22 weeks the primary assessment criteria and the final measures of corticosteroid sparing will be reviewed by a scientific committee blinded of the randomization the rct will use a bayesian design for phase ii randomized national multicentre clinical trial that aims at comparing a new treatment to a reference based on a binary endpoint i e complete clinical response at week 22 which offers greater flexibility and simplicity of inference to the monitoring for patient safety and evidence of efficacy of small randomized trials",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym itac induction therapy with antitnfα vs cyclophosphamide in severe behçet disease",
    "INVESTIGATOR": "coordinating investigator pr david saadoun centre de reference des maladies autoimmunes et systémiques rares department of internal medicine and clinical immunology 83 bd de l hôpital 75013 paris hospital pitie salpetriere tel 0142178088 email david saadoun psl aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects included 52 patients 26 patients in each arm",
    "SITES": "number of sites multicentre national study including 28 centres",
    "FUNDING": "sponsor assistance publique hôpitaux de paris sources of funding for the trial phrc"
  },
  "FOCUS": {
    "TITLE": "full title randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent non infectious uveitis",
    "JUSTIFICATION": "scientific justification focus is the first prospective randomized study comparing standard of care mycophenolate mofetil to adalimumab in recently active non infectiuous uveitis niu with steroid dependency there is no firm evidence or randomized trials that compared classical immunosuppressive compounds to biological agents or identified the best treatment in this condition the burden of niu has been reduced with the use of immunosuppressive agents and biologics raising the question of which of these compounds should be preferentially used in recently active niu with steroid dependency",
    "OBJECTIVE": "main objective and primary endpoint primary objective the objective is to compare the efficacy of adalimumab 80mg at day 0 then 40mg 14 days from w1 to w35 subcutaneously with that of standard of care mycophenolate mofetil 2g day orally for 36 weeks in recently active noninfectious intermediate posterior uveitis and panuveitis with steroid dependency primary endpoint the primary efficacy endpoint is the treatment failure rate at 36 weeks treatment failure is defined by any of the following in at least one eye  new active inflammatory chorioretinal or retinal vascular lesions  worsening of best corrected visual acuity bcva by 3 lines  2 step increase in anterior chamber cell grade and or in vitreous haze relative to baseline  noabsence of and with steroid discontinuation between week 13 and week 19 as per protocol and without any aor any additional immunosuppressive drug or injectable steroids  study treatment permanent discontinuation secondary objectives and endpoints secondary objectives comparing adalimumab 80mg at day 0 then 40mg 14 days from w1 to w35 subcutaneously to standard of care mycophenolate mofetil 2g day orally for 36 weeks  to evaluate the cumulative incidence of treatment failure up to w55 after inclusion  to evaluate the change in best corrected visual acuity bcva logmar from baseline to week w55  to evaluate the change in ocular inflammation in the anterior chamber and vitreous from baseline to week w55  to evaluate the change in other signs including vessel leakage from baseline to week w55  to evaluate the presence of macular edema from baseline to week w55  to evaluate the quality of life related to uveitis from inclusion to w55  to evaluate steroid sparing effect from baseline to w55  to evaluate the number and time to relapse of uveitis and the characteristics of uveitis at worsening from baseline to w55  to evaluate the effect on underlying systemic disease when appropriate from baseline to w55  to evaluate the safety of adalimumab and mycophenolate mofetil up to w55 secondary endpoints  time to treatment failure up to w55  logmar bcva in each eye at w4 w8 w12 w16 w20 w24 w30 w36 and w55  anterior chamber cell grade in each at w4 w8 w12 w16 w20 w24 w30 w36 and w55  vitreous haze grade sun criteria in each eye at w4 w8 w12 w16 w20 w24 w30 w36 and w55  central retinal thickness in each eye from baseline at w4 w8 w12 w16 w20 w24 w30 w36 and w55  proportion of patients with central macular thickness 300 microns at w4 w8 w12 w16 w20 w24 w30 w36 and w55  time to optical coherence tomographic oct evidence of macular",
    "DESIGN": "design of the study this is a prospective phase iii clinical trial multicenter openlabel two arm randomized 1 1 clinical trial comparing the efficacy and safety of adalimumab and standard of care mycophenolate mofetil in subjects with recently active intermediate posterior uveitis or panuveitis despite steroid use i e oral prednisone 7 mg day or if no prednisone is available use oral corticosteroid as a replacement for prednisone equivalent prednisone dose oral corticosteroids should be at a stable dose at least 2 weeks prior to the first study drug administration on day 0",
    "INCLUSION CRITERIA": "population of study participants adult patients with recently active noninfectious uveitis niu despite oral prednisone 7 mg day or equivalent prednisone doseoral corticosteroid at equivalent dose only if prednisone is out of stock in the market if no prednisone is available use oral corticosteroid as a replacement for prednisone equivalent dose or oral corticosteroid equivalent recently active disease defined by the presence of at least 1 of the following parameters in either eye within the 3 months prior to inclusion visit  active chorioretinal or retinal vascular lesion  presence of macular edema by optical coherence  2 anterior chamber cells standardization of uveitis nomenclature sun criteria 2 vitreous haze national eye institute nei sun criteria inclusion criteria the eligibility criteria will be checked at the screening visit which takes place four weeks maximum prior to inclusion visit and at the inclusion randomization visit adult patients meeting the following criteria may be included in the study 1 provide written informed consent prior to the performance of any studyspecific procedures 2 18 years of age 3 diagnosis of noninfectious intermediate posterior or panuveitis in at least one eye fulfilling the international study group classification criteria standardization of uveitis nomenclature sun criteria of posterior or pan uveitis confirmed by documented medical history 4 recent activity of niu as defined by the presence of at least 1 of the following parameters in either eye within the 3 months prior to inclusion visit despite 7mg day of oral prednisone active chorioretinal or retinal vascular lesion",
    "EXCLUSION CRITERIA": "exclusion criteria subjects will not be included in the study if they meet any of the following criteria 1 infectious uveitis masquerade syndromes idiopathic uveitis is permitted 2 isolated anterior uveitis 3 monocular patient 4 active tuberculosis 5 positive hiv serology or hcv hbs ag test 6 history of malignancy within 5 years prior to inclusion other than carcinoma in situ of the cervix nonmetastatic squamous or basal cell carcinoma of the skin 7 history of severe allergic or anaphylactic reactions to monoclonal antibodies mycophenolate mofetil rifampicin isoniazid or fluorescein 8 infection requiring treatment with intravenous antibiotics within 3 weeks prior to inclusion 9 history of multiple sclerosis and or demyelinating disorder 10 laboratory values assessed during inclusion hemoglobin 8g dl wbc 2 0 x 103 mm3 platelet count 80 x 103 mm3 glomerular filtration rates gfr 30ml min transaminases 3 times upper normal value 11 use of the following systemic treatments during the specified periods treatment with any systemic alkylating agents within 12 months prior to inclusion e g cyclophosphamide chlorambucil any live attenuated vaccine within 4 weeks prior to inclusion 12 stage iii and iv new york heart association nyha cardiac insufficiency 13 pregnancy or breastfeeding 14 under legal protection 15 participation in another interventional study involving human participants or in the exclusion period at the end of a previous study involving human participants if applicable",
    "INTERVENTION": "investigational medicinal product s eligible patients with recently active niu will be randomized at 1 1 ratio between arm 1 adalimumab 80mg at day 0 then 40mg 14 days from w1 to w35 subcutaneously arm 2 standard of care defined by mycophenolate mofetil 2 g day orally for 36 weeks the 2 treatment groups will receive the same corticosteroid regimen all patients with niu will receive oral prednisone 10 mg day or oral corticosteroid equivalent with a maximum of 35 mg day of prednisone or oral corticosteroid at equivalent prednisone dose only if prednisone is out of stock in the marketif no prednisone is available use oral corticosteroid as a replacement for prednisone equivalent dose equivalence a common prednisonetapering programme will be applied to both groups with a decrease until discontinuation between week 13 and week 19 as long as the disease is inactive comparator arm 2 standard of care defined by mycophenolate mofetil 2 g day orally treatment for 36 weeks",
    "STATISTICS": "statistical analysis this is a prospective twoarm randomized openlabel phase iii trial comparing adalimumab to standard of care mycophenolate mofetil based on a binary primary endpoint treatment failure at week 36 of treatment randomization will be stratified on retinal vasculitis presence or not of macular oedema underlying disease idiopathic uveitis or underlying disease associated and steroid dose at inclusion 20mg d vs 20mg d this trial will be conducted using a group sequential design with one interim analysis after 50 of primary observations have been completed with efficacy and futility early stopping rules specifically assuming a probability of treatment failure primary endpoint of 50 in the soc control population versus 20 under the alternative hypothesis with adalimumab a total number of 106 patients 53 per randomization arm is required to ensure 90 power with a 2 5 one sided type i error risk accounting for one interim analysis after 50 of primary observations have been completed and using lan demets o brien flemingtype riskspending functions to define efficacy and futility nonbinding early stopping rules moreover we plan to include a total of 120 patients 60 per randomization arm to account for potential 10 of losttofollowup",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference focus aphp211032 eu no 20235051123800",
    "INVESTIGATOR": "coordinating investigator pr bahram bodaghi centre national de référence des uvéites department of ophtalmology hospital pitie salpetriere tel 01 42 16 37 28 email bahram bodaghi aphp fr scientific director if applicable pr david saadoun centre national de reference maladies autoinflammatoires et amylose département de médecine interne et immunologie clinique pitié salpétrière hospital tel 0142178042 email david saadoun aphp fr",
    "NUMBER OF INCLUSIONS": "",
    "SITES": "",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources phrc 2020"
  },
  "ICE": {
    "TITLE": "full title isatuximab in type i cryoglobulinaemia a prospective pilot study",
    "JUSTIFICATION": "scientific justification cryoglobulinaemia is defined as the presence of immunoglobulins in the serum which reversibly precipitate and form a gel when the temperature drops below 37 c and redissolve upon rewarming classification includes three subgroups based on ig composition type i cryoglobulinaemia consists of only one isotype or subclass of immunoglobulin types ii and iii are classified as mixed cryoglobulinaemia mc because they include both igg and igm components overall cryoglobulinaemia is considered a rare disease 5 10 000 in the general european and north american population although prevalence is likely to be higher in some areas such as the mediterranean basin mc vasculitis is a multiorganic disease involving kidneys joints skin and peripheral nerves in type i cryoglobulinaemic vasculitis searching for an underlying plasmacell neoplasms is mandatory cryoglobulinaemia composed of igg is more often found in multiple myeloma or monoclonal gammapathy of unknown significance mgus the course of mc vasculitis varies widely and the prognosis is influenced by both mcinduced damage to vital organs and co morbidities associated with underlying diseases type i cryoglobulinaemic vasculitis is a plasma cell associated disorder at the crossroad between autoimmunity and plasmacell neoplasm treatment should be modulated according to the underlying associated disease and the severity of internal organ involvement the overall 10year survival after a diagnosis of cryoglobulinaemic syndrome ranges from 50 to 90 in case of renal involvement the main therapeutic goal must be the cure of the underlying haematological disease overwhelmingly plasmacell neoplasms the most common neoplasias are multiple myeloma predominantly associated with type i cryoglobulinaemia and hyperviscosity in more than 50 of cases treating the underlying monoclonal disorder has been associated with improvement stabilization of cryoglobulinaemic symptoms in most patients with type i cryoglobulinemia although negativation of serum cryoglobulins was achieved in only half the patients",
    "OBJECTIVE": "main objective and primary endpoint the primary objective is to assess the complete clinical response rate of isatuximab in type i igg cryoglobulinemia primary endpoint complete clinical response rate of cryoglobulinemia vasculitis symptoms at week w 20 secondary objectives and endpoints secondary objectives safety and tolerability of treatment as assessed by frequency and severity of adverse clinical events early complete response rate at w12 complete partial improvement in some but not all organs involved at baseline and non clinical no clinical improvement response rate at w12 and w20 rate of cryoglobulinemia clearance rate of negativation of rheumatoid factor activity rate of normalization of c4 complement level early failure rate at w4 non clinical response at w4 clinical relapse rate and the time to relapse course of plasma cell associated disorder evolution of gammaglobulin level quality of life scores sf36 appendix 1 rate of infections severe or not and other complications birmingham vasculitis activity score bvas appendix 2 immunomonitoring deep immunophenotyping cytokines production spectrometry fish analysis single plasma cell repertoire",
    "DESIGN": "design of the study this is a phase 2 pilot prospective study of 21 patients with type i igg cryoglobulinemia treated by isatuximab isatuximab will be perform intravenously at 10mg kg at day 0 week w 1 w2 w3 and w4 then every 2 weeks for a total of 12 infusions scope of the trial phase ii prospective multicenter study from the french plasma cell neoplasm and cryoglobulinemia network is composed of hematologists internists rheumatologists dermatologists and nephrologists all patients will receive subsequently the same therapy 21 patients with type i igg cryoglobulinaemia will be treated by isatuximab isatuximab will be administred intravenously at 10mg kg at day 0 w1 w2 w3 and w4 then every 2 weeks for a total of 12 infusions",
    "INCLUSION CRITERIA": "population of study participants adult patients with type 1 igg active cryoglobulinemia vasculitis inclusion criteria 1 age 18 years 2 written informed consent 3 monoclonal gammopathy of unknown significance mgus with monoclonal igg component 4 active cryoglobulinemia vasculitis defined by positive or history of positive type i igg cryoglobulinemia and a clinically active cryoglobulinemia with skin joint renal pulmonary cardiovascular muscular digestive central and or peripheral neurological involvement 5 treated naïve or relapsers type i cryoglobulinemia patients 6 affiliated to national french social security system 7 contraception a male participants a male participant must agree to use a highly effective method of contraception during the participation period and for at least 5 months after the last dose of study treatment and refrain from donating sperm during this period",
    "EXCLUSION CRITERIA": "exclusion criteria 1 patient with a vasculitis unrelated to cryoglobulinemia 2 patient with nonactive cryoglobulinemia vasculitis 3 patient with diagnosis of multiple myeloma except indolent myeloma 4 patient treated with immunosuppressant e g alkylating agent rituximab chemotherapy for plasma cell neoplasms introduced or increased in the month prior to the inclusion 5 live vaccines within 30 days prior to baseline or concurrently with isatuximab 6 infection requiring hospitalization and or use of parenteral iv or im antibiotics antibacterials antivirals antifungals or antiparasitic agents within 60 days prior day 0 7 active tuberculosis 8 hiv positive positive ag hbs positive hcv rna 9 any clinically significant uncontrolled medical conditions that in the investigator s opinion would expose excessive risk to the patient or may interfere with compliance or interpretation of the study results 10 hypersensitivity or history of intolerance to steroids mannitol pregelatinized starch sodium stearyl fumarate histidine as base and hydrochloride salt arginine hydrochloride poloxamer 188 sucrose or any of the other components of study therapy that are not amenable to premedication with steroids and h2 blockers or would prohibit further treatment with these agents 11 hypersensitivity to the active substances isatuximab and premedication or to any of their excipients 12 received any investigational drug within 14 days prior to inclusion or within 5 halflives of the investigational drug whichever is longer 13 participation in another interventional study or being in the exclusion period at the end of a previous study 14 vulnerable populations o pregnant or breastfeeding women o persons deprived of liberty by judicial or administrative decision o persons under psychiatric care without their consent",
    "INTERVENTION": "investigational medicinal product s isatuximab administered intravenously at 10mg kg at day 0 w1 w2 w3 and w4 then every 2 weeks for a total of 12 infusions comparator treatment none",
    "STATISTICS": "statistical power and sample size justification we used the onesample multiple testing procedure for phase ii clinical trials report definitions fleming t r 1982 biometrics volume 38 pages 143151 to calculate the sample size report definitions p0 is the maximum response proportion of a poor drug p1 is the minimum response proportion of a good drug n is the sample size if the number of responses r 1 p0 is rejected if the number of responses r p1 is rejected alpha is the probability of rejecting that p p0 when this is true beta is the probability of rejecting that p p1 when this is true summary statements statistical analysis this is a pilot prospective phase ii clinical trial that aims at evaluating safety and efficacy of isatuximab in type 1 cryoglobulinemia vasculitis we hypothesize that up to 70 of the patients receiving isatuximab will achieve a complete remission of cryoglobulinemia vasculitis at week 20 w20 continuous variables cf variables described in primary and secondary objectives will be presented with the median and iqr or with the mean sem categorical variables will be presented with counts and proportions statistical comparisons will be performed by using the mannwhitney test for quantitative unpaired data ttest for quantitative paired data kruskalwallis for multiple comparisons spearman correlation test for correlations ttest for quantitative paired data analysis will be used to compare immunological changes between day 0 and week 12 and 20 after isatuximab all statistical tests will be twotailed with a significance level of 0 05",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference ice study isatuximab in type 1 cryoglobulinemia",
    "INVESTIGATOR": "coordinating investigator pr david saadoun department of internal medicine and clinical immunology centre national de référence maladies autoimmunes systémiques rares hospital pitié salpétrière tel 0142161051 email david saadoun aphp fr scientific director if applicable pr bertrand arnulf department of immunohematology hospital saint louis email bertrand arnulf aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects included 21 patients",
    "SITES": "number of sites multicenter national study including 17 centers",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial sanofi funds the trial and will provide isatuximab budget 350 000 euros plus the supply of isatuximab"
  },
  "GRAALL-2014": {
    "TITLE": "",
    "JUSTIFICATION": "",
    "OBJECTIVE": "objectives primary objective to prospectively validate the new risk model based on mrd1 response level and kmt2a mll and ikzf1 gene status by comparing historical results of graall 2005 with those of graall2014 in an identical population of patients ph b lineage all aged 18 to 59 years old to evaluate the efficacy of blinatumomabbased consolidation and maintenance therapy in term of dfs in hr patients graallquest substudy by comparing to historical results of graall2005 in an identical population of patients with hr features graallquest study secondary objectives to appreciate the tolerance of blinatumomabbased consolidation cycles in bridge to allosct or within further consolidation and maintenance therapy to evaluate mrd level monitored by igtcr to evaluate cumulative incidence of relapse cir and nonrelapse mortality nrm diseasefree survival dfs and overall survival os to evaluate rfs cir nrm and os after censoring at sct in first cr evaluation criteria primary evaluation criterion disease free survival dfs at 4 years depending on the status of kmt2a mll and ikzf1 genes and on mrd1 assessed after the induction cure or on d1 of consolidation 1 dfs at 3 years in the graallquest study secondary evaluation criteria cir nrm and os dfs cir nrm and os after censoring at allosct in first cr mrd followup at different treatment times cf infra mrd monitoring adverse events after blinatumomab graallquest",
    "DESIGN": "type of study multicenter open not controlled study sr patients phase ii multicenter open non controlled graallquest hr patients",
    "INCLUSION CRITERIA": "indication patients aged 1859 years old with de novo phnegative blineageall graall2014 b inclusion criteria patient 1 whose blood and bone marrow explorations have been completed before the steroids prephase 2 aged 18 to 59 years old with not previously treated including intrathecal injection blineageall newly diagnosed according to the who 2008 definition with 20 bone marrow blasts 3 whose karyotype shows no t 9 22 and or the absence in molecular biology of bcrabl 4 with ecog 3 5 with or without central nervous system cns or testis involvement 6 without other evolving cancer except basal cell carcinoma of the skin or in situ carcinoma of the cervix or its radiotherapy or chemotherapy treatment should be finished at least since 6 months 7 having signed a written informed consent 8 with efficient contraception for women of childbearing age excluding estrogens and iud 9 with health insurance coverage 10 who have received or being receiving the steroid prephase secondary all antecedent of chemo or radiotherapy can be included graallquest inclusion criteria patient 1 included in graall2014 b 2 with hr ball 3 ecog 3 4 in cr after one or two induction cures and having received the three blocks of consolidation n 1 5 with or without allogeneic donor",
    "EXCLUSION CRITERIA": "graall2014 b non inclusion criteria patient 1 with lymphoblastic lymphoma and bone marrow blasts 20 burkitttype all or with antecedents of cml or other myeloproliferative neoplasm 2 with contraindication to anthracyclines or any other general or visceral contraindication to intensive therapy except if considered related to the all a asat sgot and or alat sgpt 5 x uln b total bilirubin 2 5 x uln c creatinine 1 5x uln or creatinine clearance 50 ml mn 3 myocardial infarction within 6 months prior to inclusion in the trial cardiomyopathy nyha grade iii or iv lvef 50 and or rf 30 4 hiv htlvi or hcv seropositivity or chronic hbv hepatitis hbsagpositive 5 pregnant βhcg positive or nursing woman 6 not able to bear with the procedures or the frequency of visits planned in the trial 7 unable to consent under tutelage or curatorship or judiciary safeguard 8 women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least three months thereafter patients not willing to ensure not to beget a child during participation in the study and at least three months thereafter 9 treated with any other investigational agent or participation in another trial within 30 days prior to entering this study graallquest non inclusion criteria patient 1 with ecog status 3 after consolidation 1 2 with abnormal laboratory values as defined below after consolidation 1",
    "INTERVENTION": "experimental drug prescription outside ma blinatumomab blincyto hr patients enrolled in the graallquest study experimental drugs prescription according to ma cyclophosphamide methotrexate vincristine cytarabine vp16 dexamethasone 6 mercaptopurin daunorubicin idarubicin prednisone lasparaginase granulocyte colony stimulating factor gcsf reference treatment induction all patients will receive an induction course patients without hcr at the end of induction will receive salvage therapy the differential diagnosis of ph blineageall should be done during the prephase so that these patients receive graaph2014 igtcr mrd1 level will be evaluated at the end of the induction cycle orat day 1 of the first consolidation phase consolidation 1 all patients in hcr after induction eventually followed by salvage will receive 0 1 or 2 interim standby blocks before the first consolidation comprising 3 blocks of chemotherapy blocks s1 s2 s3 these standby blocks will allow to recover from potential toxicities of the induction notably hepatic to avoid modifying the order of the following consolidation blocks and to respect the dosage intensity hr versus sr patients will be attributed to a risk group during the first consolidation according to mrd1 level need for salvage to obtain chr presence of ikzf1 gene deletion and kmt2a mll gene rearrangements all hr patients will be proposed the phase ii graallquest study up to 95 inclusions after this number has been reached hr patients who would have been eligible for graall quest will continue to participate to the study and its followup planned in graall 2014 b igtcr mrd2 level will be evaluated at the end of the consolidation 1 or on day one of consolidation 2 consolidation 2 after first consolidation sr patients will continue the standard protocol and receive the consolidation 2 blocks s4 s5 s6 95 hr patients will be traited in phase ii graallquest study and will receive blinotumomab consolidation 2 is composed of 3 blocks b4 blina b5 hdarac b6 hd mtx hr versus vhrmrd vhrmrd is defined by mrd1 103 or the need of a salvage cure to reach hcr or mrd2 104 patients eligible for allosct with a suitable donor will receive blinatumomab continuous infusion until conditioning regimen igtcr mrd3 level will be evaluated at day 1 of late intensification or prior to sct in allografted patients chemotherapy induction graall2014 b prednisone 60 mg m2 d po d114 * vincristine 2 mg d ivd d1 d8 d15 d22 daunorubicin 50 mg m2 d iv 30 min ** d1 d2 d3 30 mg m2 d iv 30 min d15 d16 cyclophosphamide 750mg m2 d iv 3h d1 d15 lasparaginase 6000 ui m2 d siv 1h d8 d10 d12 d20 d22 d24 d26 d28 *** gcsf 5 µg kg d sc or iv d18 until neutrophil 1g l it mtx arac depomedrol d1 d8 * only from d1 to d7 if age 45y ** reduced to 30 mg m2 d if age 45y *** at d8 d10 d12 d20 d22 d24 if age 45y substituted by erwinase if immunization to e coli lasparaginase salvage idarubicin 12 mg m2 d iv 1h d1 d2 d3",
    "STATISTICS": "statistical justification of sample size each year approximately 100 patients with phnegative bcpall may be recruited frontline in the graall2014 b trial after hcr achievement one may anticipate approximately 40 sr patients year and 50 hr patients year including 3035 vhrmrd patients after consolidation 1 all sr patients will be treated by the standard graall protocol without new agent nor hsct in first chr the objective is here to demonstrate in an uncontrolled study the noninferiority in terms of 4year dfs which must be at least of 60 in the control group historical reference with a margin of inferiority of 15 justifying the absence of allosct in first cr with a 0 05 unilateral alpha risk and a 0 90 power the calculated sample size is 110 patients about 50 hr patients year will be eligible for graallquest study with dfs as primary endpoint dfs will be compared to historical graall2005 results 50 at 3 years the objective is here to demonstrate a 50 to 65 dfs improvement with a 0 05 alpha risk and a 0 90 power in the twosided setting the calculated sample size is 91 patients considering a dropout rate of about 5 95 patients should be included in the present study ref sample size tables for clinical studies machin d campbell m et al wiley 2009",
    "DSMB": "independent surveillance committee planned yes",
    "ACRONYM": "acronym graall2014 b and graallquest",
    "INVESTIGATOR": "coordinator pr hervé dombret hématologie hôpital saint louis paris tél 33 0 1 57 27 68 47 0 1 42 49 96 48 email herve dombret aphp fr",
    "NUMBER OF INCLUSIONS": "number of selected subjects 500 patients frontline 95 patients for the graallquest study",
    "SITES": "number of centers about 80 centers expected belgium france switzerland",
    "FUNDING": "sponsor assistance publique hôpitaux de paris financing phrc"
  },
  "ETOLE": {
    "TITLE": "full title evaluation of tomosynthesis in the characterization and management of breast",
    "JUSTIFICATION": "rationale tomosynthesis is an innovative technique developed in digital mammography for obtaining a sectional image of the breast mammography has the main disadvantage of being an imaging projection that creates overlays which eliminates tomosynthesis",
    "OBJECTIVE": "objective and primary endpoint evaluate if birads classification obtained with tomosythesis is superior to classification obtained by conventional mammography in terms of specificity and noninferior in terms of sensitivity joint analysis of true negative and false negative rates according to birads scale as compared to the histological results or followup outcome see gold standard below objectives and secondary endpoints evaluate if tomosynthesis with synthetic tomography allows a better detection of certain signs of poor prognosis for malignant lesions size and multicentricity of the tumour lymph node extension skin or pectoral infiltration if tomosynthesis with synthetic tomography modifies the number of additional views and or number of additional examinations including ultrasound breast mri and biopsy assess whether tomosynthesis reduces the necessary number of ultrasound and compare the differences in ratings birads obtained by tomosynthesis with synthetic mammography and then with ultrasound to the differences obtained with conventional mammography alone and then combined with ultrasound if tomosynthesis with synthetic mammography changes the radiation dose received by the patient if tomosynthesis with synthetic mammography improves the reproducibility of the birads classification for abnormalities the costs analysis of tomosynthesis with synthetic mammography compared to mammography and or mammography ultrasound",
    "DESIGN": "experimental design a randomized multicentric study phase iii diagnostic study according to the classification of gluud gluud 1 during the inclusion phase 18 months a tomosynthesis system will be installed at each site by the manufacturer all patients with a clinical or breast imaging abnormally at each of these sites during the study period and having given informed consent will be randomized to either a conventional mammography or tomosynthesis 4 incidences with synthetic mammography diagnostic method evaluation of tomosynthesis in the characterization and management of breast reference diagnostic method conventional digital mammography",
    "INCLUSION CRITERIA": "population concerned women having clinical or breast imaging abnormalities inclusion criteria patient having clinical or breast imaging abnormalities classified as birads 3 4 5 table 1 5 patient over 18 years old signed informed consent",
    "EXCLUSION CRITERIA": "noninclusion criteria patients at high risk of breast cancer mutations brca 1 or 2 carriers li fraumeni or history of thoracic radiation will be excluded because of their greater sensitivity to ionizing radiation 3 3 15 1 4 11 patient unable to give informed consent for physical mental or legal reasons patient not affiliated with french social security insurance patient under treatment for breast cancer when mammography is not recommended according to good practice by the french health authority has pregnant patient",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis the analysis comparison of the birads classifications obtained by mammography and then by tomosynthesis will rely on the construction of simultaneous confidence intervals for the ratios of true negative rates specificity and false negative rates 1sensitivity obtained with each technics in the mammography tomosynthesis arm as described by alonzo et al",
    "DSMB": "dsmb data safety monitoring board yes",
    "ACRONYM": "acronym etole",
    "INVESTIGATOR": "coordinating investigator professor cédric de bazelaire service de radiologie hôpital saintlouis paris tél 33 1 42 49 91 33 courriel cedric debazelaire aphp fr",
    "NUMBER OF INCLUSIONS": "number of subjects required 2000 subjects",
    "SITES": "number of centers 4 centers saintlouis hospital tenon hospital lariboisière hospital and hegp",
    "FUNDING": "sponsor assistance publique hôpitaux de paris"
  },
  "MAC-HAPLO-MUD": {
    "TITLE": "full title randomized prospective phase iii clinical trial comparing hla 10 10 matched unrelated donor and haploidentical allogeneic hematopoietic stem cell transplantation after myeloablative conditioning regimen",
    "JUSTIFICATION": "scientific justification an unrelated adult donor who is hlamatched to the recipient at the allelelevel at hlaa b c dqb1 and  drb1 is considered the best choice in the absence of an hlamatched sibling for patients needing hematopoietic stem cell transplantation sct however using matched unrelated donors mud is limited by 1 a prolonged time to identify and schedule donation for some mud allowing some patients to relapse before transplantation can be performed and 2 limited availability of fully hlamud for the noncaucasian population alternative donors single hla mismatched unrelated donor unrelated umbilical cord blood and grafts from haploidentical related donors are still associated with higher nonrelapse mortality and delayed immune reconstitution a more recent strategy for haploidentical haplo related donor sct haplosct have improved dramatically outcomes using tcell replete grafts with administration of posttransplantation cyclophosphamide ptcy which targets alloreactive t cells generated early after an hla mismatched transplant sparing regulatory t cells and leaving unaffected the nondividing hematopoietic stem cells and standard posttransplant immune suppression with a calcineurin inhibitor cni and mycophenolate mofetil from retrospective studies haplosct with ptcy are associated with similar overall and progressionfree survivals as with mud stem cell transplantation mud sct but with lower rates of toxicity and graft versus",
    "OBJECTIVE": "main objective and primary endpoint main objective to improve the 1year progression free survival without acute grade iiiv gvhd and without moderate or severe chronic gvhd using of the haplo donor compared with 10 10hla mud after myeloablative sct primary endpoint a 1year progression free survival without grade iiiv acute gvhd and without moderate or severe chronic gvhd of 65 after haplo sct versus 50 after 10 10hla mud secondary objectives and endpoints secondary objectives 1 to compare the two arms in terms of clinical and biological outcomes kinetic of haematopoietic reconstitution and graft failure gvhd progression free survival relapse non relapse mortality overall survival interval between inclusion and transplant rehospitalizations treatment related morbidity quality of life chimerism immune reconstitution 2 to search for prognostic factors of the main outcome globally and in each arm 3 to search for treatmentbycovariate interactions on the main outcome secondary endpoints interval between inclusion and transplant absolue numbers of neutrophils and platelets at m1 m2 m3 m6 and m12 chimerism at m1 m3 m6 m12 m24 acute gvhd incidence and grading chronic gvhd incidence and grading relapse incidence progression free survival severe infections ctcae grade 34 incidence of veinoocclusive disease incidence of cardiac toxicities nonrelapse mortality overall survival quality of life questionnaire ebmt",
    "DESIGN": "design of the trial randomized prospective phase iii clinical trial comparing hla 10 10 matched unrelated donor and haploidentical allogeneic hematopoietic stem cell transplantation after myeloablative conditioning regimen scope of the trial our goal is to show a superiority of haplosct primary endpoint but even if similar results between both arms are obtained this study might revolutionize the strategy of sct since haplo donors will be used in priority compared with mud quick procedure cheaper and available for",
    "INCLUSION CRITERIA": "population of trial subjects patients 15 year of age or older with high risk hematological malignancies and with an indication of allogeneic hematopoietic stem cell transplantation inclusion criteria  patients  aged 15 to 55 years old  with aml all smd smp requiring allogeneic stem cell transplantation  at least in partial response of their malignant disease  without hla matched related donor  with a strong probability to have both a related haplo  donor and a hla10 10 matched donor available the patient needs to have at least 5 mud identified outside  the book bmdw bone marrow donors worldwide or using the easy match software to be included  with usual criteria for hsct ecog 2 no severe and uncontrolled infection cardiac function compatible with high dose of cyclophosphamide adequate organ function asat and alat 2 5n total bilirubin 2n creatinine 150 µmol l except if those abnormalities are linked to the hematological disease  with health insurance coverage  understand informed consent or optimal treatment and followup  prescription of two effective contraception methods must be prescribed during all the duration of the study  having signed a written informed consent 2 parents for patients aged less than 18",
    "EXCLUSION CRITERIA": "exclusion criteria  patients  with cancer in the last 2 years except basal cell carcinoma of the skin or in situ carcinoma of the cervix  with uncontrolled infection  with seropositivity for hiv or htlv1 or active hepatitis b or c  yellow fever vaccine  heart failure according to nyha ii or more  bile duct obstruction  preexisting acute hemorrhagic cystitis  renal failure with creatinine clearance 30ml min",
    "INTERVENTION": "experimental group haplo donor myeloablative sct with use of cyclophosphamide 50 mg kg day by intravenous route at d 3 and d 4 after stem cell transplantation treatment transplant modalities 1 conditioning regimen for patients with myeloid malignancies a for haploidentical sct thiotepa 5mg kg day day 7 and 6 fludarabine 40mg m2 day day5 to2  iv busulfan 3 2mg kg day day5 to3 b for hlamatched unrelated donor sct fludarabine 30mg m2 day day6 to2 iv busulfan 3 2mg kg day d6 to3 for patients with all fludarabine 30 mg m2 day on days 7 to 5 and tbi 200 cgy twice daily on days 4 to 2 total dose 1200 cgy 2 stem cell source bone marrow for haploidentical sct peripheral blood stem cell pbsc for hlamatched unrelated transplantation 3 gvhd prophylaxis for haploidentical sct cyclophosphamide 50 mg kg day at d 3 and d 4 ciclosporine and mycophenolate mmf from d 5 for hlamatched unrelated donor sct antithymocyte globuline thymogobuline 5 mg kg total dose 2 5mg kg at day 3 and 2 cyclosporine at day 1 and mmf at day 1 in the absence of gvhd mmf will be stopped at d 35 in both arms",
    "STATISTICS": "statistical analysis justification of sample size we hypothesize the 1year progression free survival without grade iiiv acute gvhd and without moderate or severe chronic gvhd will be of 65 after haplo sct versus 50 after 10 10hla mud 172 patients in both arms n 344 overall are required to demonstrate such a difference based on a twosided logrank test 0 05 and power 0 80 hr 0 62 with a required total number of events of 146 the bayesian interim analysis will not inflate interim analysis at midinclusion this will be based on the bayesian computation of stopping rules based on the modeling of the log hazard ratio hr of the main endpoint spiegelhalter 1994 non informative prior of the loghr will be considered terminal analysis after the observation of the required number of events",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "abbreviated title machaplomud",
    "INVESTIGATOR": "coordinating investigator pr régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of subjects included 344",
    "SITES": "number of sites 36 centres",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial industrial and patients associations funding"
  },
  "SHORTCUT": {
    "TITLE": "full title efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients a multicentre randomized noninferiority trial",
    "JUSTIFICATION": "scientific justification infections are a major cause of morbidity and mortality in solid organ transplant recipients in kidney transplant recipients ktr urinary tract infection uti represent 45 72 of all infections and 30 of all hospitalizations for sepsis acute transplant pyelonephritis are the most common complications occurring in more than 20 of patients mainly in the first year after transplantation they are associated with an increased risk of acute kidney rejection and longterm kidney graft dysfunction gram negative bacteria mainly e coli account for more than 70 of uti in ktr as those infections are favored by urinary tract modifications defects and immunosuppression they are often recurrent and necessitate repeated courses of antibiotics selective pressure due to antibiotic consumption along with frequent hospital admissions and immunosuppression are well known risk factors for the development of antibiotic resistant infections multidrug mdr  or extensively xdr  drug resistant enterobacteriaceae including esbl or carbapenemaseproducing organisms are thus increasingly observed in transplant units and represent a global threat as very few new antibiotics are expected in the next decade one main strategy to limit antimicrobial resistance is to reduce the duration of antibiotic treatment a 7 day course is recommended for simple acute pyelonephritis apn treated with fluoroquinolones or parenteral b lactams prolonged up to 10 or 14 days in the presence of underlying disease at risk of complications most kt teams treat patients between 14 21 days as recommended by american guidelines however the need to extend treatment duration in immunosuppressed patients is a poorly defined concept and the optimal duration of treatment for apn in ktr is not known as these patients are excluded from most studies",
    "OBJECTIVE": "main objective and primary endpoint to show that a 7 dayantibiotic therapy is not inferior to a 14 dayantibiotic therapy in the treatment of acute pyelonephritis in kidney transplant recipients primary endpoint clinical cure and no additional antibiotic treatment since the end of antibiotic treatment up to the main evaluation at day 30 clinical cure is defined as fever 38 c and no symptoms of uti secondary objectives and endpoints to compare between both arms clinical cure at day 90 and day 180 microbiological cure at day 30 90 and 180 tolerance and safety of antibiotics hospitalization length stay antibiotic consumption during total follow up acquisition of antibiotic resistant enterobacteriaceae kidney graft function and transplant rejection at day 90 and day 180  the total costs to evaluate risk factors for failure and relapse recurrence to evaluate efficacy of the antibiotic treatment at the end of treatment d7 for experimental arm and d14 for control group secondary endpoints  clinical cure at day 90 and 180  microbiological cure *at day 30 90 and 180  incidence of relapse recurrence between day 30 and day 90  incidence of adverse events imputable to antibiotic treatment  kidney function assessed according to mdrd modification of diet in renal disease or ckd chronic kidney disease  epidemiology collaboration epi  hospitalization length stay defined by the delay between the date of inclusion and the date of hospital discharge  antibiotic consumption  rectal carriage of antibiotic resistant enterobacteriaceae at inclusion and day 30",
    "DESIGN": "design of the trial multicenter controlled randomized noninferiority open label clinical trial with 2 parallel groups 1 1 7 days versus 14 days of antibiotic treatment the randomization will be stratified by date of renal transplantation 1 year and 1 year center and sex potential confounders scope of the trial phase iv trial",
    "INCLUSION CRITERIA": "population of trial subjects ktr with acute pyelonephritis inclusion criteria age 18 years ktr apn defined by fever t 38 c with or without clinical signs and or symptoms of uti and pyuria 104 white blood cells ml or 10 mm3 and positive urine culture uropathogen 103 cfu ml susceptible to the empirically administrated antibiotic no confirmed or suspected febrile non urinary bacterial infection no urologic renal complication at baseline imaging abscess obstruction  favourable early response to antibiotic treatment 48 to 60 hours after the first dose of antibiotic effective against the causative uropathogen defined by t 38 c and improvement or resolution of signs and or symptoms of urinary tract infection if present at diagnosis  written informed consent",
    "EXCLUSION CRITERIA": "exclusion criteria patients with any of the following conditions severe or complicated condition  any rapidly progressing disease or immediately life threatening illness including but not limited to septic shock current or impeding respiratory failure acute heart or liver failure  admission or stay in intensive care unit at baseline  obstruction of the urinary tract  renal perinephric or prostatic abscess  prior inclusion in this study  current participation to another interventional study dual antibiotic therapy prophylactic antibiotic such as cotrimoxazole allowed only 1 dose of aminoside is allowed before randomization first month post transplantation current indwelling catheter including bladder catheter ureteral stents percutaneous nephrostomy tubes neurogenic bladder enterocystoplasty immunodeficiency or immunosuppressive therapy not related to kidney transplantation including hematologic",
    "INTERVENTION": "comparator treatment standard 14 days antibiotic duration",
    "STATISTICS": "statistical analysis sample sizes of 235 in each group achieve 80 power to detect a noninferiority margin difference between the group proportions of 0 05 the reference group proportion is 0 95 the treatment group proportion is assumed to be 0 90 under the null hypothesis of inferiority the power was computed for the case the actual treatment group proportion is 0 90 the test statistic used is the onesided z test unpooled the significance level of the test is 0 05",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym shortcut",
    "INVESTIGATOR": "coordinating investigator dr matthieu lafaurie infectious diseases saint louis hospital paris",
    "NUMBER OF INCLUSIONS": "number of subjects included 470",
    "SITES": "number of sites 10",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial ministry of health"
  },
  "CAMOVID": {
    "TITLE": "full title camovid a multicenter randomized trial to evaluate the efficacy and safety of camostat mesylate for the treatment of sarscov2 infection covid19 in ambulatory adult patients",
    "JUSTIFICATION": "scientific justification since december 2019 a novel coronavirus called sarscov2 severe acute respiratory syndrome coronavirus 2 has caused an international outbreak of respiratory illness described as covid19 on the 22nd march 2020 2920142 confirmed cases of covid19 including 12784 deaths were reported by the world health organization 1 on the 31 march 2020 there were 52827 severe cases in france including 3532 deaths the spectrum of symptomatic infection ranges from mild to critical if most infections are not severe 15 of infected patients will require hospitalization and 5 will require intensive care unit admission 2 the diagnosis of sarscov2 infection relies on clinical symptoms and microbiological testing to test for sarscov2 infection testing centers use a reverse transcription polymerase chain reaction rtpcr on nasal swab in patients with productive cough a number of investigational agents are being explored for antiviral treatment of covid19 however to date there are no controlled data supporting the use of any specific treatment antiviral drugs or immunomodulatory drugs and their efficacy for covid19 is unknown 3 sarscov2 infects human cells through the binding of its spike s protein to the membranous aminopeptidase called ace2 angiotensin converting enzyme 2 among other tissues ace2 expression has mainly been found on pneumocytes enterocytes renal tubular cells and podocytes cellular entry of sarscov2 requires s protein priming by cellular serine protease tmprss2 which entails s protein cleavage and allows fusion of viral and cellular membranes 4 in a murine model of sarscov pneumonia iwatayoshikawa et al showed that tmprss2ko mice had weakened inflammatory cytokine responses and reduced lung injury than control mice 5 hoffmann et al found that a tmprss2 inhibitor the camostat mesylate blocked viral entry and reduce infection of human primary pneumocytes and lung cell lines by sarscov2 they also showed that the sera from convalescent sars patients crossneutralized sars2s driven entry 4 another study performed by bojkova et al 5 showed that camostat mesylate reduced cytopathogenic effect due to sarscov2 in human colonic cell lines camostat mesylate is a serine protease inhibitor that is commonly used in japan at a dose of 600 mg day and has been successfully and safely used to treat pancreatitisassociated pain 6 and postoperative reflux oesophagitis 7 side effects that have been reported are rare at these doses nausea diarrhea",
    "OBJECTIVE": "main objective and primary endpoint objective evaluate the efficacy of camostat mesylate in the treatment of sarscov2 infection in highrisk adult patients with confirmed covid19 not requiring initial hospitalization in terms of hospitalization needs up to day 21 after randomization primary endpoint proportion of patients hospitalized for covid19 deterioration or who died without hospitalization between day 1 and day 21 as an indicative basis criteria for hospitalization will be the presence of any of the following respiratory rate 24 min at rest sp02 95 on room air blood pressure 100 mmhg lethargy or unconsciousness brutal overall deterioration or lethargy in the elderly hcsp and any all other reasons requiring hospitalization left at the discretion of the physician secondary objectives and endpoints secondary objectives in adult patients diagnosed with laboratory confirmed covid 19 not requiring initial hospitalization to evaluate the impact of camostat mesylate compared to placebo on  safety up to day 21  efficacy in terms of need for hospitalization for covid19 management by independent blinded committee review  overall clinical improvement at day 21  clinical efficacy in terms of intensive care needs up to day 21  clinical efficacy in terms of time to hospitalization up to day 21  clinical efficacy on respiratory functions up to day 21  overall survival at day 21 and 90 after randomization  patientreported outcome on initial symptoms up to day 21  virological serological and immunological efficacy up to day 90 including surrogacy assessment of candidate markers up to day 90  renal complications up to day 21  liver complications up to day 21  covid19 transmission within the same household secondary endpoints  adverse events aes number of aes number of serious aes saes investigational medication discontinuation for any reason up to 21 days  independent endpoint adjudication committeereviewed proportion of patients hospitalized between day 1 and day 21 for covid19 deterioration the independent eac will review patients files blinded to the randomized group and determine whether hospitalization criteria were related to covid19 or not  who covid19 clinical improvement ordinal scale 3 at day",
    "DESIGN": "design of the study multicenter singleblinded placebocontrolled twoarm parallel 1 1 randomized phase iii trial",
    "INCLUSION CRITERIA": "population of study participants ambulatory adult highrisk patients with laboratory confirmed covid19 not requiring initial hospitalization inclusion criteria 1 patients 18 years old 2 patients with an increased risk of severe covid19 belonging to one or more of the following groups * age 50 years * body mass index 30 kg m² * diabetes * hypertension * chronic renal failure egfr 60 ml min * chronic heart disease *asthma chronic obstructive pumonary disease cystic fibrosis * chronic liver disease * chronic neurological disease * solid organ transplant * bone marrow transplant * sickle cell anemia major thalassemias * active or currently treated or 1 year diagnosed cancer * active or currently treated or 1 year diagnosed malignant blood disease * immunosuppressive treatment observed for more than 1 month 3 laboratory confirmed sarscov2 infection with mild covid19 fulfilling all the following criteria  positive sarscov2 rtpcr nasal or saliva swab samples or positive sarscov2 antigen test performed within 96h of inclusion visit and  clinical symptoms and signs consistent with sarscov2 infection including but not limited to fever upper respiratory tract infection signs digestive signs muscle pain anosmia dysgueusia 1 4 informed consent to participate to the trial 5 patients must be able and willing to comply with study visits and procedures",
    "EXCLUSION CRITERIA": "exclusion criteria 1 initial need for hospitalization for covid19 management defined as any of the following severity criteria respiratory rate 24 min at rest sp02 95 on room air blood pressure 100 mmhg lethargy or unconsciousness brutal overall deterioration or lethargy in the elderly recommendations hcsp all other reasons requiring immediate hospitalization left at the discretion of the physician 2 pregnancy and breastfeeding 3 participation to another interventional drug trial 4 subject protected by law under guardianship or curatorship 5 absence of health insurance 6 known hypersensitivity to camostat mesylate 7 known person sharing the same household already included in the study 8 participation to another covid19 ambulatory interventional study",
    "INTERVENTION": "investigational medicinal product s camostat mesylate oral administration 600mg day 2 x 100mg every 8 hours for 14 days day 1 to day 14 comparator treatment placebo tablets following the same schedule as investigational drug",
    "STATISTICS": "statistical analysis descriptive analyses will use either frequencies and percentages for categorical variables or median and interquartile range for quantitative variables number of missing values will be reported the primary endpoint probability of hospitalization within 21 days will be compared between groups using a twosided z test secondary endpoints will be compared across groups using fisher s exact test when comparing probabilities between groups and wilcoxon s rank sum test when comparing quantitative endpoints all analyses will be performed under the intentiontotreat principle a 5 twosided significancelevel will be used for comparisons of secondary endpoints",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference camovid",
    "INVESTIGATOR": "coordinating investigator dr david boutboul scientific director pr lara zafrani",
    "NUMBER OF INCLUSIONS": "number of participants included n 596 planned from the current knowledge on sarscov2 infection in adults we expect roughly 20 of newly diagnosed highrisk patients being hospitalized within 21 days 8 the design initially included a planned interim analysis after one third of observations had been completed a maximum total sample size of 536 evaluable patients 268 per treatment group would allow 90 power to detect an absolute difference of 10 in the probability of hospitalization at day 21 between groups e g reduction from 20 to 10 using a ztest with onesided 2 5 significance level for efficacy using lan demets riskspending functions o brien fleming boundaries approximation for efficacy and futility stopping rules overall 596 patients 298 in each group would be included to anticipate a potential 10 dropout rate given the ambulatory followup however due to the status of the pandemics as of fall 2021 and global use of vaccines the scientific comittee decided to stop recruitment to eventually discontinue the trial early the planned interim sample size has not been reached eventually only a single final analysis will be performed at the 2 5 one sided significance level for the primary endpoints other endpoints will be analysed as planned",
    "SITES": "number of centres recruiting centers 1 emergency department of saint louis hospital paris 2 covid19 screening center at bichat hospital 3 emergency department of argenteuil hospital 4 centre de santé richerand 75010 paris 5 emergency department of h mondor hospital créteil 6 outpatient consult of the infectious disease deparment covid screening center of henri mondor hospital créteil 7 outpatient consult of the sickle cell disease and inherited red blood cell genetic disorders coordinating referral center at h mondor hospital créteil 8 postemergency internal medicine department of h mondor hospital créteil 9 department of infectious and tropical diseases public health unit groupe hospitalier sud ile de france ghsif melun 10 emergency department of lariboisière hospital paris nonrecruiting centers followup visits",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources phrc covid19200095"
  },
  "GREEN": {
    "TITLE": "full title a randomized doubleblind multicenter placebocontrolled efficacy and safety study of glenzocimab used as an addon therapy on top of mechanical thrombectomy for acute ischemic stroke",
    "JUSTIFICATION": "scientific justification emergent reperfusion is the main goal for acute ischemic stroke therapy ais endovascular therapy evt is recommended within 6 hrs of stroke onset and up to 24 hrs following perfusion imaging criteria despite the major benefit associated with mt more than 50 of the patients remain disabled at 3 months reperfusion rates after mt are critical to determine functional outcome however complete reperfusion is obtained in only 50 of the patients due to at least in part erratic emboli and or noreflow processes thrombus composition analysis has shown that platelet rich clots are more resistant to alteplase suggesting that platelets inhibition represent a relevant target to improve reperfusion nevertheless the currently available molecules are not recommended at the acute phase due to the associated sich risk therefrom there is still a need for a safe and efficient antithrombotic agent administrable at the acute phase without inducing a bleeding risk in order to reduce the size of the clot to favour cerebral reperfusion the results obtained during the escalating dose phase of the actimis study showed very promising safety data after the completion of the five cohorts where a dose progression has been carried out the study dsmb members recommended to use the highest dose 1000 mg for the consolidation phase",
    "OBJECTIVE": "study objectives primary objective to evaluate the efficacy of glenzocimab in addition to evt and compared to evt plus placebo whether or not associated with ivt on functional outcome at day 90 secondary objectives to evaluate the impact of glenzocimab in addition to evt compared to evt whether or not associated with ivt plus placebo on overall survival at day 90 and 1 year to evaluate the impact of glenzocimab in addition to evt compared to evt whether or not associated with ivt plus placebo on 1 reperfusion at the end of evt 2 early clinical improvement at 24 hrs 3 symptomatic intracranial haemorrhage at 24 hrs 4 overall intracranial haemorrhage at 24 hrs 5 serious adverse events saes 6 suspected unexpected serious adverse reactions susars at 24 hrs and at day 90 7 bleedingrelated events bres at 24 hrs and at day 90 8 quality of life at day 90 and 1 year to evaluate the cost effectiveness of glenzocimab in addition to evt compared to evt plus placebo study endpoints primary efficacy endpoint the primary efficacy endpoint is the functional outcome at day 90 assessed by the modified mrs at day 90  15 days secondary endpoints efficacy favourable functional outcome defined by a mrs score 2 at day 90 proportion of patient with severe handicap mrs 4 6 at day 90 overall survival at day90 and 1 year early reperfusion outcomes o stroke volume by brain imaging at 24 hrs o reperfusion at the end of mt procedure assessed by etici score o early neurological improvement by nihss at 24 hrs eq5d5l at day 90 and 1 year",
    "DESIGN": "design phase category this is a national multicenter prospective randomized 1 1 ratio parallel group doubleblinded placebo controlled phase ii iii study  category 2",
    "INCLUSION CRITERIA": "population of study participants patients over 18 with a clinical diagnosis of ais from a large cerebral vessel occlusion lvo between 0 and 24 hrs of symptom onset or when a patient has been seen the last time well and eligible for evt based on perfusion imaging for the time window 624 hours inclusion criteria 1 age 18 years or older age 18 years 2 no significant prestroke disability prestroke mrs must be equal to 0 or 1 3 indication of evt within the timewindow of 0 to 24 hrs in participants treated with or without intravenous thrombolysis and presenting with a clinico radiological mismatch defined by a nihss 10 and an aspect score 6 4 occlusion of the cervical or intracranial internal carotid artery ica or the proximal middle cerebral no significant prestroke disability prestroke mrs must be equal to 0 or 1",
    "EXCLUSION CRITERIA": "non inclusion criteria 1 contraindications to evt 2 contraindication to contrast agents 3 preexisting neurologic and psychiatric disease with mrs 2 4 unknown symptom s onset or last seem well 24 hours 5 patients under or needing immediate dapt administration 6 significant mass effect with midline shift as confirmed on ct mri 7 gastrointestinal or urinary tract hemorrhage in previous 21 days 8 patient with intracranial haemorrhage 9 known platelet count 100 000 mm3 10 pregnant or breastfeeding woman 11 known hypersensitivity to glenzocimab or to any of the excipients 12 known severe renal insufficiency grades 45 with a glomerular filtration rate 30ml min 1 73m2 13 participation in another interventional clinical trial within 30 days prior to the inclusion 14 persons deprived of their liberty by a judicial or administrative decision persons subject to psychiatric care under sections l 32121 et l 32131 and persons admitted to a health or social institution for purposes other than research l 11216 15 adults subject to a legal protection measure l 11218 16 the patient or his her family if the patient is unable to give his her opinion expresses an inability to return for protocol visits 17 patients receiving anticoagulants i e heparin within 48 hours and an elevated aptt greater than upper limit of normal for laboratory current use of oral anticoagulants ex warfarin and inr 1 7 current use of direct thrombin inhibitors or direct factor xa inhibitors as already mentioned in the nonauthorized concomitant treatments 18 patients who have already received another humanized fragment of monoclonal antibody with a suspicion of hypersensitivity exclusion criteria 1 withdrawal of consent 2 patient s wish to withdraw from the trial 3 persons deprived of their liberty by a judicial or administrative decision persons subject to psychiatric care under sections and persons admitted to a health or social institution for purposes other than research l 11216",
    "INTERVENTION": "concomitant treatments nonauthorized concomitant treatments patients should not receive any other experimental therapies during the 90 days of the study participation in addition to the aforementioned exclusion criteria patients should not receive a dual antiplatelet therapy dapt required after an intra and or extracranial stent or a thrombolysis with tenecteplase during glenzocimab infusion authorized concomitant treatments all other symptomatic treatments used routinely for disease related symptoms will be allowed in all patients involved in this trial specific treatments for any adverse events will also be permitted thrombolysis with alteplase antiplatelet monotherapy are allowed glenzocimab should be started as soon as possible in addition with alteplase details of all treatments or procedures must be recorded in the ecrf investigational medicinal product s glenzocimab act017 acticor biotech is formulated for iv administration as a sterile product with 20 mm sodium citrate and 130 mm sodium chloride buffer at ph of 5 0 it is supplied for clinical trial use in vials containing 50 ml of the drug product at a concentration of 10 mg ml each vial contains 500 mg of glenzocimab two vials 2x500 mg of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g comparator treatment placebo of glenzocimab is 0 9 nacl acticor biotech for iv administration it is supplied for clinical trial use in vials of 50 ml two vials of placebo of glenzocimab should be administered concomitantly for eligible patients study intervention the administered study treatment will be glenzocimab or placebo as per central randomization allocation to the study group into which the patient is randomized one arm will receive glenzocimab and the other arm the placebo in addition to evt evt itself is not added by the research glenzocimab or the placebo is intended to be administered as an iv infusion over 6 hrs with ¼ of the dose administered by a 15minute bolus and ¾ of the dose administered by 5h45min slow infusion this is the proposed scheme to obtain a rapid",
    "STATISTICS": "statistical analysis an interim analysis will be performed when 30 of the patient enrolment will be achieved 78 patients in the control group we considered that the distribution of the mrs is 0 0 10 1 0 17 2 0 19 3 0 17 4 0 16 5 0 06 6 0 15 we calculated that a sample of 258 patients would yield a power of 80 to detect a treatment effect associated with an or of 1 85 considered a twosided p value of 0 05 as we planned an interim analysis at 78 patients with an o brien and fleming scheme we increased the sample size to 260 the first interim analysis will be considered as statistically significant if the p value is below to 0 0054 the final analysis will be considered as statistically significant if",
    "DSMB": "dsmb data safety monitoring board dsmb will be composed by four members three neurologists and one statistician",
    "ACRONYM": "short title glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction study acronym green study clinical trial code aphp201028 actcs004",
    "INVESTIGATOR": "coordinating investigator prof mikael mazighi department of neurology aphp lariboisière hospital 2 rue ambroiseparé  75010 paris france scientific director if applicable jeanmarc olivot department of neurology university of hospital of toulouse",
    "NUMBER OF INCLUSIONS": "number of participants included 260",
    "SITES": "number of centres 13",
    "FUNDING": "sponsor assistance publique hôpitaux de paris aphp and by delegation délégation à la recherche clinique et à l innovation  drci clinical research and innovation department hôpital saintlouis  1 avenue claude vellefaux 75010 paris  france funding sources anr"
  },
  "TEOREM": {
    "TITLE": "full title multicenter randomized doubleblind clinical trial assessing the benefit of adherent invasive e coli eradication in adult ileal and ileocolonic crohn disease",
    "JUSTIFICATION": "scientific justification current medical treatment of crohn disease cd consists of immunosuppressive drug therapy corticosteroids azathioprine methotrexate antitnf monoclonal antibodies these agents control symptoms of cd in most patients but their withdrawal leads to disease relapse they are also associated with serious side effects infections lymphoma cancer liver toxicity antitnf monoclonal antibodies are the most efficient but are cost prohibitive moreover each year roughly 10 of responders to antitnf become refractory to treatment most often because they become tolerized to these drugs future cd drugs are small molecules or biologics that antagonize proinflammatory cytokines or gut homing of lymphocytes yet they have similar safety issues as the immunosuppressive agents currently in use the current therapeutic algorithm for cd does not take into account the site of inflammation or composition of intestinal microbiota moreover dysregulated intestinal immunity and overproduction of proinflammatory cytokines are not the only components of cd pathophysiology intestinal microbiota is abnormal and plays an important role in the pathogenesis of cd an e coli specie with adhesive and invasive properties adherentinvasive e coli aiec has been described in ileal mucosa of patients with cd aiec has been found in 36 of patients with ileal cd and 6 of controls the role of aiec in cd has been thoroughly investigated in several laboratories around the world and has shown that aiec is proinflammatory and could play an important role in intestinal inflammation associated with cd 1 as such it may be an important therapeutic target this randomized trial proposes a novel approach to the treatment of cd it is individualized to patients colonized with aiec who will be prescribed fdaapproved antibiotics that have been shown to be active against the bacteria in vitro the treatment will be discontinued after 12 weeks we hope to obtain clinical and endoscopic remission in patients who have been randomized into the experimental arm if this trial is successful it will be the first of its kind and will facilitate a new era of clinical research in patients",
    "OBJECTIVE": "primary objective and assessment criterion the primary objective of this trial is to assess whether a 12week treatment with ciprofloxacin and rifaximin is superior to placebo to obtain endoscopic remission in aieccolonized patients with ileal cd with or without involvement of the caecum or the right colon the primary endpoint is the overall response at week 12 using centralized anonymous and blinded reading of ileocolonoscopies overall response is defined by segmental response in at least one segment in which the cdeis was 8 at baseline with no more than 20 increase of cdeis in the other segment and a cdeis 8 in this segment segmental response in the segment in which the cdeis was 8 at baseline is defined by  in the case of isolated aphtoid ileitis and or colitis decrease 50 of lesions  otherwise either decrease 50 of surface of ulcerations either deep or superficial or loss of deep ulcerations if present at inclusion with no more than 20 increase in superficial ulcerated surface secondary objectives and assessment criteria the secondary objectives are cid 1 to test the correlation between endoscopic remission and aiec eradication at 12 weeks cid 1 to assess the evolution of endoscopic lesions at week 12 cid 1 to assess the rate of clinical remission without steroids antitnf and surgery at 48 weeks in patients whose aiec has or has not been eradicated and in patients who have or have not reached the primary endpoint cid 1 to assess the rate of biological remission during the study cid 1 to assess side effects in the experimental and placebo group the secondary endpoints are endoscopic remission at 12 weeks assessed by centralized reading of ileocolonoscopies defined by a cdeis 6 in all the segments cid 1 mean variation of segmental cdeis at 12 weeks centralized reading of ileocolonoscopies cid 1 complete endoscopic remission at 12 weeks centralized reading of ileocolonoscopies defined by a cdeis 3 in all the segments cid 1 no ulceration at 12 weeks cid 1 clinical remission as defined by cdai 150 without steroids antitnf and resection surgery for cd at 12 and or 48 week cid 1 biological remission as defined crp serum level 5 mg l and fecal calprotectin 250 µg g at week 4 8 12 24 36 and 48 cid 1 side effects",
    "DESIGN": "experimental design this is a phase ii clinical trial it is a multicentre prospective randomized doubleblind placebocontrolled adaptive clinical trial with two parallel arms cid 1 experimental arm oral ciprofloxacin 500 mg bid and oral rifaximin 800 mg bid for 12 weeks cid 1 control arm a placebo of ciprofloxacin bid and a placebo of rifaximin bid for 12 weeks",
    "INCLUSION CRITERIA": "population involved cd adult patients infected with aiec preinclusion criteria cid 1 age 18 to 80 years cid 1 cd of the ileum with or without involvement of the caecum or the right colon cid 1 most severe lesions are confined within the ileum and or the right colon this is defined by  segmental cdeis 8 in the ileum and or right colon  and segmental cdeis 8 in each of the other segments transverse left colon and rectum cid 1 informed consent to participate in this study cid 1 cd either clinically inactive or active but not severe cdai 450 cid 1 for patients with clinically active disease cdai 150 prescription of steroid treatments budesonide prednisone or prednisolone independently from entry in study note patients with or without previous surgery for cd with or without cd anal lesions with or without draining fistulas and setons can be enrolled inclusion criteria cid 1 patients with clinically active disease cdai 150 who respond to budesonide initial dose 9 mg d or prednisone or prednisolone initial dose 40 mg d by a 70 points decrease in cdai between the pre inclusion and the inclusion visit or patients with clinically inactive disease cdai 150 cid 1 patients colonized with aiec on initial ileal biopsies",
    "EXCLUSION CRITERIA": "nonpreinclusion and noninclusion criteria cid 1 ileal stenosis that cannot be crossed by the endoscope cid 1 infliximab treatment received less than 8 weeks before preinclusion in this study cid 1 methotrexate and azathioprine started less than three months before preinclusion cid 1 adalimumab treatment received less than 4 weeks before preinclusion in this study cid 1 vedolizumab treatment received less than 8 weeks before preinclusion in the study cid 1 hypersensitivity to ciprofloxacin to other quinolones or to any of the excipients cellulose microcrystalline crospovidone maize starch magnesium stearate silica colloidal anhydrous hypromellose titanium dioxide e171 macrogol 4000 cid 1 treatment with tizanidine probenecid",
    "INTERVENTION": "treatment being tested association of two antibiotics cid 1 oral ciprofloxacin tablets of 500 mg every 12 hours during 12 weeks cid 1 oral rifaximin tablets of 200 mg 800 mg every 12 hours during 12 weeks benchmark treatment association of two placebos a placebo corresponding to each antibiotic will be manufactured tablet of the same appearance it will be administrated every 12 hours during 12 weeks",
    "STATISTICS": "statistical analysis data will be analyzed on an intenttotreat basis the trial is based upon an adaptive scheme allowing the reestimation of the required number of included patients sample size reestimation ssr design taking into account the uncertainty of endoscopic remission rate at week 12 in the placebo arm thus one interim unblind statistical analysis will be performed once one half of the patients have been successively enrolled primary endpoint analysis concerns the comparison of the main end point ie the percentage of endoscopic remission in each group that will be compared using the chisquare test unless validity violated or the fisher exact will be used secondary endpoints will be analyzed once the whole sample size will be reached",
    "DSMB": "data safety monitoring board anticipated no",
    "ACRONYM": "acronym teorem",
    "INVESTIGATOR": "coordinating investigator dr franck carbonnel gastroenterology department kremlin bicêtre hospital 78 rue du général leclerc 94275 le kremlinbicêtre",
    "NUMBER OF INCLUSIONS": "number of subjects chosen 252 screened patients will be needed on average to obtain 62 randomized patients",
    "SITES": "number of centres 26",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding source broad medical research program mayolyspindler alpha wassermann and phrc national"
  },
  "SALMA": {
    "TITLE": "full title phase i ii clinical trial assessing the combination of sulfasalazine with standard of care induction therapy in newly diagnosed acute myeloid leukemias aml patients 60 years or older the salma study",
    "JUSTIFICATION": "scientific justification nonfavorable aml in older patients is an unmet medical need acute myeloid leukemia aml is a heterogeneous clonal myeloid neoplasm where abnormal proliferation and impaired differentiation of hematopoietic stem and myeloid progenitor cells impedes normal hematopoiesis despite the significant progress made in understanding aml oncogenesis over the past decades this disease remains devastating with about 18 000 new cases every year in europe and a fiveyear overall survival of only 17 1 the median age at diagnosis of aml is 69 years and the cure rate of patients older than 60 has not improved in the recent decades 2 the standard of care soc of newly diagnosed aml includes a 7 3 cytarabine anthracyclin combination followed by repeated courses of high dose cytarabine with or without allogeneic hematopoietic stem cell transplantation hsct 3 recent advances in this soc approach include the addition of the multikinase inhibitor midostaurine during induction and consolidation in patients with flt3 gene mutations 4 maintenance with oral azacitidine after completion of induction with or without consolidation in patients ineligible for transplantation 5 and use of a liposomal formulation of the cytarabinedaunorubicin combination instead of conventional 7 3 in patients with highrisk features 6 in patients older than 60y with adequate performance status and few comorbidities deemed fit for intensive chemotherapy a 7 3 induction course combining 3 days of idarubicin ida with a 7day continuous cytarabine arac infusion can induce complete remission cr or cr with incomplete platelet recovery in 64 of cases with nonfavorable cytogenetics 7 recent advances in the supportive care of these patients notably progresses in the antifungal armementarium have lowered the toxicity of the 7 3 induction courses with early date ed rates within the 510 range 8 however despite high cr and low ed rates with 7 3 the median eventfree survival efs remains 9 3 months in patients 60 years old with nonfavorable cytogenetics owing to frequent relapses 7 improving the antileukemic efficacy of the 7 3 induction course can contribute to better long term prognosis in these patients 9 however",
    "OBJECTIVE": "main objective and primary endpoint primary objectives phase i to assess the safety characterize the doselimiting toxicities dlts and identify the maximal tolerated dose mtd anticipated to be the recommended phase ii dose rp2d of the combination of sulfasalazine ssz with idarubicin ida and cytarabine arac in patients with newly diagnosed nonfavorable aml probability of dlt should not exceed 33 at the end of the induction cycle eoi of idaarac ssz treatment up to day 42 phase ii to assess preliminarily the antileukemia efficacy of the combination of idaarac ssz mainly in phase ii in newly diagnosed nonfavorable aml with reference from historical data on complete remission rate as defined in eln 2022 guidelines and mrd by centralized flow cytometry primary endpoints phase i documentation during the dose escalation of dose limiting toxicity dlt identification of a maximal tolerated dose mtd anticipated to be the recommended phase ii dose rp2d dose limiting toxicity dlt dlt will be defined during a safety observation period corresponding to the induction cycle with idaarac ssz up to day 42 events occurring after the onset of a second treatment cycle i e salvage or consolidation will not be considered as dlts any of the following events will be considered a dlt unless the event can be attributed by the investigator to a clearly identifiable cause such as underlying illness or secondary objectives and endpoints secondary objectives to characterize the pharmacokinetics pk and the pharmacodynamics pd of ssz ida and arac when administered in combination during the dose escalation phase 1a and to confirm it during the phase 2 of the trial to describe during the phase i of the trial the response of the leukemia to the treatment the survival of patients up to 12 months after the end of induction eoi visit to document further during the phase ii of the trial the safety profile and confirm the rp2d of the ida arac and ssz combination secondary endpoints 1 assessment of safety safety outcome measures will be assessed continuously during the study monitoring of ecgs and clinical laboratory values are integral to safety assessment adverse events ae treatment emergent adverse events teae and treatmentrelated teaes will be evaluated according to the nci ctcae version 5 0 serious adverse events will be defined per protocol according to ema ich criteria causality relationship with the experimental treatment should be assessed by the investigator frequency duration and maximal severity of each teae treatmentrelated teaes teaes leading to treatment discontinuation serious adverse events saes and deaths should be documented during phase i and ii of the trial patients should be followed until all treatment related teaes have returned to grade 1 or baseline or are deemed irreversible by the investigator 2 pharmacokinetics to assess ssz and its metabolites ida and its metabolite and arac this will allow to determine a pk model for ssz at an early and late time point and confirm the lack of interaction between ssz and ida or arac the pk plan is detailed in a section below pharmacokinetic pk study will be conducted on patients recruited in the phase i part of the trial to assess the",
    "DESIGN": "design of the study phase iii open label multicenter clinical trial with 2 subsequent phases phase i doseescalation with a design using a survival continual reassessment method to identify the maximal tolerated dose mtd and recommended phase ii dose rp2d phase ii extension at the rp2d chosen by the data and safety monitoring board dsmb to confirm the safety of rp2d and preliminarily documents its clinical efficacy",
    "INCLUSION CRITERIA": "population of study participants patients 60 years with a recently diagnosed non favorable aml and eligible for intensive chemotherapy inclusion criteria  patients aged 60 years or older  with newly diagnosed aml short course treatment with hydroxyurea and or steroids is acceptable patients with aml secondary to an antecedent myelodysplastic syndrome mds or myeloproliferative neoplasm mpn are eligible as those with therapyrelated aml  eligible for an intensive chemotherapy according to the investigator s opinion  multiparameter flow cytometry at screening compatible with mfcbased mrd monitoring according to eln criteria phase ii only  ecog performance status 2  ast and alt 3 0 x upper the limit of normal uln and total and direct serum bilirubin 1 5 x uln unless considered due to leukemia  estimated glomerular filtration rate gfr 50 ml min according to the mdrd equation  written informed consent obtained prior to any screening procedures  eligible for national health insurance in france",
    "EXCLUSION CRITERIA": "exclusion criteria  myeloid sarcoma with 20 bone marrow blasts  patient who has received a vaccine injection with live attenuated virus in the last three weeks  proven central nervous system leukemic involvement  favorable risk cytogenetics t 15 17 t 8 21 inv 16 or t 16 16 or pmlrara runx1runx1t1 cbfb myh11 fusion transcript  presence of flt3itd or tkd mandating treatment with midostaurin  concurrent therapy with any cytotoxic drug within 3 weeks before the first study dose only hydroxyurea for the control of blood counts is permitted  patients planned to received cpx351 for myelodysplasiarelated changes or therapyrelated aml  previous treatment with sulfasalazine in the last 5 years or ongoing treatment with sulfasalazine or 5 aminosalicylic acid 5asa for ulcerative colitis or inflammatory rheumatisms  history of allergic reaction to sulfonylarylamines",
    "INTERVENTION": "investigational medicinal product and auxiliairy medicinal products investigational medicinal product sulfasalazine approved and marketed for years as treatment of inflammatory diseases tablets dosed at 500 mg oral route with water at the following dose levels dl tested during the phase i dl2 0 5 g bid hence 1 0 g d days 07 dl1 0 5 g tid hence 1 5 g d days 07 dl1 0 5 g tid hence 1 5 g d days 014 dl2 1 0 g tid hence 3 0 g d days 014 dl3 1 5 g tid hence 4 5 g d days 014 dl4 2 0 g tid hence 6 0 g d days 014 dl5 2 0 g four times per day hence 8 0 g d days 014 at all dose levels patients will receive the standard of care idaarac backbone considered as auxiliary medicinal products in this clinical trial 7 consisting of comparator treatment none",
    "STATISTICS": "statistical analysis phase i a bayesian adaptive dose escalation design will be used for the trial objectives it allows sequential monitoring of data during the trial using all current evidence for straightforward inference on safety and efficacy and decision making to select and evaluate an optimal dose the design will rely on the bayesian continual reassessment method crm for the phase i with cohorts of size 1 and a maximum sample size of 20 patients 30 the target dlt rate for the definition of the mtd will be 33 within the eoi observation window the timetoevent extension of the crm survcrm design will be used depending on the anticipated accrual rate compared to the dlt observation window 31 this will allow accounting for rightcensored toxicity observation in sequential mtd estimation and dose assignment process phase ii once phase i has been completed providing the estimated mtd the rp2d will be determined based on dsmb recommendations according to safety data and efficacy signals from phase i inclusion criteria will be the same as in phase i with the addition of an additional inclusion criteria laip detected at baseline fcm assessment related to the primary endpoint of complete response with negative mrd based on historical data the rate of mrdnegative complete response in the study population is estimated at 50 british aml16 data 12 spanish pethema data 32 british aml17 data s freeman pers comm a simon minimax twostage design will be used for this phase simon r optimal twostage designs for phase ii clinical trials controlled clinical trials 1989 10 110 this phase ii assessment will require a maximum total of 44 subjects to decide whether the proportion responding p is less than or equal to 0 50 or greater than or equal to 0 70 at the first stage that is among the first 22 included patients if the number of responses is lower than or equal to r1 11 the phase ii will stopped early for futility otherwise if r1 12 enrollment will continue up to a maximum of 44 patients overall if the number of responses r becomes 28 or more the hypothesis that p 0 50 is rejected with a target type i error rate of 0 05 if the total number of responses is r 27 or less the hypothesis that p 0 70 is rejected with a target type ii error rate of 0 15 of note phase i patients treated at the rp2d of choice will be included in this analysis if they are assessable by fcm mrd presence of a laip",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference salma",
    "INVESTIGATOR": "coordinating investigator prof raphaël itzykson scientific director dr alexandre puissant",
    "NUMBER OF INCLUSIONS": "number of participants included total 64 patients phase i 20 patients phase ii 44 patients",
    "SITES": "number of centers 8 centers in phase i 13 centers in phase ii conducted only in france in hematology centers",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources fondation arc"
  },
  "ERYTHROSIM": {
    "TITLE": "full title randomized prospective trial evaluating the efficacy of the anticd38 monoclonal antibody isatuximab in the treatment of pcra by major abo mismatch after allogeneic hematopoietic stem cell transplantation",
    "JUSTIFICATION": "scientific justification a quarter of allogeneic hematopoietic stem cell transplantation are performed in a situation of major abo mismatch exposing patients to the risk of immunological pure red cell aplasia prca after transplant pcra after transplant is defined as anemia with low reticulocytes count under 10 g l after day 60 despite good leucocytes and platelet engraftment full donor chimerism associated with the persistence of recipients hemagglutinins antia or antib antibodies bone marrow evaluation when performed show erythroid hypoplasia red blood cells transfusions are necessary every two weeks until remission leading to impaired quality of life anemia repeated hospitalization iron overload and need for iron chelation therapy treatments currently used are inefficient anti cd20 monoclonal antibodies epo steroids plasma exchanges proteasome inhibitors or at risk of severe acute gvhd donor lymphocytes infusion prca has been demonstrated to be associated with the persistence of recipient s plasma cells anticd38 monoclonal antibodies which targets plasma cells secreting hemagglutinins responsible of pcra are a promising treatment 6 cases reported in the literature support a rapid and sustain efficacy chapuy nejm 2018 bathini amjhematol 2019 rautenberg bmt 2019 salas et al eur j haematol 2019 preethi et al blood cell mol dis 2020 yates et al transfusion 2021 but a prospective randomized evaluation of its efficacy and safety in this context is necessary",
    "OBJECTIVE": "main objective and primary endpoint main objective efficacy of the treatment of prca by isatuximab after allogeneic hematopoietic stem cell transplant compared to supportive care only control group reduction in prca resolution time in days primary endpoint time to obtention of transfusion independence for patients with prca time interval between randomization corresponding to the m6 posttransplant and resolution of prca date of resolution of reticulocytopenia treated or not by the anticd 38 monoclonal antibody isatuximab secondary objectives and endpoints secondary objectives 1 to evaluate the two arms in term of clinical and biological outcomes",
    "DESIGN": "design of the study randomized prospective phase ii clinical trial assessing the efficacy and safety of the anticd38 antibody isatuximab in patients with persistent prca at 6 months after allogeneic hsct including patients at day 60 after transplant will help to define the factors associated with unresolved prca to m6 and thus identify patients that could benefit of isatuximab treatment earlier in the future interim analysis will be performed after observations of 22 events primary endpoint in the trial",
    "INCLUSION CRITERIA": "population of study participants allogeneic stem cell transplant recipient 15 years of age or older with prca inclusion criteria patients  aged 15 years or older  having receiving an allogeneic hematopoietic stem cell transplantation in condition of major abo mismatch",
    "EXCLUSION CRITERIA": "exclusion criteria patients  aged 15 years  relapse of underlying disease  leucocyte chimerism 95  prca related to parvovirus b19 infection positive blood pcr  known to be hiv or to have hepatitis a b or c active infection  active tuberculosis  pregnancy βhcg positive or breastfeeding  patient receiving recombinant human erythropoietin  patient receiving proteasome inhibitor bortezomib for example  patient receiving thrombopoietin receptor agonists artpo  patient receiving plasma or plasmapheresis exchanges after transplant  planned to receive any investigational drug within 14 days or 5 halflives of the investigational drug whichever is longer  any clinically significant uncontrolled medical conditions that in the investigator s opinion would expose excessive risk to the patient or may interfere with compliance or interpretation of the study results  hypersensitivity to the active substance or history of intolerance to steroids mannitol pregelatinized starch sodium stearyl fumarate histidine as base and hydrochloride salt arginine hydrochloride poloxamer 188 sucrose or any of the other components of study therapy that are not amenable to premedication with steroids and h2 blockers or would prohibit further treatment with these agents  who have any debilitating medical or psychiatric illness  under tutorship or curatorship  who not understand informed consent for an optimal treatment and followup",
    "INTERVENTION": "experimental treatment isatuximab treatment at a dose of 10 mg kg by intravenous route the first injection of isatuximab will be performed at randomization m6  2 days a second injection may be performed at d15 2d if the reticulocytes 10 g l and a third at d29 2d if reticulocytes 10 g l patients will be assessed on day 1 day 15 day 29 day 45 2 months 3 months 6 months and 9 months after randomization",
    "STATISTICS": "statistical analysis a bilateral logrank test considering a sample size of 45 randomized patients in 2 1 30 in the experimental group with median transfusion independence under h1 of 1 5 months 15 in the control group with median transfusion independence under h1 of 4 5 months achieves a power of 86 4 with an alpha risk of 0 05 considering that only 50 of patients included at d60 will be randomized at 6 months 90 patients should be included interim analysis will be performed after observations of 22 events primary endpoint in the trial",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference erythrosim",
    "INVESTIGATOR": "coordinating investigator dr xhaard aliénor",
    "NUMBER OF INCLUSIONS": "number of participants included 90 patients 45 randomized the inclusion period will be increased to include patients even more than the 90 expected until to randomize the 45 patients needed notably if less than 50 of the 90 enrolled patients are still prca at m6",
    "SITES": "number of centres 24 centers pediatrics and adults in france",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources ministry of health phrc 2019 experimental treatment free supply by sanofi company"
  },
  "EQUAALL01": {
    "TITLE": "full title evaluation of longterm health status and quality of life in adult survivors with philadelphianegative acute lymphoblastic leukemia lymphoma treated with an intensive pediatric or pediatricinspiredinspired protocol",
    "JUSTIFICATION": "scientific justification the overall survival of adult patients 1559y with philadelphia negative acute lymphoblastic leukemia lymphoma all ll was dramatically improved by the use of full pediatric or pediatric inspired protocols graall2003 05ll03fralle2000 that aimed to reduce the risk of relapse by adopting more intensive chemotherapeutical schedule this approach led to a global improvement in overall survival 5yos 57 whatever patient age but was responsible for an excess of treatmentrelated mortality in patients older than 45 years 5ytrm in patients 45y 19 pediatric longitudinal studies pointed out that long term leukemia survivors have an increased risk of developing specific adverse events like dysmetabolic syndrome obesity decreased fertility organ dysfunction osseous events or impaired cognitive functions this study aims to evaluate the impact in term of longterm events and qol in adult patients that received an intensified therapeutic approach recently implemented in adult cooperative groups",
    "OBJECTIVE": "main objective and primary endpoint to evaluate the prevalence of late effects in adult patients treated 10 years ago for all ll with an intensified pediatric inspired protocol graall2003 05ll03fralle2000 that exposed patients to increased cumulative doses of chemotherapy central nervous system irradiation or w o allogeneic transplant after total body irradiationbased regimen w o boost irradiation on central nevous system the primary endpoint is thus defined by the prevalence of adverse events including  metabolic troubles dysmetabolic syndrome dyslipidemia diabetes  osseous events osteoporosis  cardiac and vascular troubles  neurologic troubles  lung dysfunctions  endocrinal troubles  ophthalmological troubles  fertility disorders  secondary neoplasia secondary objectives and endpoints  to evaluate the quality of life of these patients  to correlate the prevalence of late effect or qol status with previous social situation previous medical condition to all treatment schemes including administration of protocols phases delayed intensification maintenance centralnervous system irradiation allogeneic sct graftversus host disease occurrence  to elaborate riskadapted recommendations for the longterm followup of adult patients treated for all with reinforced therapeutic strategies the secondary endpoints are thus",
    "DESIGN": "design of the study this is a multicenter crosssectional interventional minimal risks and constraints human research study",
    "INCLUSION CRITERIA": "population of study participants adult patients aged 1559y at diagnosis treated ten years ago for a ph1negative acute lymphoblastic leukemia lymphoma all ll inclusion criteria  patient with philadelphianegative all or ll treated in or according to a pediatriclike or pediatricinspired protocol graall or fralle with or without allogeneic transplant  patients older than 15 years old and less than 60 years old at diagnosis  patient with a followup from first complete remission of more than 10 years  patient who gave informed signed consent for baseline examination",
    "EXCLUSION CRITERIA": "exclusion criteria  patient who experienced all ll relapse within the 5 past years  philadelphia positive all patients",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis the analysis will handle the left data truncation given only patients who survive until 2016 are able to be included in the study approximately 1000 patients were included in the graall2003 and 2005 among them 630 before august 2009 considering that 363 630 patients were alive at last followup the opportunity to include patients treated according to these protocols and a 80 inclusion success approximately 300 patients will be recruited this allows assessing the prevalence of troubles with a 95 ci width at 7 about assuming a 10 prevalence or to 0 10 assuming a 30 prevalence and detection of or at 2 5 or 2 respectively this also allows reaching a statistical power of at least 80 for detecting or at 2",
    "DSMB": "",
    "ACRONYM": "acronym equaall01",
    "INVESTIGATOR": "coordinating investigator pr nicolas boissel hematology department saintlouis hospital 33142499643 nicolas boissel aphp fr",
    "NUMBER OF INCLUSIONS": "number of participants included 300",
    "SITES": "number of sites approximatively 36 centers of the graall network",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of monetary support ministry of health"
  },
  "RECORDS": {
    "TITLE": "title rapid recognition of corticosteroid resistant or sensitive sepsis ",
    "JUSTIFICATION": "background who estimates that yearly 30 million people develop sepsis and 11million die aprocchs a phase 3 placebocontrolled trial demonstrated a 6 absolute reduction in sepsis mortality with hydrocortisone fludrocortisone a number of factors may positively negatively impact corticosteroids cs benefits in sepsis",
    "OBJECTIVE": "main objective and primary endpoint to compare the effect hydrocortisone plus fludrocortisone vs placebo on a composite of death or persistent organ dysfunction defined as continued dependency on mechanical ventilation new renal replacement therapy or vasopressors assessed at 90 days on intensive care unit icu adults and having different biological profiles for immune responses and corticosteroids bioactivity the primary endpoint is death or persistent organ dysfunction defined as continued dependency on mechanical ventilation renal replacement therapy or vasopressors and with sofa score 6 up to 90 days secondary objectives and endpoints mortality and healthrelated quality of life at 6 months daily organ function sofa score days 1 2 3 4 7 10 14 28 and 90 daily secondary infections up to 90 days daily blood and urinary levels of glucose sodium and potassium up to 28 day daily gastroduodenal bleeding up to 28 day daily cognitive function and muscles strength days 1 to 28 90 and 180 days",
    "DESIGN": "study design multiarms parallel blinded randomized controlled trial preceded by a 6month runin observational period  observational phase runin period  interventional phase",
    "INCLUSION CRITERIA": "inclusion criteria observational phase n 1 2 3 4 6 7 8 9 interventional phase n 1 2 3 4 5 6 7 8 1 patients 18 years old 2 admitted to icu with proven or suspected infection as the main diagnosis 3 community acquired pneumonia related sepsis or vasopressors dependency norepinephrine epinephrine vasopressin dopamine phenylephrine or septic shock singer 2016 vasopressor to maintain mean blood pressure of at least 65 mmhg and lactate levels above 2 mmol l or acute respiratory distress syndrome ards ranieri 2012 a acute onset i e within one week of an apparent clinical insult and with progression of respiratory syndrome b bilateral opacities on chest imaging not explained by other pulmonary pathologies e g pleural effusion atelectasis nodules etc c no evidence for heart failure or volume overload d pao2 fio2 300 mm hg  peep 5 cm h2o 4 patient who has signed an informed and written consent whevener he she is able of consent if not if not ascent from his her representant whenever he she is present at time of screening for inclusion",
    "EXCLUSION CRITERIA": "exclusion criteria observational phase n 1 2 3 interventional phase n 1 2 3 4 5 6 7 8 1 pregnancy 2 expected death or withdrawal of lifesustaining treatments within 48 hours 3 previously enrolled in this study 4 formal indication for corticosteroids according to most recent international guidelines 5 vaccination with live virus within past 6 months 6 hypersensitivity to hydrocortisone or fludrocortisone or microsined betamethasone dipropionate* or any of their excipients spc 7 women of childbearing potential not using contraception 8 nursing women * for patients included in this stratum if applicable do not apply the cream to an infected or ulcerated area",
    "INTERVENTION": "study intervention observational phase runin period additional biological samples for the restrospective part covid patients telephone followup interventional phase investigational products or their placebo will be administered to patients on the basis of records signatures investigational products included  hydrocortisone hemisuccinate 50 mg one intravenous injection every 6 hours and  9 alpha fludrocortisone 50 μg one tablet per day via a nasogastric tube all treatments will be stopped after 7 days or until the patient has left the intensive care unit whichever occurs first without tapering off",
    "STATISTICS": "sample size we will enroll a total of at most 1800 patients in this adaptative trial sites are expected to enroll at least 1or 2 patients per month by enrolling 376 evaluable patients per arm the study will have 80 power to detect a 10 absolute risk reduction from 45 to 35 which corresponds to a 20 relative risk reduction",
    "DSMB": "",
    "ACRONYM": "acronym reference records",
    "INVESTIGATOR": "coordinating investigator and scientific director pr djillali annane",
    "NUMBER OF INCLUSIONS": "",
    "SITES": "clinical sites french adult general icus",
    "FUNDING": "sponsor assistance publique hôpitaux de paris"
  },
  "KAPKEY": {
    "TITLE": "full title phase ii multicentric study of pembrolizumab in classic or endemic kaposi s sarcoma",
    "JUSTIFICATION": "scientific justification classic and endemic kaposi s sarcoma ks are lymphangioproliferations associated with human herpes virus 8 hhv8 which treatment is poorly codified chemotherapies give at best 3060 of transient responses while interferon responses are frequent this drug is often poorly tolerated in elderly patients therefore new therapies are needed classic ks represents an ideal model for evaluating new drugs since patients do not receive concomitant immunosuppressive regimens nor antiviral therapies pembrolizumab an antipd1 monoclonal antibody has recently been shown to improve survival in several solid tumors in ks few data are available on the role of pd1pdl1 axis a significant pdl1 expression on hhv8associated pleural effusion lymphomas and on ks samples have been recently reported our experience in classical and endemic ks supports the role of this pathway with expression of pdl1 by subpopulations of t cells but also nk cells in peripheral blood cells from these patients and expression of pdl1 by tumor cells in ks lesions in this study we will evaluate the benefit and safety profile of pembrolizumab in classic and endemic ks",
    "OBJECTIVE": "primary objective and assessment criterion simon s 2stage optimal design the main objective is to assess whether pembrolizumab is clinically inactive partial complete response probability π0 5 or truly active partial complete response probability π1 30 in classic and endemic kaposi s sarcoma ks using the simon s 2 stage optimal design the primary endpoint will be the best overall response rate borr defined by the occurrence of complete response or partial response following actg criteria recorded from the start of treatment until 6 months or the beginning of any other specific systemic therapy for ks if it occurs before 6 months extension phase in the event of a truly active conclusion of simon s 2step optimal design an extension phase would be performed to evaluate more elements an extension phase would be performed to further evaluate the efficacy of pembrolizumab in our setting an additional 20 patients will be included to obtain a more accurate estimate of the treatment effect up to 24 months secondary objectives and assessment criteria secondary objectives are for simon s 2 stages optimal design and extension stage 1 to assess the safety profile of pembrolizumab in classic and endemic kaposi s sarcoma 2 to characterize the efficacy of pembrolizumab related to pharmacodynamics assessment secondary endpoints efficacy endpoints different aspects of clinical response will be evaluated 1 best overall response rate according to the pga criteria until 24 months or the beginning of any other specific systemic therapy for ks if it occurs before 6 months 2 response rate at month 3 month 6 month 9 month 12 month 18 and month 24 according to actg and pga criteria 3 response rate on number of lesions at month 3 month 6 month 9 month 12 and month 24 at best response as defined following the pga 4 response rate on the size of target lesions at month 3 month 6 month 9 month 12 and month 24 atbest response as defined following the pga 5 response rate on tumor infiltration of target lesions at month 3 month 6 month 9 month 12 andmonth 24 at best response as defined following the pga 6 response rate on lymphedema circumference scale of 0 absence to 3 painful or oozing at month 3 month 6 month 12 and month 24 at best response as defined following the pga 7 time to response defined as the time to first response recorded from the start of treatment 8 time to progression defined as the time from starting treatment to progression in all patients 9 response rate according to actg and pga criteria at month 9 month 12 month 18 and month 24 for the extension stage 10 duration of response defined as the time from starting response to progression in patients achieving partial or complete response 11 quality of life following the qlc30 and dlqi kaposi at baseline cycle 5 cycle 10 cycle 15 every 3 months and eot early study termination or at months 24 safety endpoints safety will be assessed in terms of drug toxicity evaluated by clinic and on laboratory parameters and scored according to common terminology criteria for adverse events ctcae version 5 0 during all the study",
    "DESIGN": "experimental design uncontrolled openlabel multicentric phase ii study",
    "INCLUSION CRITERIA": "population involved adult with classic or endemic kaposi s sarcoma inclusion criteria the patients meeting the following criteria may be included in the study for simon s 2stage optimal design and extension stage classic or endemic histologically confirmed ks progressive disease ks with more than 10 lesions or involving more than one limb segment or with involvement 3 body surface ks with at least 4 lesions 5mm ks with at least 1 other cutaneous tumor available for repeated pharmacodynamics evaluation and be willing to provide tissue from cutaneous biopsy of a tumor lesion at least 4 weeks washout for all ks specific therapies including chemotherapy and immunotherapy provide written informed consent prior to the performance of any study specific procedures be 18 years of age on day of signing informed consent have a performance status of 0 or 1 on the ecog performance scale demonstrate adequate organ function  hematological absolute neutrophil count anc 1 000 mm3 platelets 100 000 mm3 hemoglobin 8 g dl  renal calculated creatinine clearance 30ml min using mdrd formula  hepatic ast sgot and alt sgpt 2 5xuln serum total bilirubin 1 5xuln or direct bilirubin uln for participants with total bilirubin levels 1 5xuln female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication have a health insurance",
    "EXCLUSION CRITERIA": "noninclusion criteria the patients meeting the following criteria must be not included in the study for simon s 2stage optimal design and extension stage has a known history of organ transplantation is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment has ks with symptomatic visceral involvement unless no other therapeutic option is available previously received treatments with an antipd1 antipd l1 antipdl2 antictla4 antibody or any other antibody or drug specifically targeting tcell costimulation or immune checkpoint pathways uncontrolled infection with hiv hbv or hcv infection or diagnosis of immunodeficiency that is related to or results in chronic infection patients with known hepatitis b hepbsag who have controlled infection serum hepatitis b virus dna pcr that is below the limit",
    "INTERVENTION": "investigational medicinal product s simon s 2stage optimal design phase of development phase ii treatment pembrolizumab route intraveinous infusion dose regimen 200 mg per infusion every 3 weeks duration of treatment 6 months 8 cycles extension stage phase of development phase ii treatment pembrolizumab route intraveinous infusion dose regimen 200 mg per infusion every 3 weeks duration of treatment up to 24 months 35 cycles or until confirmed complete response as defined in the simon s 2 stage optimal design if it occurs before 24 months after 6 months of pembrolizumab treatment cycle 8 and lasting 2 further cycles if the complete response is observed and confirmed during at least 1 month the pembrolizumab will be stopped comparator treatment na",
    "STATISTICS": "statistical analysis simon s 2stage optimal design this is a multicenter uncontrolled phase ii study based on a 2 stage phase ii simon s optimal design",
    "DSMB": "data safety monitoring board anticipated yes",
    "ACRONYM": "acronym kapkey",
    "INVESTIGATOR": "coordinating investigator pr céleste lebbe  dermatologie  hôpital saint louis paris  0142494679 celeste lebbe aphp fr",
    "NUMBER OF INCLUSIONS": "number of participants chosen simon s 2stage optimal design",
    "SITES": "number of centers multicentric french study for simon s 2stage optimal design 8 participating centers of the french national group groupe de cancérologie cutanée for the extension stage 10 participating centers of the french national group groupe de cancérologie cutanée",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding source msd"
  },
  "UPFRONT-MUD": {
    "TITLE": "full title upfront matched unrelated donor transplantation in pediatric patients with idiopathic aplastic anemia a phase ii feasibility study",
    "JUSTIFICATION": "scientific justification pediatric patients with idiopathic aplastic anemia aa respond better than adults to immunosuppressive therapy ist but the longterm risks of relapse ciclosporine dependence and clonal evolution are high uk investigators reported a 5year estimated failurefree survival ffs after ist of 13 3 in contrast in 44 successive children who received a matched unrelated donor mud hematopoietic stem cell transplantation hsct there was an excellent estimated 5year ffs of 95 forty of these children had previously failed ist because of those excellent results upfront fully matched unrelated donor mud hematopoietic stem cell transplantation hsct became an attractive firstline option in 2005 to 2014 a uk cohort of 29 children with idiopathic aa thus received mud hscts as firstline therapy they did not receive ist prior to hsct results were excellent with low graft versus host disease rates and only 1 death idiopathic pneumonia this cohort was then compared with historical matched controls transplanted or not outcomes for the upfront unrelated cohort hsct were similar to matched related donor hsct and superior to ist and unrelated hsct postist failure since then many investigators are offering up front mud hsct in pediatric patients worldwide however those results should be treated with extreme caution 1 the design is retrospective 2 the excellent up front mud hsct may arise from the use of alemtuzumab in the conditioning regimen alemtuzumab is not easily available worldwide and 3 there was no formal quality oflife assessment moreover this strategy is highly dependent on donor identification caucasian patients have the highest likelihood of having a mud and donor availability we thus don t know how many patients did not eventually receive hsct because of the risk of infections complications caused by unexpected donor delays or cancellation prospective trials are thus urgently needed to address the feasibility of such procedure in term of timing delay to offer mud hsct and conditioning regimen nothing is known of the use of other regimens non alemtuzumabbased in this setting",
    "OBJECTIVE": "main objective and primary endpoint main objective to realize upfront hsct within 2 months once a mud has been identified secondary objectives and endpoints secondary objectives clinical and biological outcomes  graft failure graft versus host disease gvhd progression free survival relapse nonrelapse mortality overall survival  quality of life  chimerism  immune reconstitution secondary endpoints  graft failure incidence  neutrophils and platelets engraftment at day 100 first day of 3 consecutive days with neutrophils 0 5 g l and first day of 7 consecutive days with platelets 20 g l   absolute numbers of neutrophils and platelets at m1 m2 m3 m6 and m12 day of last platelet and red blood cell transfusions  acute gvhd incidence at month 3 m3 date and maximum grading first line treatment response to steroids treatment courses in case of steroid refractory gvhd  chronic gvhd incidence date and grading at m24  relapse incidence at m12 and m24  progression free survival at m12 and m24  incidence of cmv and ebv infection at m12  severe infections ctae grade 34 à m3 m6 m12 and m24  nonrelapse mortality m24  overall survival at m24  quality of life questionnaire pedqql at inclusion post transplantation m3 m6 m12 m24  chimerism at m1 m3 m6 m12  immune reconstitution by analyzing t b nk regulatory t cell levels in the peripheral blood at m3 m6 m12 and m24 posttransplantation  ferritin levels at m3 m6 m12 m24",
    "DESIGN": "design of the study phase ii multicenter national prospective cohort study",
    "INCLUSION CRITERIA": "population of study participants pediatric patients aged less than 18 years with idiopathic aplastic anemia and an indication for treatment severe aplastic anemia or moderate aplastic anemia requiring transfusions inclusion criteria patients  age 18years old  pediatric patients aged less than 18 years with idiopathi aplastic anemia and an indication for treatment severe aplastic anemia or moderate aplastic anemia requiring transfusions  with a good probability to have a hla10 10 matched unrelated donor available the patient needs to have at",
    "EXCLUSION CRITERIA": "exclusion criteria patients  with a matched related donor available  with uncontrolled infection  with seropositivity for hiv or htlv1 or active hepatitis b or c defined by a positive pcr hbv or hcv and associated hepatic cytolysis  renal failure with creatinine clearance below 70 of higher normal values for age  pregnant βhcg positive or breastfeeding  with heart failure according to nyha ii or more  preexisting acute hemorrhagic cystitis  urinary tract obstruction  yellow fever vaccine within 2 months before transplantation  who have any debilitating medical or psychiatric illness which preclude understanding the inform consent as well as optimal treatment and followup depending of his age and understanding  with contraindication to treatments used during the research",
    "INTERVENTION": "transplant modalities 1 conditioning regimen for patients aged less than 14 years fludarabine 30mg m2 day day 6 to day 3 cyclophosphamide 30 mg kg day day 6 to day 3 and",
    "STATISTICS": "statistical analysis justification of sample size we use the simon minimax twostage phase 2 design to demonstrate success primary outcome in 70 of patients to consider treatment as a valuable option against less than 45 considered as unacceptable interim analysis an interim analysis will be performed after 12 inclusions the trial will be terminated if 5 or fewer do not receive upfront mud hsct then the study ends with conclusion of inefficacy otherwise inclusions are pursued until a total of 25 patients to conclude treatment efficacy at least 16 successes should be identified among the 25 patients",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference upfrontmud",
    "INVESTIGATOR": "coordinating investigators pr jeanhugues dalle pr régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of participants included 25 patients with an interim analysis after 12 inclusions",
    "SITES": "number of centres 13 centres in france",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources ministry of health phrcn 2019"
  },
  "HAPLORESCUE": {
    "TITLE": "full title haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide for rescuing patients with graft failure a phase ii study",
    "JUSTIFICATION": "scientific justification prognosis of patients with graft failure is dismal and re transplantation is the sole option for longterm survival currently there is no consensus concerning therapeutic options in patients with primary or secondary within the 60 days posttransplantation graft failure and finding a new donor within an acceptable delay is challenging literature is poor on the subject while the overall survival of such patients is about 30 at 1 year 1 2 this situation thus represents today a very challenging unmet medical need recently haploidentical haplo related donor stem cell transplantation haplosct have improved dramatically outcomes using tcell replete grafts with administration of posttransplantation cyclophosphamide ptcy which targets alloreactive t cells generated early after an hla mismatched transplant sparing regulatory t cells and leaving unaffected the nondividing hematopoietic stem cells and standard posttransplant immune suppression with a calcineurin inhibitor cni and mycophenolate mofetil 3 our group retransplanted a patient who experienced two consecutive graft failures and was successfully managed through a third haplosct from her son using ptcy 5 we then retrospectively collected and analyzed data from 26 primary graft failure patients transplanted between 2011 and 2017 in 15 centers on behalf of french society for stem cell transplantation and cell therapy sfgmtc the study population consisted mainly of patients with primary or secondary within the 60 days posttransplantation graft failure who underwent haplosct and received ptcy as graft versushostdisease prophylaxis the 1year overall survival was about 60 suggesting that this approach might be a valid option in this particular poor clinical situation but now need validation through a phase ii multicenter national prospective cohort study 4",
    "OBJECTIVE": "main objective and primary endpoint main objective to rescue patients with graft failure after a first allogeneic sct allosct using haplosct with ptcy primary endpoint overall survival rate compared to an historical controls of 30 at 1 year secondary objectives and endpoints secondary objectives  graft failure gvhd progression free survival relapse nonrelapse mortality  interval between first allosct and rescue haplosct  quality of life  chimerism  immune reconstitution secondary endpoints graft failure incidence neutrophils and platelets engraftment at day 100 3 consecutive days with neutrophiles 0 5 g l and 7 consecutive days with platelets 20 g l absolute numbers of neutrophils and platelets at m1 m2 m3 m6 and m12 day of last platelet and red blood cell transfusions the use of growth factors for poor hematopoietic reconstitution acute gvhd incidence at month 3 m3 date and maximum grading first line treatment response to steroids treatment courses in case of steroid refractory gvhd chronic gvhd incidence date and grading at m24 relapse incidence at m12 and m24 progression free survival at m12 and m24 incidence of cmv and ebv infection at m12 severe infections ctae grade 34 à m3 m6 m12 and m24 nonrelapse mortality m3 m6 m12 and m24 incidence of cardiac toxicities at m3 overall survival at m24 interval between first allosct and rescue haplosct quality of life questionnaire eortc qlqc30 v3 at inclusion posttransplantation m3 m12 m24 chimerism at m3 m12 immune reconstitution by analyzing t b nk regulatory t cell levels in the peripheral blood at m1 m3 m6 m12 and m24 posttransplantation",
    "DESIGN": "design of the trial phase ii multicenter national prospective cohort study scope of the trial primary or secondary within the 60 days post transplantation graft failure is a rare but devastating condition after sct a recent strategy for haplo related donor transplantation which has had some success is transplantation of tcell replete grafts with intensive immune suppression few retrospective noncontrolled registry studies recently suggest that outcomes after haplosct using ptcy approach might be superior to actual standard of care i e retransplantation from an unrelated donor moreover haplosct with ptcy is a quick procedure cheap and available for almost all patients this study might thus favor this strategy in case of primary or secondary within the 60 days post transplantation graft failure after 1st sct",
    "INCLUSION CRITERIA": "population of trial subjects patients over 3 years old and all hematological diseases suffering from primary or secondary within the 60 days posttransplantation graft failure after a 1st allogeneic hematopoietic stem cell transplantation allosct inclusion criteria patients aged from 3 years and older all hematological diseases suffering from primary or secondary within the 60 days posttransplantation graft failure after a 1st allosct with usual criteria for allosct ecog 2 no severe and uncontrolled infection cardiac function compatible with high dose of cyclophosphamide",
    "EXCLUSION CRITERIA": "exclusion criteria patients  aged 3 years old  with uncontrolled infection  with seropositivity for hiv or htlv1 or active hepatitis b or c defined by a positive pcr hbv or hcv and associated hepatic cytolysis  yellow fever vaccine within 2 months before transplantation  cancer in the last 5 years except basal cell carcinoma of the skin or in situ carcinoma of the cervix  uncontrolled coronary insufficiency recent myocardial infarction 6 month current manifestations of heart failure uncontrolled cardiac rhythm disorders ventricular ejection fraction 50  heart failure according to nyha ii or more  preexisting acute hemorrhagic cystitis  renal failure with creatinine clearance 30ml min  urinary tract obstruction  pregnant βhcg positive or breastfeeding  who have any debilitating medical or psychiatric illness which preclude understanding the inform consent as well as optimal treatment and followup  tutorship or curatorship  contraindications to treatments used during the research",
    "INTERVENTION": "transplant modalities medical product provided by the sponsor conditioning regimen fludarabine 30mg m2 day from day 6 to day 4 cyclophosphamide 14 5 mg kg day at day 6 and day 5 except for patients who received a total dose of cyclophosphamide 100mg kg during the first bone marrow transplantation total body irradiation 2 gray on day 1 source of stem cell source peripheral blood stem cell minimal target dose of 4 106 cd34 cells kg of recipient gvhd prophylaxis cyclophosphamide 50 mg kg day at d 3 and d 4 ciclosporine from day 5 residual 200 à 300ng l mycophenolate mofetyl at 15mg kg x2 day from day 5 prevention of ebv reactivation rituximab 150mg m2 at day 5 post haplosct",
    "STATISTICS": "statistical analysis overall survival will be estimated using the kaplan maier s estimator with its 95 confidences intervals comparaison with the historical controls of 30 at 1 year will be performed using the onesample logrank test proposed by sun x et al in 2011 terminal analysis will be performed after the followup of the last included patient",
    "DSMB": "trial will have a data monitoring committee yes",
    "ACRONYM": "acronym haplorescue",
    "INVESTIGATOR": "coordinating investigator pr régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of subjects included for an objective of 31 patients to be allografted we anticipate 35 patients to include",
    "SITES": "number of sites 37 centres in france 2 centres in belgium affiliated to sfgmtc 1 centre in switzerland affiliated to sfgmtc",
    "FUNDING": "sponsor assistance publiquehôpitaux de paris sources of funding for the trial phrck 2019"
  },
  "FIRST": {
    "TITLE": "full title upfront related donor transplantation in patients with myelodysplastic syndrome a phase 2 trial",
    "JUSTIFICATION": "scientific justification three recent prospective transplant no transplant studies concluded to an advantage of os with transplantation in patients with high or intermediate2 ipss risk not significant in kröger s study 1 3 no prospective randomized trial has assessed the pretransplant therapy in mds patients yet but some information can be extracted from these 3 recent studies in the french study n 162 72 patients with a donor received hsct previously treated by hypomethylating agent hma in 71 of them 3 there was a trend to a better survival in patients achieving a complete remission with pre graft therapy hr 0 55 p 0 088 and higher risk of death in unresponsiveness patients transformed into aml hr 2 36 p 0 008 in nakamura s study n 384 83 of patients with a donor were transplanted previously treated by hma in 68 2 the multivariable cox model for overall survival os and leukemiafree survival showed an excess risk in patients treated by hma moreover responders still have a higher risk of mortality as compared to patients who did not receive any pregraft therapy hr 2 417 p 0 0054 in the german study the aim was to initiate azacytidine at inclusion and to transplant patients after 4 cycles if a donor was identified1 among 170 registered patients 162 initiated 5aza but 36 of them were lost during this pregraft therapy before allocation to donor or nodonor arm for different reasons including death n 12 after 4 cycles of 5aza 79 81 patients donor arm were transplanted the multivariable analysis showed remission status did not influence os those 3 previous clinical trials thus suggest that a substantial number of patients planned for transplantation are not transplanted nowadays while no evidence of hma benefit before hsct has been clearly identified this phase 2 study aim to assess the feasibility of upfront hsct in patients with high risk mds in order to increase the probability to be transplanted and to achieve a subsequent remission and better survival",
    "OBJECTIVE": "main objective and primary endpoint primary objective to demonstrate an improved diseasefree survival dfs in patients undergoing upfront transplantation from a related donor as compared to 0 35 historical prospective cohort primary endpoint dfs 2 years after transplantation secondary objectives and endpoints secondary objectives clinical and biological outcomes  overall survival os  incidence of transplantation after donor identification  incidence of transformation into aml  relapse or progression  engraftment  acute and late rejection  nonrelapse mortality nrm  acute gvhd  chronic gvhd  severe infections ctae grade 34  cardiac events grade 24 ctae secondary endpoints  os at 24 months after inclusion and after transplantation  nrm at 24 months after transplantation  cumulative incidence of transformation into acute myeloid leukemia from inclusion at 24 months  acute gvhd and grading at 100 days post hsct  chronic gvhd and grading at 2 years post hsct  engraftment at m3 hematological recovery and donor chimerism 95  graft failure acute or late rejection and non engraftment at 2 years post hsct  severe infections ctae grade 34 at m3 m6 m12 and m24  cardiac events grade 24 ctae at m1 and m3",
    "DESIGN": "design of the study this study uses an uncontrolled phase 2 openlabel design to increase the level of incidence external comparisons will be secondly performed to i demethylating agents using individual patient data from a prospective cohort robin 2015 or ii 5azacytidine using aggregated data from a published randomized clinical trial kröger 2021",
    "INCLUSION CRITERIA": "population of study participants adults 50 years and older patients with mds diagnosis for whom transplantation is indicated from a related donor identified inclusion criteria inclusion criteria  age 50 and 70 years  an hla matched sibling donor or familial haploidentical donor has been identified  the disease fulfills at least one of the following criteria o intermediate2 or high risk according to classical ipss o intermediate1 risk if marrow fibrosis grade i or poor risk cytogenetics according to r ipss or classified high or very high risk according to r ipss or if the mds is therapyrelated neoplasm",
    "EXCLUSION CRITERIA": "exclusion criteria exclusion criteria  marrow blast 15 at time of inclusion  mds with excess blast 10 and npm1 mutation or a recurrent genetic abnormality related to aml who 2022  chemotherapy aml like intensive chemotherapy or demethylating agent to treat mds at the current stage  disponibility of an unrelated donor 10 10 mud in absence of genoidentical donor  patient with uncontrolled infection  cancer in the last 5 years except basal cell carcinoma of skin or in situ carcinoma of the cervix  renal failure with creatinine clearance 30ml min according to cockroft formula  with contraindications to treatments used during the research  uncontrolled coronary insufficiency recent myocardial infarction 6 month current manifestations of heart failure uncontrolled cardiac rhythm disorders ventricular ejection fraction 50  with heart failure according to nyha ii or more",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis a twosided onesample logrank test calculated from a sample of 55 subjects achieves 90 36 power at a 0 050 significance level to detect a proportion surviving of 0 5500 in the new group when the proportion surviving in the historic control group is 0 3500 such an historical proportion has been estimated from our previous french cohort study as published in leukemia where a 2year dfs rate of 35 was",
    "DSMB": "dsmb yes",
    "ACRONYM": "acronym reference first allo mds",
    "INVESTIGATOR": "coordinating investigator dr marie robin department of hematology hôpital saintlouis paris",
    "NUMBER OF INCLUSIONS": "number of participants included 55 patients",
    "SITES": "number of centres multicenter national study 16 hematology departments in france 3 centres aphp",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources fondation msd avenir"
  },
  "APARR": {
    "TITLE": "full title evaluation of an optimized allogeneic hematopoietic stem cell transplantation protocol with posttransplant cyclophosphamide in patients aged 40 to 60 years old with acquired aplastic anemia refractory or in relapse after immunosuppression",
    "JUSTIFICATION": "scientific justification hematopoietic stem cell transplantation hsct is a major therapeutic option for patients with acquired aplastic anemia aa improved survival has been achieved in patients younger than 40 years old thanks to better donor selection conditioning regimens and graft versus host disease prophylaxis together with improved supportive care however this has never been the case for patients over the age of 40 for whom the overall survival after hsct never exceeded 60 at 5 years using available sibling or unrelated donor ref 3 thus the standard immunosuppressive therapy ist associating cisclosporine horse antithymocyte globuline together with the addition of eltrombopag epag is now considered as the standard of care in adult patients older than 40 years with aa ref 1 indeed outcomes for patients who are refractory to firstline ist remain poor because of the lack of other nontransplant treatment and because of the poor results of transplantation at this age ref 2 37 during the past 2 decades there has been a significant decrease in infectionrelated mortality in this population after initial ist but risk of hemorrhage and longterm fatigue are still present moreover clonal evolution including paroxysmal nocturnal hemoglobinuria pnh myelodysplastic syndrome mds and acute myeloid leukemia aml still occur in the longterm with a grim prognosis for mds aml ref 2 the overall survival of such adult patients with acquired aa refractory or in relapse after ist outside hsct is thus about 60 at 2 years ref 2 recently new strategies to prevent acute and chronic graft versus host disease including tcell replete grafts with administration of posttransplantation cyclophosphamide ptcy have revolutionized the field these changes extended the option of hsct primary for patients with refractory relapse aa who lack an hla matched donor ref 4 more recently the optimized baltimore protocol using ptcy strategy also appears to improve engraftment and reduce graft versus host disease gvhd in other more classical setting sibling and matched unrelated hsct outside aa ref 5 one of the first cause of death after hsct in patients older than 40 years of age with refractory relapse aa is gvhd and the use of the optimized baltimore protocol for all type of donors haplo but also sibling and matched unrelated",
    "OBJECTIVE": "main objective and primary endpoint main objective to demonstrate a benefit in terms of the 2 year grfs graft versus host disease gvhd and primary and secondary graft failurefree survival from 50 historical rates in patients with refractory relapse aa undergoing hsct ref 8 up to 70 using an optimized hsct procedure marrow as source of stem cells and a ptcy strategy on patients over 40 years old and not only in haploidentical donor setting primary endpoint 2year grfs following hcst this primary composite endpoint is measured as the time from hsct to the first of the following events primary and secondary graft failures grade 34 acute gvhd severe chronic gvhd and death secondary objectives and endpoints secondary objectives to demonstrate a benefit in terms of clinical and biological outcomes  primary and secondary graft failure  mortality overall survival  quality of life treatment related morbidity and notably severe infections cardiac toxicities  chimerism  immune reconstitution secondary endpoints 100day engraftment 3 consecutive days with neutrophiles 0 5 g l and 7 consecutive days with platelets 20 g l with donor chimerism 85 on the total blood absolute numbers of neutrophils and platelets at m1 m3 m6 m12 m24 and day of last platelet and red blood cell transfusions acute gvhd incidence grade 24 at m3 chronic gvhd incidence at m24 severe chronic gvhd at m24 secondary graft failure at m12 and m24 severe infections ctcae grade 34 at m1 m3 m6 m12 m24 incidence of cardiac toxicities at m12 incidence of cmv and ebv infection at m12 mortality at m12 m24 overall survival at 12 months and 24 months",
    "DESIGN": "design of the study a phase ii multicenter national prospective singlearm trial",
    "INCLUSION CRITERIA": "population of study participants patients aged from 40 to 60 years with refractory relapse aa after ist eligible to hsct inclusion criteria patients aged from 40 to 60 years old suffering from acquired refractory severe idiopathic aplastic anemia after at least 6 months treatment with antithymocyte globulin and cyclosporine with t eltrombopag or in relapse allograft validated in the national multidisciplinary expertise meetings of the french reference centre for aplastic anemia with an available genoidentical donor or 10 10 matched donor or haploidentical donor with the absence of donor specific antibody detected in the patient with a mfi 1500 antibodies to the distinct haplotype between donor and recipient usual criteria for hsct ecog 2 no severe and uncontrolled infection cardiac function compatible with high dose of cyclophosphamide with adequate organ function asat and alat 3n conjugated bilirubin 2n or total bilirubin 2n if not available clearance creatinine 50ml min with health insurance coverage women of childbearing potential and men must use contraceptive methods during their participation to the research and for 12 months and 6 months after the last dose of cyclophosphamide respectively having signed a written informed consent nb the authorized contraceptive methods are for women of childbearing potential and in absence of permanent sterilization oral intravaginal or transdermal combined hormonal contraception oral injectable or transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius sexual abstinence need to be evaluated in relation to the duration of clinical trial and the preferred and usual lifestyle of the participants",
    "EXCLUSION CRITERIA": "exclusion criteria patients with morphologic evidence of clonal evolution patients with isolated bone marrow cytogenetic abnormalities are also eligible excepted chromosome 7 abnormalities and complex karyotype with seropositivity for hiv or htlv12 or active hepatitis b or c and associated hepatic cytolysis cancer in the last 5 years except basal cell carcinoma of the skin or in situ carcinoma of the cervix pregnant βhcg positive or breastfeeding yellow fever vaccine and all others live virus vaccines within 2 months before transplantation and during the research with uncontrolled coronary insufficiency recent myocardial infarction 6month current manifestations of heart failure according to nyha ii or more ventricular ejection fraction 50 with renal failure with creatinine clearance 50ml min any contraindication mentioned in the smpc and the investigator s brochure of all medicinal products planned to be used in the trial including conditioning regimen gvhd prophylaxis prevention of ebv reactivation infection prophylaxis known allergy or intolerance to all medicinal products and or excipients planned to be used in the trial including conditioning regimen gvhd prophylaxis prevention of ebv reactivation infection prophylaxis according to investigator s brochure and smpc who have any debilitating medical or psychiatric illness which precludes understanding the inform consent as well as optimal treatment and followup under legal protection tutorship or curatorship under state medical aid participation to another interventional trial on a medicinal product or cell therapy individuals meeting any of the exclusion criteria verified at the screening inclusion visit will be ineligible to participate at the study",
    "INTERVENTION": "transplants modalities 1 conditioning regimen thymoglobulin 0 5 mg kg à d9 2 mg kg at d8 and 2 5 mg kg à d7 fludarabine 30mg m2 day i v day 6 to day 2 pre transplant cyclophosphamide 14 5 mg kg day i v day 6 and day 5 and total body irradiation 2 gray on day 1",
    "STATISTICS": "statistical analysis sample size calculation a twosided onesample logrank test calculated from a sample of 52 subjects achieves 80 power at a 0 05 significance level to detect a 2years grfs of 70 in the new group when the 2 years grfs in the historic control group is 50 if all patients are followed 2 years analysis of primary endpoint several interim analyses of the primary outcome measure are planned once every 12 months unless less than 20 enrolled patients based on a bayesian approach at the end of the trial accrual followup grfs will be estimated using kaplan meier method with its corresponding 95 confidence interval and compared to historical rate using one sample twosided logrank test an additional terminal analysis will use external patients from an observational cohort with propensity score weighting to ensure an unbiased comparison and enhance the level of evidence of the treatment effect",
    "DSMB": "study will have a data safety monitoring board yes",
    "ACRONYM": "acronym reference aparr",
    "INVESTIGATOR": "coordinating investigator régis peffault de latour",
    "NUMBER OF INCLUSIONS": "number of participants included 52 patients",
    "SITES": "number of centres 28 centers affiliated at sfgmtc in france",
    "FUNDING": "sponsor assistance publique hôpitaux de paris funding sources phrcn 2022"
  }
}